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Summary
A series of studies is described in which both clinical and basic techniques have been 
used to investigate insulin’s role as a vascular hormone and the relationship of this to 
metabolic insulin sensitivity and vascular endothelial function. These techniques 
(described in chapter 2) have been used to investigate:
• the physiological mechanisms of insulin-mediated vasodilation (chapter 3)
• the relationship between insulin’s metabolic and vascular actions (chapter 4)
• the effect on insulin sensitivity of induced endothelial dysfunction (chapter 5)
• the relationship between structural components of skeletal muscle and insulin 
action (chapter 6)
• the associations among insulin sensitivity, insulin vasodilation and basal 
endothelial function in insulin-resistant subjects (chapter 7)
• the sensitivity of platelets to agonist-induced aggregation with respect to different 
levels of insulin sensitivity (chapter 8)
• the role of immunogold electron microscopy in direct visualisation of GLUT4 
translocation in skeletal muscle cells (chapter 9)
Chapter 3: Physiological mechanisms of insulin-mediated vasodilation in man
In this clinical physiological study, the effects on insulin/glucose-mediated 
vasodilation of co-infusions of L-NMMA, angiotensin II, and ouabain were studied, 
in a double-blind, random-order, placebo-controlled manner using bilateral venous- 
occlusion strain-gauge plethysmography. It was concluded that insulin-mediated 
vasodilation may be dependent on endothelial nitric oxide production or stimulation
of the Na+K+ATPase pump or both; however, this data cast doubt upon the widely- 
prevalent assumption that insulin-mediated vasodilation is specifically NO- 
dependent.
Chapter 4: Insulin-mediated vasodilation and glucose uptake are functionally 
linked in man
This clinical physiology study was designed to test the hypothesis that insulin- 
mediated vasodilation and insulin sensitivity are functionally related. Eighteen 
healthy volunteers attended on two separate occasions for measurement of whole- 
body insulin sensitivity and forearm vasodilation in response to an intra-arterial 
infusion of insulin and glucose. In multiple regression analysis, insulin-mediated 
vasodilation was, indeed, a significant independent predictor of insulin sensitivity.
Chapter 5: Systemic inhibition of endothelial nitric oxide synthesis does not 
impair insulin sensitivity in man.
In this clinical physiology study, an experimental state of systemic endothelial 
dysfunction was induced in healthy male volunteers and the effect on whole-body 
insulin sensitivity was assessed in a randomised double-blind, placebo-controlled 
manner. The results indicate that impairment of endothelial nitric oxide synthesis 
does not result in an impairment of whole-body insulin sensitivity, suggesting that 
substrate delivery to nutritive capillary beds is unlikely to be rate-limiting for insulin- 
mediated glucose uptake.
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Chapter 6: Skeletal muscle capillary density is unrelated to insulin’s
vasodilator action
Skeletal muscle fibre type is known to be associated with insulin sensitivity. Since 
fibre type is also related to capillary density, this study set out to test the hypothesis 
that insulin’s vasodilator action is linked with muscle capillary density, which would 
support the notion that skeletal muscle structure and function may be a significant 
‘third factor’ accounting for the observed association between insulin’s metabolic 
and vascular actions. Following immunohistochemical staining of sections of muscle 
biopsy samples from 13 healthy volunteers in whom insulin sensitivity and local 
msulin/glucose-mediated vasodilation had already been measured, it was concluded 
that the quantity of capillary endothelium in muscle is unlikely to be a significant 
determinant of insulin’s vascular action.
Chapter 7: Insulin action and endothelial function in type 2 diabetes and
essential hypertension
Twenty seven men participated in this clinical physiology study (9 controls, 9 
hypertensives and 9 type 2 diabetics) which was designed to characterise insulin 
action and basal endothelial function. There was a trend for reduced insulin- 
mediated vasodilation in type 2 diabetic patients although statistical significance was 
not achieved due to high biological variability. Pooled analysis revealed a significant 
association between (1) insulin’s metabolic and vascular actions, (2) insulin 
sensitivity and basal endothelial NO production, and (3) insulin-mediated 
vasodilation and basal endothelial NO production. Multiple regression analysis with 
basal endothelial NO production as the dependent variable revealed that a model
11
including insulin-mediated vasodilation and age accounted for over 40% of the 
variance. The fact that insulin sensitivity did not persist as an independent predictor 
is supportive of the hypothesis that insulin-stimulated endothelial NO production is a 
key intermediate mechanism linking insulin-mediated glucose uptake with basal
i. ■ (-■
endothelial function.
$
Chapter 8: Sensitivity of washed platelets to thrombin-induced aggregation is 
not associated with whole-body insulin sensitivity
Previous studies have demonstrated that platelet aggregation is increased in 
association with insulin resistance. However, it remains unclear whether this feature 
is intrinsic to platelet function or secondary to influencing factors in plasma. In the 
present study, a washed platelet preparation was used to determine sensitivity of 
platelets to thrombin-induced aggregation in the absence of plasma. There was no 
association between platelet aggregation and either insulin sensitivity or insulin- 
mediated vasodilation. This negative result might be due to differences in technique 
from previous studies and supports the notion that plasma factors associated with 
insulin resistance exert influences on platelet function rather than there being 
intrinsic platelet defects secondary to insulin resistance.
Chapter 9: Direct visualisation of glucose transporter protein GLUT4 in
skeletal muscle using immunogold electron microscopy
In this pilot study, a collaboration was initiated with experts in membrane 
biochemistry and cell ultrastructure with a view to developing the technique of 
immunogold electron microscopy for use in direct visualisation of key cellular
12
proteins involved in the insulin signalling pathway. The primary aim of this ongoing 
work is to demonstrate and quantify GLUT4 translocation to myocyte t-tubules in 
response to insulin stimulation. Once this technique is established, it is planned to 
explore mechanisms of GLUT4 translocation to provide clues for possible defects 
which may underlie cellular insulin resistance.
Conclusions
• Insulin is a vasoactive hormone.
• Mechanisms of insulin-mediated vasodilation include stimulation of endothelial 
NO production and membrane hyperpolarisation via stimulation of 
Na^ATPase.
• Insulin-mediated vasodilation occurs gradually over 40-50 minutes suggesting 
involvement of intermediate mechanisms.
• Cellular glucose uptake augments insulin-mediated vasodilation.
• Whole-body insulin-stimulated glucose uptake and local insulin/glucose 
vasodilation are functionally linked.
• Systemic inhibition of NO production does not impair whole-body insulin- 
mediated glucose uptake.
• Skeletal muscle capillary density is not associated with insulin’s vascular action.
• Insulin resistance is not associated with increased sensitivity of washed platelets 
to thrombin-induced aggregation.
• Insulin-mediated vasodilation is preserved in older men but is blunted in parallel 
with reductions in insulin sensitivity.
• Vasoconstriction in response to local inhibition of NO synthase is delayed during 
hyperinsulinaemia compared with fasting conditions suggesting that insulin 
stimulates eNOS activity.
• Insulin sensitivity correlates with basal endothelial NO production in both young 
and older men.
• Insulin-mediated vasodilation correlates with basal endothelial NO production in 
older, but not in young men.
• Insulin's stimulation of endothelial NO production may be a key intermediate 
mechanism linking insulin sensitivity with basal endothelial function.
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Chapter 1
Introduction and background
1.0 Introduction
Insulin is best known as a metabolic hormone but also exerts effects on vascular 
tone. Therefore, plasma insulin concentrations and/or resistance to insulin action 
have been proposed as potential common factors linking metabolic and 
cardiovascular disorders. The purpose o f  this thesis is to explore the complex 
relationship between insulin’s metabolic and vascular actions and how this is related 
to vascular endothelial function.
1.0.1 Physiological actions o f insulin [figure 1.1]
Insulin is a peptide hormone which is secreted from pancreatic (3-cells into the portal
\
circulation in response to various stimuli including glucose and amino acids. One o f 
its main roles is to facilitate cellular uptake o f  these building blocks for storage as 
glycogen and protein. The main sites o f peripheral glucose disposal are skeletal 
muscle (>80%) and adipose tissue (5-10%) (DeFronzo et al, 1992). Stimulation o f 
insulin receptors in these tissues results in a complex intracellular signalling cascade 
(section 1.10.4) ultimately resulting in translocation o f glucose transporter proteins 
(GLUT-4) to the cell surface and subsequent glucose uptake. Insulin also exerts an 
important influence on the liver resulting in suppression o f gluconeogenesis and 
stimulation o f lipogenesis. In addition, it is a growth factor, an effect which may be 
mediated via IGF-1 receptors. Lastly, it stimulates cellular uptake o f potassium, a 
mechanism which may partly explain its vascular action (section 1.3).
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1.0.2 What is 'insulin resistance’?
The nature of ‘resistance’ to these actions of insulin is incompletely understood. 
There are several inherited syndromes of profound insulin resistance which 
commonly involve the insulin receptor itself. For example, in Type A Syndrome the 
defective receptors cannot stimulate the intracellular cascade which promotes 
glucose uptake and metabolism. Compensatory high insulin levels are unable to 
overcome the defect resulting in hyperglycaemia, but continue to exert growth 
effects via IGF-1 receptors causing the syndrome’s characteristic features, including 
acanthosis nigricans (Moller & Flier, 1991).
However, in the majority of cases, the degree of resistance to insulin action is 
multifactorial, involving a combination of polygenic and environmental influences, 
resulting in considerable (2-3 fold) variation when measured in apparently healthy 
subjects (Hollenbeck & Reaven, 1987). Thus, insulin resistance is a continuous 
variable within a normal population. In the majority of subjects at the top end of this 
spectrum, compensatory hyperinsulinaemia maintains normal glucose tolerance, but 
in a proportion of insulin resistant subjects, this is an inadequate response and 
impaired glucose tolerance ensues. Type 2 diabetes is more likely to supervene in the 
context of more severe hepatic insulin resistance and p-cell failure (DeFronzo et al, 
1992).
1.0.3 How is insulin resistance measured?
Quantification of the degree of insulin sensitivity or resistance in man involves 
obtaining a measurement of glucose disposal. High insulin-mediated glucose disposal
17
equates with high sensitivity / low resistance and vice-versa. Several techniques have 
been used to quantify this, including the intravenous glucose tolerance test, the 
minimal model technique (Bergman et al, 1987) and the insulin suppression test 
(Greenfield et al, 1981). However, it is generally accepted that the ‘gold standard’ is 
the hyperinsulinaemic euglycaemic clamp technique (section 2.4.1), in which a fixed 
rate o f  insulin is infused and plasma glucose is kept constant (‘clamped’) by infusing 
20% glucose at a variable rate. After 2 -3 hours, steady-state is achieved where the 
rate o f  glucose infusion is equal to the rate o f  insulin-mediated glucose disposal. 
Thus, insulin sensitivity is expressed as mg glucose / kg body weight / minute ( ‘M- 
value’). Clearly, this technique is impractical in large-scale studies and a surrogate 
index tends to be used, for example ‘FIRJ’ (fasting insulin resistance index) which 
equates to fasting [insulin] x fasting [glucose] divided by 25; FIRI has been shown to 
correlate well with clamp-derived M-values (Figure 1.2) (Cleland et al, 1996).
1.0.4 Insulin resistance - a beneficial physiological response?
Insulin resistance has most impact on glucose pathways (figure 1.3) resulting in 
hyperstimulation o f fat and protein anabolic pathways by compensatory 
hyperinsulinaemia. It occurs as a normal physiological response in certain 
circumstances o f physiological stress, such as major trauma, sepsis, starvation, 
pregnancy and puberty, with the result that essential glucose substrate is diverted 
from muscle metabolism and priority given to energy storage, CNS nutrition, growth 
and healing. Thus, in times o f physical adversity, selective insulin resistance may 
confer an important survival advantage, which may explain why it appears so 
prevalent in an apparently healthy population.
18
Figure 1.2
Fasting insulin resistance index (FIRI) plotted against 
clamp-derived insulin sensitivity in 31 subjects with normal 
glucose tolerance
1.5 —I
1.0 —
—  0.5 -
• •  •
g)Q0
-0.5 -
r=- 0.67, p< 0.001
- 1.0 -
Insiiin sensitivity (M) rrg/kg/min
19
k
f l
OX OX c*3
S a s
. . .  fe o  !
1 a  3 |
I M M !
20
en
ha
nc
em
en
t 
of 
in
su
lin
’s 
ot
he
r 
ac
tio
ns
.
1.0.5 Epidemic o f insulin resistance in Western Society
Unfortunately, a survival mechanism for starvation and physical stress may be a 
recipe for disaster in the modern world. While life expectancy has dramatically 
increased in Western society, mainly due to reductions in child mortality, prevention 
o f  malnutrition, effective management o f infectious disease and disease prevention 
policies, lifestyle issues are exerting an increasingly important influence on health. 
The Western diet is high in unrefined carbohydrate and saturated fat. The ready 
availability o f  food is promoting an epidemic o f obesity. In an age o f technology and 
high psychological stress, levels o f physical activity have been dramatically reduced 
resulting in a vicious circle o f  inactivity, obesity and insulin resistance (figure 1.4).
There is already evidence for a global epidemic o f  type 2 diabetes. Currently, there 
are 100 million patients worldwide; it has been predicted that this figure will double 
by the year 2020 (O ’Rahilly, 1997). The notion that Western lifestyle is the culprit 
responsible for this epidemic is supported by the high prevalence o f  type 2 diabetes 
in migrant groups such as South Asians, Aborigines and Polynesians (O ’Dea, 1991). 
For example, the prevalence o f diabetes in South Asians aged 40-75 in the UK is 
20-30%, compared with a prevalence in the indigenous population o f 2-3% 
(O ’Rahilly, 1997). The fact that these same people groups have a high incidence of 
cardiovascular disease (McKeigue et al, 1988) leads us on to consider possible 
aetiological mechanisms which might link insulin resistance (and associated 
hyperinsulinaemia) with cardiovascular disease (figure 1.5).
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1.1 Endothelial function and insulin sensitivity in health and disease
1.1.1 The role o f the endothelium in vascular smooth muscle control
The role of the endothelium in modifying vascular smooth muscle cell (VSMC) tone 
has been extensively reviewed elsewhere (Vane et al, 1990; Moncada et al, 1991; 
Meidell, 1994). In summary, the endothelium is responsible for local regulation of 
blood flow, production of growth factors and control of haemostasis. Four main 
enzyme systems interact to regulate blood flow; these produce the following 
vasoactive substances: (1) endothelin, (2) prostacyclin and thromboxane A2 (which 
also exert effects on platelet adhesion), (3) angiotensin II and the kinins (which also 
act as local growth factors) and (4) nitric oxide (NO). These vasoactive substances 
produced by the endothelium operate in VSMCs by three main mechanisms: via 
cGMP, via cAMP, or via changes in intracellular Ca2+. Endothelial cells are highly 
metabolically active and under stress from a variety of sources including mechanical 
forces, free radical oxidation, poor nutrient supply and blood-borne toxins (figure 
1.6). Endothelial NO production is arguably the most important mechanism for 
protection against endothelial dysfunction and disruption which are central to the 
process of atherothrombosis. Not only is NO a potent vasodilator, it also acts as an 
anti-inflammatory factor, an anti-oxidant, and an anti-thrombotic agent as well as 
regulating local production of growth factors and involvement in autoregulatory 
control (Griffith et al, 1987; Griffith et al, 1990) (figure 1.7) A fine balance of 
sophisticated control mechanisms is required to ensure maintenance of local blood 
flow, blood fluidity and vessel architecture. Any reduction in endothelial NO 
production may predispose to atherothrombosis and subsequent vascular occlusion 
(figure 1.8).
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The endothelium may also be an important site of cross-talk between the metabolic 
and vascular requirements of the tissue. As we have seen, insulin appears to exert a 
significant influence on VSMC tone via endothelial mechanisms. It may be that 
endothelial function or dysfunction is an important factor in the link between 
insulin’s metabolic and vascular actions. More speculatively, it is possible that insulin 
action on endothelial cells is important for production of adequate basal NO 
production - defective insulin action may result in endothelial dysfunction and 
predisposition to atherothrombosis. This notion is explored further in chapter 7.
1.1.2 Definition o f 'endothelial dysfunction ’
The term ‘endothelial dysfunction’ is, in practice, synonymous with the 
demonstration of abnormal endothelial nitric oxide production. This, in turn, can 
represent either abnormal NO synthesis (eg reduced activity of eNOS) or increased 
NO quenching (eg by superoxide or other cellular free radicals). The notion that 
defects in NO production go hand-in-hand with global dysfunction of other 
endothelial mechanisms is a common assumption for which there is very little 
evidence. However, it has become accepted in the scientific community that 
measurement of either stimulated or basal NO production is the ‘gold standard’ 
method for assessing endothelial function. Unfortunately these measurements are 
invasive and labour-intensive, rendering them unsuitable for large-scale studies. 
Limb blood flow can be assessed by a number of methods (section 1.2.2) the most 
commonly used being venous-occlusion plethysmography (section 2.7.1). A number 
of different compounds have been infused via a limb artery to demonstrate local 
vasodilation via stimulation of endothelial NO production; these include
acetylcholine (eg McVeigh et al, 1992; Panza et al, 1993b), methacholine (eg 
Steinberg et al, 1996) and bradykinin (eg Kelm et al, 1996; Nuutila et al, 1996). It is 
becoming clear that any comparisons between studies using different stimulating 
agents should be interpreted with caution, since each agent may have specific effects 
in addition to stimulation o f endothelial NO; for example, there is evidence that 
acetylcholine may cause vasodilation partly via a NO-independent mechanism 
(Parsons et al, 1994). In all such protocols, it is vital to study in parallel the effects 
o f  an endothelium-independent donor o f  NO (eg sodium nitroprusside) which is 
used as an experimental control to assess sensitivity o f adjacent vascular smooth 
muscle to NO.
An alternative approach is to assess basal endothelial NO production (eg Calver et 
al, 1992; Petrie et al, 1996a). The most commonly used method for this in man is 
measurement o f the vasoconstrictor response to a local infusion o f No-monomethyl- 
L-arginine (L-NMMA) which is a stereospecific substrate inhibitor o f  endothelial NO 
synthase. Vasoconstriction to L-NMMA in the human forearm is dose-dependent 
with maximal reduction in blood flow in the order o f 30-40% (Vallance et al, 1989). 
Therefore, basal production o f endothelial NO contributes significantly to the 
determination o f resting blood flow. It is likely that this method o f assessing 
endothelial function is more physiologically relevant since stimulation by 
pharmacological doses o f  agonists is artificial. However, it remains unclear whether 
L-NM MA has any other effects which may confuse interpretation o f blood flow 
responses. Again, it is common practice to use an experimental control which is 
usually the endothelium-independent vasoconstrictor, noradrenaline.
29
Damaged endothelial cells release a number o f  products into plasma which can be 
measured. Thus, levels o f ‘endothelial markers’ such as von Willebrand factor 
(vWF), tissue plasminogen activator (tPA), thrombomodulin, can be used to build up 
a profile o f the severity o f endothelial dysfunction (Stehouwer et al, 1997). 
However, in view o f their lack o f specificity, these markers may only be useful in 
large-scale studies, where the more invasive and labour-intensive procedures are not 
practical.
1.1.3 Association o f insulin resistance and endothelial dysfunction in metabolic 
and cardiovascular disease
Although insulin has a variety o f metabolic actions, the term ‘insulin sensitivity’ 
usually refers to the hormone’s ability to dispose o f glucose from the intravascular 
compartment into tissues, predominantly skeletal muscle and adipose tissue. 
Abnormalities o f  insulin action, including a reduction in insulin sensitivity (or ‘insulin 
resistance’), are present not only in metabolic disorders such as type 2 diabetes 
(DeFronzo et al, 1992) and obesity (Ludvik et al, 1995)), but also in cardiovascular 
conditions such as essential hypertension (Ferrannini et al, 1987) and chronic cardiac 
failure (Swan et al, 1994). Notably, all these disorders are also characterised by 
vascular endothelial dysfunction (see 1.5.2) (McVeigh et al, 1992; Williams et al 
1996; Steinberg et al, 1996; Laine et al, 1998; Calver et al, 1992; Panza et al, 1993a; 
Drexler et al, 1993). The demonstration that insulin, in addition to its classical 
metabolic role, functions as a vasodilator, with a major component o f this action 
being NO-dependent (Steinberg et al, 1994; Scherrer et al, 1994a) has
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fuelled interest in the putative mechanisms and functional significance of insulin as a 
vascular hormone. Further elucidation of defects in insulin action, at both a 
metabolic and vascular level, may help to explain some of the pathophysiological 
mechanisms of the observed association between metabolic and cardiovascular 
diseases (De Fronzo & Ferrannini, 1991).
1.1.4 A physiological relationship between insulin sensitivity and endothelial 
function
In healthy non-obese subjects there is a three-fold variation in insulin sensitivity 
(Hollenbeck & Reaven, 1987) as measured by the hyperinsulinaemic, euglycaemic 
clamp technique (section 2.4.1). Given the association of insulin resistance and 
endothelial dysfunction in metabolic and cardiovascular disease, in conjunction with 
the common observation of parallel improvement in these parameters in response to 
a variety of interventions, a hypothesis was generated that vascular endothelial 
function should explain a significant amount of the variance in insulin sensitivity in a 
physiological setting, ie there should be a correlation between these two variables 
across the range of insulin sensitivity found in healthy man. This hypothesis was 
tested by our group in a study undertaken prior to the work presented in this thesis. 
The results (along with others: section 1.2.5) formed a vital platform for the studies 
presented in this thesis:
Fifteen healthy male volunteers, aged 2 1 - 3 5  years, completed one study day of 
hyperinsulinaemic euglycaemic clamp (section 2.4.1) to measure whole-body insulin 
sensitivity, and two study days of forearm venous occlusion plethysmography
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(section 2.7.1) to measure both stimulated and basal endothelial nitric oxide 
production (section 1.5.2). In univariate analysis, individual measurements o f  insulin 
sensitivity (M) were positively related to individual mean L-NM MA responses 
(surrogate measurements for basal endothelial nitric oxide production) (r = 0.52, p < 
0.05, [figure 1.9]). However, no significant relationships were observed between M 
and nor-adrenaline, acetylcholine or sodium nitroprusside responses. In multiple 
regression analysis, in a model taking into account age, body mass index, mean 
arterial pressure, plasma glucose level, serum cholesterol level, alcohol intake, 
smoking status, family history and physical activity level, the L-NM MA response 
accounted for 43% o f the variance in insulin sensitivity (p < 0.01) (Petrie et al, 
1996a).
1.2 Insulin as a vasodilator hormone
1.2.1 Mechanism o f insulin action in skeletal muscle
An important site o f insulin’s metabolic actions is skeletal muscle. This tissue has 
been shown to be the main site o f reduced insulin-mediated glucose disposal in both 
essential hypertension (Natali et al, 1991) and type 2 diabetes (DeFronzo et al,
1992). Insulin’s main role in skeletal muscle is to promote glucose uptake into cells 
for storage as glycogen. In the post-prandial period, resting muscle takes up glucose 
by increasing the arteriovenous fractional extraction under the influence o f  insulin. 
According to the Fick Principle, glucose uptake is a product o f  the arteriovenous 
glucose gradient and blood flow; therefore glucose would be disposed o f  much more 
efficiently if an increase in blood flow resulted in augmented substrate delivery. 
However, there is considerable debate in the literature concerning the rate-limiting
32
Figure 1.9
Basal endothelial nitric oxide production (percentage 
change in FBF ratio in response to intra-arterial L- 
NMMA) plotted against whole-body insulin sensitivity 
in 15 healthy male volunteers. From Petrie et al, 1996a.
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step for insulin-mediated glucose uptake. If substrate delivery is the rate-limiting 
step (in other words, if skeletal muscle blood flow is a determinant of glucose 
uptake), then it can be argued that endothelial dysfunction, resulting in a relative 
inability of mediators, including insulin, to stimulate muscle blood flow, may be the 
underlying mechanism accounting for the association of atherosclerosis and other 
cardiovascular disorders with insulin resistance (Baron, 1994). The crux of this 
argument rests on insulin’s role as a vasodilator hormone and also whether this 
action is physiologically relevant in terms of glucose disposal. Evidence for and 
against this will now be considered.
1.2.2 Vascular effects o f systemic insulin infusion in man
Systemic hyperinsulinaemia appears to augment skeletal muscle blood flow by 20- 
60%, (Iannaccone et al, 1989; Laakso et al, 1990; Scherrer et al, 1994a; Anderson et 
al, 1991; Laakso et al, 1992; Bennett et al, 1990; Vollenweider et al, 1994) but this 
is by no means a universal finding (Utriainen et al, 1995; Capaldo et al, 1991; 
DeFronzo et al, 1985; Natali et al, 1994; Yki-Jarvinen et al, 1987; Nuutila et al, 
1996). There are several possible reasons for the differing results in these studies:
• the extent of insulin’s vasodilator action may be dependent on the level of 
systemic hyperinsulinaemia achieved. In most of the studies where insulin was shown 
to have a significant vasodilator effect, insulin levels were maintained in or above the 
high-physiological range.
• methodological differences in the measurement of limb blood flow are a source 
of variation. Baron’s group in Iowa use a thermodilution technique to measure leg 
blood flow (Baron, 1994) while most European groups employ the technique of
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venous-occlusion plethysmography to measure forearm blood flow (Petrie et al, 
1996a; Tack et al, 1996); more recently Yki-Jarvinen and colleagues in Finland have 
used high-resolution positron emission tomography (PET) to investigate insulin’s 
vascular effects and appear to conclude that insulin does, indeed, have significant 
vasodilator actions (Raitakari et al, 1996; Utriainen et al, 1997). In addition, the site 
of measurement may be important. There may be important differences between the
'■ j
upper and lower limb circulations in response to insulin. 1 ’
• experimental design can affect the interpretation of results. For example, a 
double-blind, placebo-controlled, randomised design is more valid to detect small 
changes in blood flow than a ‘before-after’ experimental design. Also, the length of 
the protocol is of relevance, since insulin-mediated vasodilation is often not apparent 
until 40-50 minutes after the start of insulin infusion (Ueda et al 1998a).
1.2.3 Insulin and the sympathetic nervous system
One problem when interpreting blood flow data from studies in which insulin is 
infused systemically is that there is parallel stimulation of the sympathetic nervous 
system which has haemodynamic consequences both centrally and in the periphery. 
Evidence for this mechanism comes from recordings of muscle sympathetic nerve 
activity under conditions of insulin stimulation (Scherrer et al, 1994b). This appears 
to be a direct effect of insulin, and not simply baroceptor-mediated; in experimental 
animals with induced lesions of the anterolateral third ventricle, central sympathetic 
outflow in response to systemic insulin infusion is abolished (Muntzel et al, 1994). 
Presumably, activation of the sympathetic nervous system in combination with the 
peripheral vasodilatory action of insulin act to maintain blood pressure during
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systemic hyperinsulinaemia. It has long been known that patients with insulin- 
dependent diabetes mellitus who have advanced autonomic neuropathy may become 
hypotensive after injecting insulin; this suggests that insulin’s peripheral vasodilatory 
effects are preserved while the central compensatory effects are lost (Mathias et al, 
1987).
In addition to its central actions, insulin appears to modulate peripheral responses at 
the adrenergic receptor level. Thus, it has been demonstrated that insulin augments 
forearm blood flow via a p-adrenergic mechanism (Lembo et al, 1996), and it has 
been shown that insulin attenuates both ai and ct2 responses in the human forearm 
(Sakai et al, 1993; Lembo et al, 1994). More recently Lembo et al (1997) have 
demonstrated that these effects of insulin on adrenergic responses are abolished by 
concominant inhibition of nitric oxide synthase, suggesting that nitric oxide is 
involved in a mediating role. However, not all of the evidence is in support of 
insulin’s role as a modulator of peripheral sympathetic nervous system responses 
(Randin et al, 1994).
The time course of muscle sympathetic nerve activity in response to a systemic 
insulin infusion has a similar delay (slow rise over 1-2 hours) to that of insulin- 
mediated vasodilation (Anderson et al, 1991). In patients who have undergone 
sympathectomy for hyperhidrosis, the magnitude of insulin-mediated vasodilation is 
similar but the time to achieve steady-state is significantly reduced - the changes are 
all seen within the first hour (Sartori et al, 1996). This evidence suggests that insulin 
acts at the periphery to overcome the vasoconstictive influence of a stimulated
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central sympathetic nervous system. Removal of this central component appears to 
allow insulin’s vasodilator effects to take place more quickly.
1.2.4 Vascular effects o f local insulin infusion in man
As outlined above, the majority of studies suggest that significant increases in limb 
blood flow occur in response to systemic hyperinsulinaemia, although there is 
marked variation in the results due to a number of confounding factors including 
activation of the sympathetic nervous system. In order to avoid confounding changes 
in systemic haemodynamics, some groups have infused insulin locally to a limb via a 
major artery. The majority of studies employing this technique have yielded negative 
results (Sakai et al, 1993; Chisholm et al, 1975; Creager et al, 1985; Natali et al, 
1990); those that do demonstrate a significant augmentation of blood flow reveal, at 
best, a 20-25% rise (Andres et al, 1961; Gelfand & Barrett, 1987; Neahring et al,
1993). Studies conducted by our own group in the human forearm, using a double­
blind placebo-controlled protocol and physiological local insulin concentrations (70- 
80 pU/ml), detected a 20% rise in flow after 90 minutes (figure 1.10) (Ueda et al, 
1998a).
Therefore, it appears that local hyperinsulinaemia has a less marked vasodilator 
action than a systemic insulin infusion despite similar plasma concentrations. This is 
an unexpected finding if one accepts that sympathetic activation induced by systemic , 
hyperinsulinaemia causes peripheral vasoconstriction to counter insulin’s vasodilator 
action - in the absence of sympathetic activation one might expect an augmentation 
of insulin’s vasodilator action. One possibility is that sympathetic stimulation is 
actually causing direct peripheral vasodilation, although there is very
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Figure 1.10
Time course of percentage change in forearm blood flow ratio 
(mean + S.D.)in response to intra-arterial infusion of (a) placebo 
(b) insulin ImU/min (c) insulin 5mU/min. Double-blind, random 
order study design. * p < 0.05 From Ueda et al, 1998a.
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little evidence for this.
1.2.5 Augmentation o f insulin-mediated vasodilation by glucose 
Another explanation may be that glucose availability may be important for insulin’s 
vascular action. Normally, during clamp studies, 20% glucose is infused systemically 
along with insulin to avoid hypoglycaemia (DeFronzo et al, 1979). If a 
hyperglycaemic clamp is carried out, with co-infusion of somatostatin to suppress 
insulin secretion, no effect on limb blood flow can be demonstrated with increasing 
glucose levels (Baron, 1993). However, clamping glucose levels at 20mmol/l in the 
presence of insulin causes augmentation of limb blood flow by around 50%, 
compared with clamping at 5mmol/l (Baron, 1993).
During local studies there is no risk of systemic hypoglycaemia and, therefore, it is 
not common practice to co-infuse glucose with insulin via a limb artery. Our own 
group addressed this issue by studying local insulin infusion with and without co- 
infusion of intra-arterial glucose, in sufficient concentration to maintain local venous 
euglycaemia. During this study, I learned the techniques of brachial artery 
cannulation and venous-occlusion plethysmography under the supervision of Drs 
Ueda and Petrie.
In a preliminary study, intra-arterial infusion of D-glucose at 75 pmol/min with high- 
physiological doses of intra-arterial insulin was shown to maintain euglycaemia in 
samples obtained from a deep vein of the infused arm. Furthermore, venous 
sampling from the other arm revealed that glucose levels remained unchanged,
39
confirming that there was no significant systemic effect of the local insulin infusion. 
We then proceeded to investigate the stereospecificity of the effect of glucose on the 
vasodilating effect of insulin by co-infusing D- or L-glucose (metabolically-inactive 
isomer) on separate study days at 75 pmol/min for 30 min with saline and 
subsequently for 90min with 5 mU/min of insulin (resulting in high-physiological 
insulin levels in deep venous effluent) in a double blind, cross over design (n=8). 
Blood samples were taken every 10 minutes for measurement of glucose and every 
30 minutes for measurement of insulin and potassium. The infusion rate (D/L 
glucose plus saline) was 2 ml/min throughout. The mean±SD change in forearm 
blood flow (figure 1.11) during infusion of insulin with D-glucose (47.1±21.3%) was 
significantly greater than that during infusion of insulin and L-glucose (6.1 ±12.2%), 
p=0.01, 95% Cl 23.1, 58.8). Infusion of both D- and L-glucose alone prior to 
insulin administration tended to reduce forearm blood flow but there was no 
significant difference in this response between the two treatments. There were no 
differences in serum potassium or insulin concentrations in the deep venous effluent 
between the two treatments (Ueda et al 1998a).
Therefore, augmentation of local insulin-mediated vasodilation by D-glucose is not 
due to an osmotic effect of glucose since we compared D-glucose with its stereo­
isomer L-glucose, which is metabolically inactive. This observation suggests either 
that a local fall in extracellular glucose may impair insulin’s vascular action or that 
insulin-mediated vasodilation may be more closely related to tissue glucose uptake 
than to insulin concentrations per se. Under physiological circumstances, insulin is
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Figure 1.11
Percentage change in forearm blood flow (FBF) ratio over 
time in response to intra-arterial infusion of insulin 
(5mU/min) with either D-glucose (75 umol/min) or L- 
glucose (metabolically-inactive stereoisomer). Double­
blind, random order study design. ** p < 0.01 From Ueda 
etal, 1998a.
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secreted in response to a post-prandial rise in blood glucose; thus, hyperinsulinaemia 
in any vascular bed is likely to be accompanied by an increase in supply of substrate 
(glucose). If the vasodilating effect of insulin was dependent on the stimulation of 
tissue glucose uptake, this effect might be masked during isolated local 
hyperinsulinaemia. This latter suggestion may be relevant in understanding the 
association between endothelial function and insulin sensitivity (see below).
1.3 Mechanisms of insulin-mediated vasodilation
1.3.1 Insulin as an endothelium-dependent vasodilator
Two earlier studies conducted in man reported that insulin causes vasodilation via 
release of endothelial nitric oxide. In one (Scherrer et al, 1994a), prior local intra- 
arterial infusion of L-NMMA completely abolished insulin-mediated vasodilation in 
the forearm during a systemic insulin infusion. In the same study, vasoconstrictor 
responses to increasing doses of L-NMMA during euglycaemic hyperinsulinaemia 
were significantly higher than under basal conditions, while there were no differences 
in reponses to norepinephrine. In the other study (Steinberg et al, 1994), 
approximately 20% of leg blood flow was shown to be nitric oxide-dependent under 
basal conditions, while the value was nearer 40% during hyperinsulinaemia.
More recently, a number of studies have supported the notion that insulin is an 
endothelium-dependent vasodilator. It has been noted in children that a bolus of 
intravenous insulin causes an increase in nitric oxide production, as measured by 
urinary nitrite/nitrate excretion (Tsukahara et al, 1997). Furthermore, using multiple 
regression analysis, it has been shown in man that limb blood flow response to local 
nitric oxide synthase inhibition (a measure of basal nitric oxide production), together
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with the degree o f forearm muscularity, explained over 50% o f the variation in 
insulin-mediated blood flow, as measured by PET scanning (Utriainen et al, 1996a). 
It has also been demonstrated that forearm vasodilation secondary to  local intra- 
arterial infusions o f insulin can be completely abolished by co-infusion o f  L-NMMA 
in man (Van Veen et al, 1997). A number o f in vitro studies provide supportive 
evidence: in rat vessels, insulin’s ability to attenuate adrenergic preconstriction was 
abolished by prior incubation with L-NMMA (Wu H-Y et al, 1994) while, more 
recently, insulin was shown to vasodilate rat cremasteric arterioles in vitro, an effect 
which was inhibited by either incubation with L-NM MA or endothelial removal 
(Chen & Messina, 1996). However, in the hamster cremasteric microcirculation 
insulin retained its ability to cause vasodilation despite blockade o f  nitric oxide 
synthase (McKay & Hester, 1996), suggesting that endothelium-dependent 
mechanisms are unlikely to be the only explanation for insulin-mediated vasodilation 
in certain vascular beds.
The mechanisms o f insulin-stimulated nitric oxide production remain to be fully 
elucidated. In this regard, our own group has recently demonstrated that 
concomitant intra-arterial infusion o f L-arginine significantly augments the 
vasodilator response to local insulin/glucose infusion compared with control (intra- 
arterial D-arginine) (Ueda et al, 1998b). This suggests that insulin-stimulated uptake 
o f L-arginine (the substrate o f nitric oxide synthase) by endothelial cells may lead to 
an increase in nitric oxide production. In this study eight healthy male volunteers 
(aged 20-40 years) underwent intrabrachial infusions o f  L-arginine or D-arginine (40 
pmol/min, hydrochloride salts) along with insulin (5mU/min) and glucose (75
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pmol/min) for 90 minutes on two separate days in a double-blind random-order 
crossover design. On a third day, the same subjects received L-arginine alone (40 
pmol/min) for the same time period. Forearm blood flow was measured using 
bilateral strain-gauge venous-occlusion plethysmography (section 2.7.1). The 
vasodilator response to L-arginine with insulin/glucose was significantly greater than 
that observed with D-arginine and insulin/glucose (figure 1.12). Infusion o f  L- 
arginine alone had no effect on forearm blood flow. Local steady-state insulin 
concentrations were approximately 500 pmol/L (high physiological) in both 
insulin/glucose conditions. Local L-arginine concentrations were approximately 900 
pmol/L (nine-fold excess) at steady-state in both L-arginine conditions. From these 
results it appears that during local hyperinsulinaemia (similar to post-prandial 
conditions), L-arginine (but not D-arginine) administration produces stereospecific 
vasodilation. The mechanism for this effect is unclear since it is known that L- 
arginine, which is the substrate for the classical pathway o f  NO synthesis (via 
stereospecific NO synthase), is present in high concentrations in endothelial cells; 
thus, administration o f additional L-arginine should not affect blood flow in health 
(Chowienczyk & Ritter, 1997). It has been suggested that a non-enzymatic pathway 
for the generation o f NO may explain the unexpected vasodilator effects o f arginine 
(Chowienczyk & Ritter, 1997). Thus, formation o f NO from either enantiomer o f 
arginine and hydrogen peroxide in conditions o f local oxidative stress may account 
for reports o f normalisation by L-arginine o f vascular responses in states o f 
endothelial dysfunction (Drexler et al, 1991), and o f non-stereospecific vasodilator 
effects o f  arginine at high concentrations (MacAllister et al, 1995). However, the 
results from our study demonstrating a clear stereospecific effect o f L-arginine
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Figure 1.12
Time course of percentage change in forearm blood flow ratio 
in 9 healthy male volunteers in response to intra-arterial 
infusion of (a) insulin, D-glucose & L-arginine (b) insulin, D- 
glucose & D-arginine (c) L-arginine & vehicle. Double-blind, 
random order study design. ** p < 0.01 From Ueda et al, 
1998b.
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would be more consistent with the notion that L-arginine transport into endothelial 
cells may be rate-limiting during conditions of active production of NO. This notion 
is supported by in vitro studies in cultured endothelial cells, which show that insulin 
stimulates system y+, a transporter system which facilitates cellular uptake of L- 
arginine (Sobrevia et al, 1996). The prolonged time-course of insulin-mediated 
vasodilation observed in most in vivo studies would be compatible with the 
hypothesis that insulin promotes de novo synthesis of the system y + transporter.
Alternatively, there is evidence that insulin causes a rise in intracellular Ca2+ levels in 
rat aortic endothelial cells with subsequent stimulation of constitutive nitric oxide 
synthase (Han et al, 1995). One possible mechanism for this depends on insulin's 
stimulation of endothelial Na+-K+ ATPase: as there are no voltage-gated Ca** 
channels in endothelial cells, hyperpolarisation leads to an increase in intracellular 
[Ca++] (Luckhoff & Busse, 1990) which may activate the Ca^-dependent enzyme 
eNOS.
An alternative opinion is that insulin does not stimulate endothelial nitric oxide 
production per se but rather, in some way, modulates the responsiveness to agents 
such as acetylcholine. Taddei et al (1995) proposed that insulin was not a significant 
vasodilator, but was able to shift the blood flow dose-response curve to
acetylcholine; more recently, the same group reported a correlation (albeit weak) in
/
a group of hypertensive patients between insulin-mediated vasodilation and the slope 
of the acetylcholine dose-response curve (Natali et al, 1997). However, studies on 
human gluteal vessels in vitro revealed that after 20 minutes of incubation with
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insulin, the acetylcholine dose-response curves remained unchanged (McNally et al,
1995), and this casts doubt on the idea that insulin effects are mediated through this 
indirect mechanism
Finally, there is evidence that insulin stimulates endothelial vasoactive agents other 
than nitric oxide. During systemic hyperinsulinaemia, insulin caused increased 
circulating levels of 6-keto PGF-la and decreased levels of endothelin - 
interestingly, this effect was observed only in women (Polderman et al, 1996), and 
the significance is uncertain.
In chapter 3, a study is presented which sets out to explore the physiological 
mechanisms of insulin-mediated vasodilation and to establish the role of endothelial 
nitric oxide production in comparison with other putative mechanisms for insulin’s 
vascular action.
1.3.2 Direct effects o f insulin on vascular smooth muscle cells 
Insulin has long been known to stimulate a variety of ion pumps (such as Ca2+- 
ATPase, Na+-K+ ATPase and the Na+-H+ exchanger) on VSMCs thus causing 
hyperpolarisation, closure of voltage-gated calcium channels and vasodilation 
(Sowers, 1996). Recent work supports the notion of insulin acting as a vasodilator 
via effects on membrane potential: insulin and insulin-like growth factor-1 (IGF-1) 
have both been shown to stimulate Na+-K+ ATPase activity independently of nitric 
oxide synthase activation (Gupta et al, 1996; Standley et al, 1997). In addition, 
inhibition of Na+-K+ ATPase activity by ouabain in the human forearm has been
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shown to abolish insulin-mediated vasodilation (Tack et al, 1996). In addition, an 
increase in intracellular Ca2+ levels in VSMCs and platelets has been demonstrated in 
conjunction with insulin resistance (Baldi et al, 1996), the proposed mechanism 
being abnormal modulation of the Ca2+-ATPase pump (Zemel et al, 1992). 
Furthermore, addition of insulin to cultured VSMCs causes a transitoiy rise in 
intracellular Ca2+ levels in VSMCs with subsequent attenuation of Ca2+ entry. Based 
on these results it has been proposed that insulin may stimulate constitutive nitric 
oxide synthase in VSMCs (Touyz et al, 1994), thereby reducing contractility.
1.4 Are insulin’s metabolic and vascular actions functionally related ?
1.4.1 Concept o f metabolic and vascular 'cross-talk'
In recent years the concept of metabolic and vascular ‘cross-talk’ has emerged 
(Clark et al, 1995). In relation to insulin and cardiovascular physiology this concept 
is teleologically attractive and has been supported by data from several recent 
studies. Theoretically, ‘cross-talk’ couples tissue blood flow (nutrient supply) with 
its specific metabolic needs. In his review, Clark et al (1995) advance the notion of 
‘nutritive’ and ‘non-nutritive’ capillary networks in skeletal muscle, blood flow to 
which is controlled by specific functional vascular shunts sensitive to the tissue’s 
metabolic requirements. It is, of course, already known that changes in the 
immediate local environment during exercise can influence blood supply, for 
example pH, and levels of K+ or CO2, and it is conceivable that in the anabolic state, 
for example during insulin-stimulated glucose uptake, blood flow is altered to 
facilitate glucose uptake to the most appropriate areas. This could occur via a
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specific vascular effect of insulin at an arteriolar level, or secondary to a product of 
intracellular glucose metabolism.
1.4.2 Evidence supporting a functional association between insulin sensitivity and 
insulin-mediated vasodilation
It has been demonstrated, using doses of insulin ranging from physiological to 
pharmacological, that there is a dose-dependent effect of insulin on skeletal muscle 
glucose uptake. This may be due to a combination of increased fractional glucose 
extraction and increased limb blood flow (Laakso et al, 1990). In a series of studies 
from Baron’s group, clamp-derived insulin sensitivity (whole-body glucose uptake) 
was significantly correlated with insulin-mediated vasodilation (Baron et al, 1995) 
but not with arteriovenous fractional extraction of glucose (Baron, 1994), implying 
that insulin-mediated glucose uptake is more closely associated with insulin’s ability 
to stimulate blood flow. Furthermore, it has been demonstrated that vascular 
sensitivity to insulin, as assessed by relaxation in preconstricted dorsal hand veins, is 
closely associated with whole-body insulin sensitivity, suggesting a functional link 
between these two processes (Feldman et al, 1995).
Results from a number of in vitro studies provide evidence that glucose uptake may 
be important in promoting VSMC relaxation (Graier et al 1993; Kahn et al, 1995; 
Sobrevia et al, 1996). Two important in vivo studies have already been cited above: 
insulin-mediated vasodilation appears to be progressively augmented by increasing 
levels of glycaemia in man (Baron, 1993) and we have recently demonstrated that 
insulin’s local vasodilator action is significantly augmented by co-infusion with
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physiological D-glucose; this does not occur with the stereo-isomer L-glucose, 
which is metabolically inactive (Ueda et al, 1998a).
In further support of metabolic and vascular coupling of insulin action are recent 
data in hypertensive patients demonstrating a correlation between insulin-mediated 
blood flow and whole-body insulin sensitivity (Natali et al, 1997; Baron & Steinberg, 
1997). However, Yki-Jarvinen and colleagues were unable to demonstrate any 
relationship between insulin sensitivity and forearm vasodilation in response to 
systemic hyperinsulinaemia in healthy subjects (Utriainen et al, 1996a; Utriainen et 
al, 1996b). In support of this conclusion, the same group used positron emission 
tomography and [18F]fluoro-2-deoxy-D-glucose uptake to demonstrate a 
dissociation of insulin-stimulated blood flow and glucose uptake in thigh skeletal 
muscle; however, despite this finding, they demonstrated a significant relationship 
between the insulin-induced increase in leg blood flow and whole-body insulin 
sensitivity (Raitakari et al, 1996). In a recent study, in which similar methods were 
used, the same group showed that insulin-stimulated muscle blood flow co-locahzed 
with regional glucose uptake, suggesting that insulin redirects flow to areas where it 
stimulates glucose uptake and, therefore, that the vascular and metabolic actions of 
insulin may, indeed, be functionally coupled (Utriainen et al, 1997).
1.4.3 Evidence questioning the physiological relevance o f any functional link 
between insulin’s metabolic and vascular actions
There is also a body of data which does not support the notion that tissue glucose 
uptake and skeletal muscle blood flow are functionally related. In one study, when
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human volunteers were fed a mixed physiological meal, arteriovenous glucose 
extraction was found to be the main determinant of limb glucose uptake; this rose by 
a factor of five, while blood flow increased by only 16% (Mijares & Jensen, 1995). 
In another study, no significant increases in forearm blood flow were observed 
during an oral glucose tolerance test (Kelly et al, 1988). The results of these two 
studies question the physiological significance of any functional link between glucose 
uptake and blood flow.
Furthermore, dissociation of insulin-mediated glucose uptake from blood flow was 
observed in a study in which both limb blood flow and muscle sympathetic nerve 
activity were stimulated to similar degrees at different systemic insulin 
concentrations, ranging from 100 to 400pmol/l (Anderson et al, 1991). Moreover, 
fructose, which causes an increase in cellular metabolism without stimulation of 
insulin secretion, did not result in any increase in blood flow or muscle sympathetic 
nerve activity in human volunteers (Vollenweider et al, 1993). This result, of course, 
does not rule out the possibility that the coupling signal for promotion of blood flow 
is unique to intracellular glucose metabolism.
In summary there is evidence both for and against the existence of a functional 
relationship between insulin-mediated glucose uptake (insulin sensitivity) and insulin- 
mediated vasodilation, although the balance of recent evidence supports the idea that 
insulin-stimulated blood flow is positively related to peripheral glucose uptake by 
skeletal muscle. How physiologically relevant this relationship is remains a matter 
for debate. What also remains unclear is how any functional coupling between
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insulin's metabolic and vascular actions might be of pathophysiological relevance in 
the link between metabolic and cardiovascular disease. These questions are further 
explored in chapters 4 and 7 where detailed clinical physiology studies are carried 
out on healthy volunteers as well as patients with either essential hypertension or 
type 2 diabetes.
Given that insulin-mediated vasodilation is, at least in part, endothelium-dependent, 
it is possible that endothelial function plays a pivotal role in metabolic and vascular 
'cross-talk'. The following sections will go on to discuss the importance of 
endothelial function (or dysfunction) with respect to metabolic and vascular control 
mechanisms.
1.5 Does endothelial dysfunction cause relative insulin resistance ?
1.5.1 Reduced substrate delivery to skeletal muscle secondary to vascular 
etidothelial dysfunction - evidence for and against
Vascular endothelial dysfunction could, in theory, be related to insulin resistance in a 
number of ways (Anderson & Mark, 1993; Baron, 1994; Petrie et al, 1996a; Pinkney 
et al, 1997). Blunting of the endothelium-dependent component of insulin-mediated 
vasodilation could reduce substrate delivery to target tissue resulting in a reduction 
in insulin-stimulated glucose uptake. In support of this hypothesis it has been 
demonstrated in obese subjects (Laakso et al, 1990) and in patients with type 2 
diabetes (Laakso et al, 1992) and IDDM (Baron et al, 1991) that there is blunting of 
insulin-mediated vasodilation in parallel with reductions in whole-body insulin 
sensitivity. However, the physiological relevance of these studies has been
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questioned. In many of these clamp studies, pharmacological doses of insulin were 
used, and in those involving subjects with type 2 diabetes, glucose values were 
clamped at the relatively hypoglycaemic value of 5mmol/l. In another study, in which 
glucose levels were clamped at fasting levels in subjects with type 2 diabetes, no 
blunting of the blood flow response to insulin was observed (Dela et al, 1995). It has 
been suggested that substrate delivery is only likely to be rate-limiting for glucose 
disposal at supra-physiological insulin levels maintained for many hours and 
therefore does not explain the physiological association between endothelial function 
and insulin sensitivity (Yki-Jarvinen, 1995).
One approach to resolve this issue is to manipulate limb blood flow during 
hyperinsulinaemia and assess whether insulin-mediated glucose uptake is affected. 
There is some evidence from these studies that skeletal muscle blood flow may be a 
determinant of insulin-mediated glucose uptake; infusion of L-NMMA into the 
femoral artery during a clamp reduces insulin-mediated stimulation of blood flow 
(via inhibition of endothelial nitric oxide production) resulting in a 25% decrease in 
limb glucose uptake (despite a 50% increase in arteriovenous fractional glucose 
extraction) (Baron et al, 1995). This observation is consistent with the notion that 
20-30% of insulin-mediated glucose uptake is blood flow dependent. In the same 
study, whole-body insulin sensitivity correlated significantly with the decrement in 
limb blood flow as a result of L-NMMA infusion; the authors’ interpretation of this 
was that blood flow is more important in determining glucose uptake in insulin 
sensitive individuals (Baron et al, 1995).
However, similarly designed experiments have produced contrary results. In human 
studies, forearm blood flow has been augmented by 100% using intra-arterial 
adenosine (Natali et al, 1994) and bradykinin (Nuutila et al, 1996) without a 
detectable effect on forearm glucose uptake. These results provide evidence against 
a significant role for muscle blood flow in determining glucose disposal, but it should 
be borne in mind that infiisates used to alter blood flow may also have metabolic 
properties which affect glucose uptake. This is likely to be the case with bradykinin 
(Dietze et al, 1996) and may partly explain why bradykinin antagonists administered 
to rats cause a significant reduction in insulin-mediated glucose disposal (Kohlman 
et al, 1995).
A recent controlled study, in which PET scanning was used to  measure forearm 
blood flow, showed no defect in insulin-stimulated muscle blood flow in a group o f 
patients with type 2 diabetes, implying that insulin’s metabolic function is impaired 
but its vascular action is preserved in this condition (Utriainen et al, 1997). In a 
group o f patients with essential hypertension, calf blood flow measured during 
systemic hyperinsulinaemia was not directly related to insulin sensitivity and there 
was no difference compared with a group o f healthy matched controls (Hunter et al,
1997). On the other hand, Wascher and colleagues (1997) found that insulin- 
mediated forearm vasodilation was blunted in subjects with either obesity or type 2 
diabetes. Co-infusion o f L-arginine not only normalised the vasodilator responses to 
insulin, but also improved insulin sensitivity. However, these data should be 
interpreted with caution since intravenous L-arginine may elicit systemic insulin 
release (Guigliano et al, 1997).
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The study described in chapter 5 was designed to test whether whole-body insulin 
sensitivity is affected by artificially inducing a state of temporary endothelial 
dysfunction - any reduction in insulin-mediated glucose disposal would support the 
notion that tissue blood flow and substrate delivery were rate-limiting to glucose 
uptake and, therefore, that endothelial dysfunction might be a significant determinant 
of insulin resistance.
1.5.2 Other potential mechanisms for damaged endothelium to affect glucose 
uptake
There are other theoretical mechanisms by which endothelial dysfunction could 
cause insulin resistance. For example, reduced activity of the endothelial enzyme 
lipoprotein lipase could result in dyslipidaemia with subsequent effects on insulin- 
mediated glucose metabolism (Ahn et al, 1993). Insulin must traverse the endothelial 
barrier to exert its metabolic effects and therefore dysfunctional transport 
mechanisms could limit insulin’s metabolic effectiveness (Yang et al, 1989).
1.6 Does a reduction in insulin-mediated glucose uptake affect endothelial 
function ?
Rather than being a consequence of endothelial dysfunction, it is more tempting to 
conclude on current evidence that peripheral insulin resistance is a cause of this 
defect (Stehouwer et al, 1997). A number of putative mechanisms for this have 
already been alluded to above and these will now be expanded.
1.6.1 Hepatic insulin resistance, increased oxidised lipid sub-fractions and 
endothelial dysfunction
Hepatic insulin resistance is associated with a shift in substrate metabolism resulting 
in increased serum concentrations of free fatty acids, triglycerides and oxidised 
LDL-cholesterol (Reaven et al, 1993; see section 1.9.1 for further explanation of 
possible mechanisms). If oxidation of circulating LDL (particularly small dense 
LDL) occurs at an endothelial level, the oxidised particles generated have the 
potential to cause endothelial dysfunction (and hence atherogenesis) either by direct 
cellular damage or by quenching nitric oxide production (DiCorleto & Soyombo, 
1993; Davda et al, 1995). Furthermore, there is recent evidence that increased post­
prandial circulating concentrations of triglyceride-rich particles and remnant particles 
may be deleterious to the endothelium (Vogel et al, 1997; Plotnick et al, 1997). One 
interesting speculation is that insulin, secreted post-prandially, plays a role in 
boosting endothelial nitric oxide production to buffer this temporaiy increase in 
lipid-induced oxidant stress.
1.6.2 Glucose uptake, ATP generation and endothelial function
There are a number of putative mechanisms by which cellular glucose uptake could 
be linked with vascular tone. One hypothesis is that insulin-stimulated glucose 
uptake may determine blood flow in response to the hormone by causing an increase 
in ATP production, as a consequence of aerobic glycolysis. This will provide energy 
for membrane ion pumps (for example Na+-K+ ATPase) resulting in 
hyperpolarisation and changes in Ca2+ fluxes in both endothelium and vascular 
smooth muscle cells leading to vascular relaxation by mechanisms discussed above.
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Furthermore, if nitric oxide synthase activity is enhanced by stimulation of ATP- 
dependent ion pumps such as Na+-K+ ATPase, insulin-stimulated glucose uptake 
may result in increased nitric oxide production as a consequence of endothelial cell 
glucose metabolism; conversely, reduced glucose uptake would be predicted to lead 
to diminished nitric oxide production. Additionally, since another consequence of 
increased intracellular glucose levels is shunting through the pentose monophosphate 
pathway, which produces NADPH, an essential co-factor for nitric oxide synthase 
(Wu G et al, 1994), any reduction in glucose uptake might indirectly affect NOS 
activity. Finally, of special note is a study demonstrating nitric oxide production 
secondary to insulin stimulation in endothelial cell culture and subsequent blocking 
of this in the presence of wortmannin, which inhibits PI 3-kinase, an essential 
enzyme involved in intracellular insulin-stimulated glucose transport and metabolism 
(Zeng & Quon, 1996) (figure 1.13). This suggests that there is a common post- 
receptor pathway for insulin’s metabolic and vascular actions which may partly 
explain the functional link between them.
1.6.3 Chronic hyperglycaemia, insulin resistance and endothelial dysfunction - a 
special case in type 2 diabetes
Chronic hyperglycaemia has deleterious effects on both insulin sensitivity and 
endothelial function. In type 2 diabetes, glucotoxicity exacerbates peripheral insulin 
resistance by down-regulating post-insulin-receptor signalling and by impairing 13- 
cell function (Richter et al, 1988; Rosetti et al, 1990; Yki-Jarvinen, 1995). Glucose 
activates endothelial nitric oxide synthase, by triggering a rise in intracellular Ca2+ 
levels (Graier et al, 1993) and by stimulating the system y+ transporter for L-arginine
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Figure 1.13
Direct measurement of nitric oxide production in 
human umbilical vein cell culture in response to 
insulin. Wortmannin inhibits PI3-kinase; L- 
NAME inhibits NOS; genestein inhibits tyrosine 
kinase. From Zeng & Quon, 1996.
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(Sobrevia et al, 1996); this may explain the observation of increased microvascular 
flow in the early stages of diabetes. However, chronic hyperglycaemia appears to 
cause down-regulation of insulin’s stimulatory effect on system y+ (Sobrevia et al,
1996). Lastly, advanced glycosylation end-products (AGEs), which form in an 
environment of chronic hyperglycaemia, cause endothelial damage, probably by 
stimulating the production of oxygen free radicals (Brownlee et al, 1988; Poston & 
Taylor, 1995).
1.6.4 Insulin resistance and endothelial dysfunction - a potential positive feedback 
cycle
If both mechanisms to relate insulin sensitivity and endothelial function discussed 
above are valid, there is a theoretical potential for a damaging positive feedback 
cycle. Defective metabolic pathways associated with insulin resistance may result in 
a reduction in basal endothelial NO production and relative endothelial dysfunction. 
This, in turn, may reduce the efficacy of vasodilation to nutrient vascular beds 
resulting in further impairment of insulin-mediated glucose uptake and compensatory 
hyperinsulinaemia. Thus, a vicious cycle is created (figure 1.14).
1.7 Are insulin sensitivity and endothelial function both influenced by a 
‘ third factor’ ?
The danger of interpreting data demonstrating consistent association of two 
variables is that there might be an underlying confounding factor (or factors) 
influencing each variable. One way to take account of this is to employ multiple
59
- - 
en
do
th
eli
al 
dy
sfu
nc
tio
n
0
(ft
0
>
s
o . .
S '.2
^  £o <i>a t  l«o.
o
*
eo
c3 
.O*o4> 
t+-i
<u _>
55 & R 3O a ^
13 £2
c
4> . f i
S' *eU o^ ‘2
<2 « ^  c£ fP .23 ca  c >*
ctj T 3  -C — y  ce 0) —  c  <u c JS
+ -J
c* O2 T3 +-> c
<t> 4)
S  ~a o c a, aJ >> 0) JC oc
2
C/1
eeCOc .2'3 5/5 c  q
M  *-«
3  . £
2 * £ «
2 ■£ CO fa cj *2
^  -O•H On «2 £ c3  a> - 3
.SP-5 C00 3^
a>o
CO
60
sk
el
et
al
 m
us
cle
 
bl
oo
d 
flo
w 
is 
ra
te
-li
m
iti
ng
 
for
 c
el
lu
la
r 
gl
uc
os
e 
up
tak
e 
an
d 
(2)
 c
el
lu
la
r 
gl
uc
os
e 
up
tak
e 
an
d 
m
eta
bo
lis
m
 
de
te
rm
in
es
 m
us
cle
 
blo
od
 
flo
w 
via
 a
n 
en
do
th
el
iu
m
-d
ep
en
de
nt
 m
ec
ha
ni
sm
.
regression analysis, a technique which has been used in several o f the studies 
presented in this thesis. This type o f analysis is limited by the number o f factors 
measured - it is always possible that a potential ‘third factor’ explains an observed 
relationship but simply has not been measured. Three o f the most attractive 
candidates for ‘third factors’ in the insulin action / endothelial function association 
are discussed in greater detail:
1.7.1 The role o f skeletal muscle structure and function in metabolic and 
cardiovascular disease
Associations have been noted between skeletal muscle fibre types and both 
metabolic and cardiovascular disorders. Subjects with obesity (Lilloja et al, 1987; 
W ade et al, 1990; Simoneau & Bouchard, 1993), central obesity (Lilloja et al, 1987; 
Krotkiewski & Bjorntorp, 1986), hypertension (Juhlin-Dannfelt et al, 1979; Frisk- 
Holmberg et al, 1983) and type 2 diabetes (Lilloja et al, 1987) have a reduced 
capillary density, a predominance o f type IIB glycolytic, fast-twitch fibres and a 
relative lack o f type I oxidative, slow-twitch fibres. The oxidative capacity o f  
skeletal muscle fibres is correlated with capillary density and fibre type is a 
determinant o f blood flow and peripheral resistance; in muscles composed o f  
predominantly type I fibres, there is evidence o f  increased basal blood flow (Frisk- 
Holmberg et al, 1981).
The relationships among fibre type, capillary density, haemodynamics and 
metabolism are illustrated by the effects o f exercise. Chronic aerobic exercise 
training results in a shift from type IIB to type IIA fibres (Anderson & Henriksson,
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1977a) and also an increase in muscle capillary density (Anderson & Henriksson, 
1977b; Krotkiewski et al, 1983). It is possible that the increase in oxidative capacity 
and promotion of skeletal muscle blood flow associated with exercise could mediate 
the observed improvement in insulin sensitivity and reduction in total peripheral 
resistance. Thus, physical inactivity is associated with hypertension (Paffenbarger et 
al, 1983), while chronic aerobic exercise training results in significant improvements 
in blood pressure control (Tipton, 1991). Aerobic training reduces insulin resistance 
(Holloszy et al, 1987) but anaerobic training does not have the same beneficial effect 
(Yki-Jarvinen & Koivisto, 1983).
In addition, there are interesting comparisons between effects of the ageing process 
on skeletal muscle structure and function and disease states. Advancing age results 
in inactivity and concomitant reduced muscle mass, a relative shift to type ECB fibre 
types and a decrease in maximal aerobic capacity. It is generally accepted that blood 
pressure and total peripheral resistance rise with age; this is paralleled by a fall in 
insulin-mediated glucose uptake (Shimoketa et al, 1991). These metabolic and 
cardiovascular conditions tend to have a familial pattern and, likewise, the structure 
of skeletal muscle is largely inherited (Komi & Karlsson, 1979); furthermore, 
relatives of patients with both type 2 diabetes (Nyholm et al, 1996) and essential 
hypertension (Beatty et al, 1993) had 15-20% lower values than controls for 
predicted maximum oxygen consumption.
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The possibility that skeletal muscle structure and function accounts for the observed 
relationship between insulin’s metabolic and vascular actions is explored further in 
chapter 6.
1.7.2 Distribution o f adiposity, hepatic insulin resistance and endothelial 
dysfunction
One issue which is emerging from the recent literature is the possible confounding 
role of obesity/dyslipidaemia when variables such as endothelial function and insulin 
sensitivity are measured in patients with conditions such as essential hypertension 
and type 2 diabetes. For example, it was demonstrated in one study that body mass 
index accounted for 50-60% of the variance of leg blood flow response to 
methacholine during a hyperinsulinaemic clamp. The more obese the subject, the 
more this response was blunted (Steinberg et al, 1996); of particular interest was the 
observation that a group of type 2 diabetic patients with similar mean BMI exhibited 
no further blunting of endothelium-dependent vasodilation. Furthermore, the same 
group have recently shown that blunting of methacholine-stimulated leg blood flow 
was induced by systemic free fatty acid infusion with co-infusion of somatostatin to 
suppress insulin secretion. When the protocol was repeated in the presence of 
insulin, this blunting of endothelial function was reversed (Steinberg et al, 1997). 
This result is supported by results of a study in which the free fatty acid, oleic acid, 
was shown to inhibit nitric oxide synthase in endothelial cell culture (Davda et al, 
1995). Thus it seems that dyslipidaemia per se may be a causal factor for both 
endothelial dysfunction and insulin resistance, and this phenomenon may explain 
some of the conflicting results when patients with metabolic and cardiovascular
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disorders are studied without careful control for variations in body mass index. 
When patient groups are studied in chapter 7, great care has been taken to match for 
age and BMI.
1.7.3 The role o f endogenous corticosteroids in metabolic and cardiovascular 
disease
Endogenous and exogenous glucocorticoid excess is associated with hypertension, 
insulin resistance and central adiposity. Glucocorticoids are known to decrease 
insulin-mediated glucose uptake (Holmang & Bjomtorp, 1992), and mediate the 
increased insulin requirement associated with stress and infection in diabetic patients; 
they also inhibit endothelium-dependent vasodilation in animal models (Walker et al,
1995). Proliferation of capillary endothelium induced by insulin in rat skeletal muscle 
is abolished by administering concomitant corticosterone (Holmang et al, 1996), and 
insulin-mediated vasodilation in man can be abolished by administration of oral 
dexamethasone 48 hours prior to a clamp study (Scherrer et al, 1993). Possible 
mechanisms for this include central modulation of sympathetic outflow (via effects 
on neuropeptide Y or corticotrophin releasing hormone) and peripheral effects on 
insulin-mediated glucose uptake, with consequent effects on endothelial NOS 
activity. Skeletal muscle fibre types also appear to be modified by corticosteroids; in 
Cushing’s syndrome there is a predominance of type II fibres (Rebuflfe-Scrive et al, 
1988). Furthermore, sensitivity to glucocorticoids in man, as assessed by dermal 
vasoconstrictor responses, correlate significantly with reduced glucose tolerance, 
insulin resistance and increased levels of plasma triglycerides (Walker et al, 1996). 
Therefore, enhanced availability of cortisol at its receptor (either through increased
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production, local synthesis or impaired metabolism) may account for the association 
of insulin action, endothelial function and skeletal muscle morphology; in fact it has 
been suggested that ‘metabolic syndrome X’ is, in effect, sub-clinical Cushing’s 
syndrome (Bujalska et al, 1997).
1.8 Insulin resistance and endothelial function in essential hypertension
1.8.1 Associations o f insulin resistance /  hyperinsulinaemia with hypertension 
The association of essential hypertension with hyperinsulinaemia was first noted over 
30 years ago (Welbom et al, 1966). Since then, a number of cross-sectional 
epidemiological studies have confirmed the association between blood pressure and 
insulin levels (Haffher et al, 1992a; Modan et al, 1985; Zavaroni et al, 1989; Jiang et 
al, 1993; Feskens et al, 1995), although the results of a number of studies dispute the 
significance of this association (eg Asch et al, 1991; Dowse et al, 1993; Muller et al, 
1993). Results from this type of epidemiological study appear to depend on how 
rigorously the investigators control for confounding factors, especially body mass 
index, distribution of adiposity and ethnicity. While it is clearly important to take 
account of confounding factors, it is equally important not to control for a closely- 
related co-variable since a false-negative result may occur - this may be the case for 
body mass index (section 1.8.2). Prospective studies have shown that individuals 
with hyperinsulinaemia have a higher risk of going on to develop hypertension 
(Haffher et al 1992b; Bao et al, 1996). In addition, subjects with impaired glucose 
tolerance in 1968 had a significantly increased risk of being hypertensive 20 years 
later (Salomaa et al, 1991). However, not all groups are in agreement (Vaccaro et 
al, 1996).
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What has become clear is that hyperinsulinaemia per se does not directly elevate 
blood pressure; for example, artificial chronic elevation o f insulin levels in dogs does 
not affect blood pressure (Brands et al, 1991) and patients with insulinoma do not 
tend to have hypertension (Fujita et al, 1992). The probable explanation for these 
findings is that hyperinsulinaemia is only associated with hypertension when it occurs 
as a compensatory response to defects in insulin-mediated glucose uptake (or insulin 
resistance) mainly in skeletal muscle. W hole-body insulin-mediated glucose uptake, 
measured using the euglycaemic hyperinsulinaemic clamp technique is reduced in 
patients with essential hypertension (Ferrannini et al, 1987; Lind et al, 1995). Whilst 
it remains unclear if there is a causal association between these parameters, it is o f 
interest to note that insulin resistance is present in normotensive offspring o f  
hypertensive patients (Beatty et al, 1993; Endre et al, 1994), suggesting that the 
metabolic defect precedes blood pressure elevation.
1.8.2 Obesity as a possible confounding factor
It has been suggested that obesity is a confounding factor which can account for an 
apparent relationship between insulin action and blood pressure, since it is well 
recognised that insulin resistance is closely associated with elevations in body mass 
index (BMI) (Jarrett, 1992). To address this issue, clamp data on 333 subjects were 
pooled from a number o f European centres so that meaningful multivariate analyses 
could be carried out. In a model simultaneously accounting for sex, age, BMI and 
fasting insulin level, both systolic and diastolic blood pressures remained significantly 
inversely related to insulin sensitivity (Ferrannini et al, 1997). In addition, age was
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positively related to blood pressure levels independently of insulin sensitivity, 
whereas BMI was not; in other words, the association of BMI with blood pressure is 
likely to be mediated via changes in insulin sensitivity (Ferrannini et al, 1997).
1.8.3 Mechanisms linking insulin action with blood pressure 
What mechanisms underlie the relationship between insulin action and blood 
pressure? As already discussed above, insulin’s physiological effect on the 
cardiovascular system is two-fold. Firstly, it acts as a peripheral vasodilator (Laakso 
et al, 1992; Anderson et al, 1991; Baron, 1993; Natali et al, 1997; Utriainen et al, 
1997; Ueda et al, 1998a) mainly in skeletal muscle vascular beds. Secondly, it has 
pressor effects mainly via stimulation of the sympathetic nervous system (Anderson 
et al, 1991) and enhancement of renal sodium absorption (Ferrannini et al, 1993). 
The net effect is a balance of pressor and depressor effects and blood pressure is 
maintained. Therefore, if either the pressor effect is enhanced or the depressor effect 
is blunted, blood pressure increases. In obese subjects there is evidence for both an 
enhanced sympathetic drive in response to hyperinsulinaemia (Scherrer et al, 1994b) 
as well as blunting of insulin-mediated vasodilation (Laakso et al, 1990) thus 
providing a possible mechanism for hypertension. In patients with essential 
hypertension, there is recent evidence to suggest that insulin-stimulated muscle 
blood flow is impaired (Laine et al, 1998), a result which concurs with previous 
findings that insulin-induced vasodilation is correlated with blood pressure (Baron, 
1993, Feldman et al, 1993). However, supraphysiological doses of insulin were used 
in these studies; when physiological doses were used for shorter periods no 
correlation was found between insulin-mediated vasodilation and blood pressure
67
(Anderson et al, 1991; Hunter et al, 1997). Therefore, it remains unclear whether 
blunting o f insulin-mediated vasodilation contributes to  hypertension via increased 
peripheral vascular resistance.
1.9 Insulin resistance and atherosclerosis (figure 1.15)
1.9.1 Insulin action, blood pressure and cardiovascular risk 
Reaven (1988) speculated that defects in insulin action may be involved in mediating 
the atherosclerotic complications o f hypertension. A recent study evaluated the 
importance o f the association o f insulin resistance with blood pressure in terms o f 
cardiovascular risk. In multivariate analysis (Ferrannini et al, 1997), when diastolic 
BP values were simultaneously related to age, insulin sensitivity and fasting insulin 
levels only 18% o f  the variability o f  diastolic BP was explained; furthermore, in a 
group where the mean+SD value for insulin sensitivity was 34+11.8 pmol/min/kg, 
the predicted impact on blood pressure o f  a decrease in insulin sensitivity o f 10 
pmol/min/kg was +1.4mmHg (similar to that associated with a 10 year difference in 
age). At first glance one might conclude that insulin resistance is a fairly insignificant 
contributor to the problem o f hypertension and cardiovascular risk. However, at a 
population level, it has been calculated that a small (2mmHg) increase in arterial BP 
will result in a 17% increase in incidence o f cerebrovascular disease and a 10% 
increase in incidence o f  ischaemic heart disease (Collins et al, 1990).
The question o f whether hyperinsulinaemia / insulin resistance affects cardiovascular 
outcome continues to be a source o f  controversy. Several longitudinal studies have 
implicated hyperinsulinaemia as an independent risk factor for coronary heart disease
68
69
Fi
gu
re
 
1.
15
Pu
ta
tiv
e 
m
ec
ha
ni
sm
s 
by 
wh
ic
h 
in
su
lin
 
re
si
st
an
ce
, 
hy
pe
ri
ns
ul
in
ae
m
ia
 
an
d 
hy
pe
rg
ly
ca
em
ic
 
ma
y 
co
nt
ri
bu
te
 
to 
the
 
at
he
ro
th
ro
m
bo
tic
 
pr
oc
es
s 
ei
th
er
 d
ir
ec
tly
 
or 
via
 
a 
re
du
ct
io
n 
in 
ni
tr
ic
 
ox
id
e’
s 
pr
ot
ec
tiv
e 
ef
fe
ct
s 
on 
the
 
va
sc
ul
ar
 e
nd
ot
he
liu
m
.
(reviewed in Morris et al, 1994; Despres et al, 1996). However, there are a number 
o f negative studies (eg Ferrara et al, 1994; Orchard et al, 1994; Yarnell et al, 1994). 
Again, interpretation o f  results depends on the process o f accounting for co-variates 
in multivariate analyses. For example, Yarnell et al (1994) corrected for serum 
triglyceride concentrations and body mass, and concluded that there was no 
significant independent association between fasting insulin levels and ischaemic heart 
disease. However, if defects in insulin action are causally linked with obesity and 
hepatic lipid handling, correcting for these co-variates may mask a valid association 
between insulin action and atherosclerotic risk. Defects in lipoprotein metabolism are 
known to be involved in the pathogenesis o f  atherosclerosis (Ross 1993). Insulin 
plays a major role in lowering plasma triglyceride levels mainly by suppression o f 
VLDL1 and apolipoprotein B production (Malmstrom et al, 1997a). Furthermore, it 
has been demonstrated that this suppression is defective in association with insulin 
resistance, thus providing a mechanism for hypertriglyceridaemia secondary to 
defective hepatic insulin action (Malmstrom et al, 1997b). Plasma triglyceride levels 
are related, in turn, to levels o f small dense LDL which increase oxidative stress at 
an endothelial level, thus predisposing to atherosclerosis (Paolisso et al, 1996).
Insulin, by virtue o f its action as a growth factor, may play a direct role in 
atherogenesis at the level o f vascular smooth muscle (Stout, 1989). Furthermore, 
there is evidence that insulin levels may contribute to increased re-stenosis rates after 
coronary angioplasty (Sobel, 1996), suggesting a direct role for insulin in the 
process o f atherogenesis.
1.9.2 Insulin and platelet aggregability’
When atherosclerotic plaques rupture, intimal damage ensues. Platelets are 
stimulated to form aggregates which adhere to the damaged area. These platelet 
aggregates may increase in size until they block the flow o f blood, resulting in 
thrombosis. Anit-platelet drugs inhibit platelet aggregation and have proven efficacy 
in reducing throm botic events (Antiplatelet Trialists Collaboration, 1994).
In newly-diagnosed type 2 diabetes there appears to be significant platelet 
hyperaggregation in whole blood (Mandal et al, 1993; Menys et al, 1995). After 
metabolic control o f  blood glucose there is significant reduction in platelet 
aggregability, suggesting that both hyperinsulinaemia and hyperglycaemia may be 
influencing aggregation mechanisms (Mandal et al, 1993). The role of 
hyperinsulinaemia and insulin resistance on platelet glucose transport and on the 
metabolic function o f  platelets is poorly understood. In one study, platelet 
aggregation was measured in healthy volunteers before and after intravenous insulin: 
aggregation was significantly reduced after insulin suggesting that insulin may have 
important anti-aggregatory properties (Kahn et al, 1993). One group has used 
platelet-rich plasma (PRP) to study the relationship between insulin and platelet 
aggregability: firstly, they demonstrated an anti-aggregatory effect o f insulin to 
platelet stimulation by collagen or ADP in PRP from healthy volunteers (Trovati et 
al, 1994). They also measured cGMP production and concluded that insulin’s anti­
aggregatory effect was via a cGMP-dependent mechanism. They went on to show 
that this effect was significantly impaired in the insulin resistant states o f  obesity and 
type 2 diabetes (Trovati et al, 1995) and, recently, they demonstrated that lean
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patients with type 2 diabetes exhibited normal insulin anti-aggregation (Anfossi et al,
1998), suggesting that insulin resistance is the most important underlying mechanism 
for this effect rather than hyperglycaemia. The L-arginine/nitric oxide pathway has 
been known for some time to be an important mechanism regulating aggregation in 
platelets (Radomski et al, 1990), and it appears likely that insulin’s anti-aggregatory 
effect is mediated via production o f nitric oxide and consequent elevated levels o f 
cGMP (Trovati et al, 1996; Trovati et al, 1997). W hether stimulation o f nitric oxide 
production is a direct effect o f insulin or as a result o f insulin-stimulated transport o f 
L-arginine or D-glucose remains to be elucidated. Unfortunately, there are a number 
o f  methods o f studying platelet aggregation (PRP, ‘washed’ platelets, and whole 
blood) and a number o f  different aggregatory stimuli (ADP, collagen, thrombin, 
sodium arachidonate and platelet-activating factor). Results from one method are 
often not reproduced using alternative methods and there are questions concerning 
the physiological relevance o f some o f the methods used. However, evidence from 
these limited and preliminary studies would indicate that platelet aggregability is 
increased in conditions o f insulin resistance and this may be a key factor in terms of 
predisposition to thrombotic vascular disease.
In chapter 8, pilot data are presented on insulin action and platelet aggregability. The 
technical experience gained from collecting these pilot data has allowed a number of 
well-designed platelet aggregation studies to be initiated.
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1.9.3 Insulin resistance and cardiovascular disease - the clinical relevance?
Having identified insulin resistance as a potential independent cardiovascular risk 
factor and having proposed lifestyle intervention and insulin-sensitising drugs as 
potential risk-reduction strategies, one might argue that the issue of insulin 
resistance still remains more of academic interest than realistic clinical relevance. For 
although weight loss and aerobic exercise have been shown to improve insulin 
sensitivity, attempts in clinical practice to instigate major lifestyle changes are usually 
disappointing (NIH Technology Assessment Conference Panel, 1993, Eriksson et al,
1997), and the initial experience of insulin-sensitising drugs has been marred by the 
possibilty of serious side-effects, exemplified by the recent withdrawal of 
troglitazone in the UK due to case reports of hepatic disease.
However, it is becoming clear that insulin-resistant subjects benefit more from 
traditional risk-reduction management for cardiovascular disease and, therefore, it 
may be that the main clinical relevance of insulin resistance is to help target those 
people in whom we should attempt to reduce cardiovascular risk more aggressively. 
For example, analysis of the type 2 diabetic sub-groups in a number of recent blood 
pressure lowering trials has revealed a 2 - 3 fold increase in relative risk reduction 
for cardiovascular events (UKPDS Study Group, 1998; Hansson et al, 1998, Curb et 
al, 1996) irrespective of the class of anti-hypertensive agent used. Furthermore, 
aiming for a target diastolic BP of < 80mmHg compared with < 90mmHg resulted in 
a 50% further reduction in cardiovascular event rate in type 2 diabetic patients 
(Hansson et al, 1998) emphasising the importance of aggressive risk reduction. In
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addition, it has long been known that diabetic patients benefit more than non-
j
diabetic counterparts from thrombolysis following myocardial infarction as well as
k
from cessation of smoking in terms of reduction of cardiovascular morbidity and 
mortality.
Physicians must not ignore the main root cause of insulin resistance and its sequelae. 
While adherence to lifestyle advice is disappointing in adults, efforts must be 
directed, firstly, at prevention of obesity and inactivity (especially in children and 
young adults) and, secondly, at improving counselling methods to help tackle the 
difficult stages of major behaviour change. American public health physicians having 
already been forced to address these issues faced with the continuing ‘triumph of 
obesity’ (Foreyt & Goodrick, 1995).
1.9.4 Treatment o f itisulin resistance and endothelial dysfunction in metabolic and
cardiovascular disease
(a) Non-pharmacological approaches
Evidence from studies where either non-pharmacological or therapeutic
interventions were studied may provide useful pointers to the mechanisms
underlying the links between metabolic and vascular disease. Aerobic exercise is 
known to increase insulin sensitivity (Rodnick et al, 1987; Kahn et al, 1990; Ikeda et 
al, 1996; Erikkson et al, 1997) probably via a variety of cellular mechanisms
(Mikines et al, 1989; Houmard et al, 1991). Weight loss is associated with
favourable changes in blood pressure (Ikeda et al, 1996) and endothelial function 
(Steinberg et al, 1996) possibly via a combination of increased insulin sensitivity,
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reduced sympathetic drive (Scherrer et al, 1994b) and beneficial changes in hepatic 
lipogenesis (section 1.6.1), and aerobic exercise results in blood pressure lowering 
(Halbert et al, 1997), an effect which is probably mediated by changes in 
metabolism, although the exact mechanisms involved remain unclear (Ikeda et al,
1996). Exercise-induced improvements in endothelial function have also recently 
been demonstrated, both in healthy subjects (Kingwell et al, 1997) and in patients 
with chronic heart failure (Homig et al, 1996).
(b) Pharmacological approaches
Various pharmacological approaches to both metabolic and cardiovascular disease 
have been shown to affect insulin sensitivity or endothelial function or both. Data on 
the effects of anti-hypertensive drugs on insulin sensitivity are confusing. On the one 
hand, it has been proposed that ACE inhibitors and a-blockers improve insulin 
sensitivity (Pollare et al, 1989a; Vuorinen-Markkola & Yki-Jarvinen, 1995; Giorda 
et al, 1995) and that thiazide diuretics and ^-blockers reduce insulin sensitivity 
(Murphy et al, 1982; Pollare et al, 1989b). On the other hand, there are a number of 
well-designed controlled studies which report no significant metabolic effects of 
ACE inhibitors, thiazides or cardioselective P-blockers (Heinemann et al, 1995; 
Harper et al, 1994; Harper et al, 1995; Hunter et al, 1998).
Lipid lowering therapy has been shown to improve endothelial function (Stroes et al, 
1995; Anderson et al, 1995), and there is some evidence to suggest that pravastatin 
lowers insulin levels in patients with hypercholesterolaemia and hypertension (Chan 
et al, 1996) although it is of interest that hypercholesterolaemia per se does not
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appear to be associated with insulin resistance (Karhapaa et al, 1993). 
Hypercholesterolaemia-induced endothelial dysfunction can be reversed by 
administering L-arginine, the precursor o f nitric oxide (Tsao et al, 1994; Clarkson et 
al, 1996), presumably because the rate-limiting step is the formation o f nitric oxide 
which is rapidly quenched by superoxide anions. However, in hypertension L- 
arginine does not appear to have a beneficial effect on endothelial function (Panza et 
al, 1993b) while in IDDM it may be o f  some benefit (Poston & Taylor, 1995).
Insulin-sensitising agents, such as the thiazolidinedione derivatives, appear to exert 
their effects on post-receptor binding steps in the transduction o f the insulin 
response (Kotchen, 1996). Limited data in man appear to suggest that these agents 
also cause significant reduction o f blood pressure (Nolan et al, 1994, Ogihara et al, 
1995). In vitro data using pioglitazone suggest that insulin’s vascular effects are 
modified: agonist-induced vasoconstriction is blunted while stimulated endothelium- 
dependent vasodilation is augmented (Kotchen et al, 1996). The most likely 
mechanism for these effects is a reduction in VSMC intracellular Ca2+ (Pershadsingh 
et al, 1993; Zhang et al, 1994). However, it is also possible that troglitazone exerts 
beneficial effects by an anti-oxidant action. Structurally, it is very similar to vitamin 
E, a natural anti-oxidant which has been shown to improve both endothelial function 
and insulin action. For example, vitamin E attenuated the blunting o f  acetylcholine- 
induced vascular relaxation in diabetic rats (Keegan et al, 1995), and in man it 
appears to improve insulin action in both normal subjects and those with type 2 
diabetes (Paolisso et al, 1993). Furthermore, patients with myocardial infarction had 
fewer additional coronary events on pharmacological doses o f  vitamin E compared
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with placebo (Stephens et al, 1996). In addition, the related anti-oxidant vitamin C 
improves insulin action in both normal subjects and diabetics (Paolisso et al, 1994), 
as well as improving endothelial function (Ting et al, 1995).
Thus, in general terms, endothelial function and insulin sensitivity are often affected 
in parallel by a variety of non-pharmacological and therapeutic interventions 
employed in both metabolic and cardiovascular disorders. However, this is not 
always the case; for example, fish oil appears to improve dyslipidaemia (Goh et al,
1997) and endothelial dysfunction (Chin & Dart, 1994) while exerting an adverse 
effect on insulin sensitivity (Rivellese et al, 1996).
1.10 Mechanisms of cellular insulin resistance
Insulin stimulates glucose disposal in muscle and adipose tissue. In muscle, this is 
achieved via a co-ordinated program of insulin-stimulated cellular events leading to 
increased glucose transport and increased activities of the enzymes involved in 
glycogen synthesis. The mechanism by which insulin controls both glucose transport 
and glycogen synthesis is becoming increasingly well understood. It has long been 
established that skeletal muscle is the primary site of post-prandial glucose uptake 
stimulated by insulin; furthermore, it is clear that muscle from individuals with 
insulin resistance exhibits blunted rates of insulin-stimulated glucose transport and 
glucose metabolism to glycogen, (reviewed in Reaven 1988 & De Fronzo et al, 
1992).
77
1.10.1 Insulin-stimulated glucose transport and the role o f GLUT-4 
Insulin stimulates glucose uptake into adipocytes and muscle by virtue of the specific 
expression of an insulin-regulatable glucose transporter, GLUT4. The translocation 
of this transporter from an intracellular site to the plasma membrane in insulin- 
exposed cells is responsible for the large increase in glucose transport observed. 
Under basal conditions in both fat and muscle, >90% of GLUT4 is sequestered 
intracellularly (Slot et al, 1991; Slot et al, 1997). It has been suggested that the 
majority of the intracellular GLUT4 is housed in vesicular structures similar to small 
synaptic vesicles observed in neuroendocrine cells (Slot et al, 1991; Slot et al, 1997; 
Martin et al, 1998). Indeed, the fusion of GLUT4-containing vesicles with the 
plasma membrane appears to be mechanistically similar to the fusion of synaptic 
vesicles with presynaptic membranes, as related proteins have been shown to be 
involved in both fusion reactions (see for example Cain et al, 1992; Martin et al, 
1996; Volchuk et al, 1996; Martin et al, 1998).
Skeletal muscle is the main tissue involved in the insulin-induced stimulation of 
glucose uptake. Studies using euglycaemic-hyperinsulinemic clamps have established 
that when insulin is maintained in the high physiological range, most of the infused 
glucose is taken up by skeletal muscle and converted to glycogen (James et al, 1986; 
Kraegen et al, 1993). It has long been established that insulin treatment, exercise or 
electrical stimulation all rapidly stimulate glucose transport in skeletal muscle, and 
that these effects are mediated by increased Vmax for glucose transport (reviewed in 
Zorzano et al, 1996). Recent studies have established that GLUT4 translocation in
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muscle is sufficient to account for the effects of insulin on glucose transport (Lund 
et al, 1995; Zorzano et al, 1996; Lund et al, 1997).
Glucose transport into skeletal muscle is rate limiting for the pathway for glucose 
utilisation. Individuals with type 2 diabetes exhibit insulin resistance in skeletal 
muscle (Pedersen et al, 1990). As muscle accounts for up to 40% of the body mass, 
this insulin resistance is of singular importance in the development of 
hyperglycaemia. A primary defect in insulin-stimulated glucose transport has been 
identified in such individuals, which, together with defective glucose 
phosphorylation, underlies the insulin resistance observed in this tissue (Eriksson et 
al, 1992; Haring and Mehnert, 1993; Bonadonna et al, 1996).
1.10.2 Subcellular localisation and translocation o f GLUT4 in skeletal muscle. 
Muscle fibres contain highly specialised organelles associated with the contractile 
properties of this tissue. For example, there are deep invaginations of the plasma 
membranes of muscle cells which interact with the terminal cistemae of the 
sarcoplasmic reticulum, the t-tubules. T-tubules possess insulin receptors, and thus 
may be a potential site for translocation of glucose transporters in response to insulin 
in addition to the sarcolemma (Zorzano et al, 1996). There is some debate regarding 
the relative contributions of translocation of GLUT4 to the sarcolemma and t- 
tubular regions. Biochemical and immuno-EM evidence has clearly demonstrated 
insulin-stimulated translocation of GLUT4 to both these sites in rat skeletal muscle 
(reviewed in Zorzano et al, 1996). The present consensus suggests that t-tubules 
contain more GLUT4 per unit membrane than the sarcolemma after insulin
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treatment, suggesting some heterogeneity in the translocation process to these 
different plasma membrane domains (reviewed in Zorzano et al, 1996). ( A l  chapter 
9, a pilot collaborative venture is described in which the technically-demanding
technique of immunogold electron microscopy was set up with a view to studying
r ~
GLUT4 translocation in human skeletal muscle.) ,
Immunolocalisation of GLUT4 in both human (Friedman et al, 1991) and rat 
(Rodnick et al, 1992) skeletal muscle has indicated that GLUT4 is associated with 
intracellular membranes, corresponding to a perinuclear compartment located close 
to the Golgi, between myofibrils, and in vesicular structures close to both the 
sarcolemma and the T-tubules. Like the situation in adipocytes, skeletal muscle 
GLUT4 does not co-localise with the tram  Golgi reticulum marker, TGN38.(Martin 
et al, 1996). Similarly, proteins known to be resident in GLUT4-containing vesicles 
in adipocytes, such as VAMP2, cellubrevin, vpl65 and SCAMPs have also been 
identified in GLUT4-containing vesicles in skeletal muscle (see for example Martin 
et al, 1996; Martin et al, 1998). Despite the profound differences in subcellular 
architecture and methods of subcellular fractionation, insulin-responsive GLUT4- 
containing vesicles from these tissues exhibit very similar sedimentation coefficients, 
buoyant densities and protein composition, suggesting that the compartment(s) to 
which GLUT4 is(are) targeted in muscle and fat are highly related structures (see 
Hanpeter et al, 1995; Kandror et al, 1995).
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1.10.3 The SNARE hypothesis and GL UT4 translocation
The SNARE hypothesis describes a series of protein-protein interactions which 
regulate the docking and fusion of specific membrane compartments in regulated 
exocytosis (Siidhof, 1995). It is now well accepted that GLUT4 translocation shares 
mechanistic similarity with regulated exocytosis, hence the SNARE hypothesis 
represents a useful framework within which to consider aspects of GLUT4 cell 
biology. SNARE protein homologues have been shown to function in regulated and 
constitutive exocytosis in a variety of cell types, suggesting that they may be general 
fusion proteins. To that end, the proteins VAMP2 and Syntaxin-4 have been 
identified in GLUT4-expressing cells, and shown to be required for GLUT4 
translocation using a variety of techniques (see for example Cain et al, 1992; Martin 
et al, 1996; Martin et al, 1998). It has been demonstrated that the main GLUT4- 
storage organelle in adipocytes is enriched for VAMP2 and that VAMP2 and 
syntaxin 4 play central roles in GLUT4 translocation in response to insulin in 
adipocytes (Martin et al. 1996, 1998). Thus, using adipocytes as a paradigm for 
insulin-stimulated GLUT4 translocation, an important role for VAMP2 and syntaxin 
4 would be expected in skeletal muscle. To date, there is no information on either 
the expression levels or the co-localisation of VAMP2 and GLUT4 in human 
skeletal muscle.
1.10.4 Insulin signalling
Insulin activates a range of cellular signalling pathways via the intermediary of multi- 
phosphorylated protein substrates for the insulin receptor, IRS-1 and IRS-2 (White
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& Kahn, 1994; Withers et al, 1998). These proteins serve as focal points for the 
assembly o f a complex array o f  signalling enzymes in response to insulin binding its 
receptor. Insulin stimulated glucose transport in both muscle and fat requires the 
activation o f phosphatidylinositol 3'-kinase (Backer et al, 1992). The activation o f 
this lipid kinase leads to the activation o f  protein kinase B and the subsequent 
activation o f glycogen synthase kinase -3. These enzymes are thought to be key 
players in insulin-stimulated glucose disposal (Okada et al, 1994). Although some 
studies o f PI3 kinase levels in rodent models o f diabetes have been published (see 
Shepherd et al, 1996) relatively few data are available from human muscle samples 
for these enzymes.
1.11 Aims of thesis and hypotheses to be tested
Following on from work previously carried out in our department, namely the 
association o f insulin sensitivity with endothelial function in healthy subjects (Petrie 
et al, 1996a) and the demonstration that co-infusion o f D-glucose augments local 
insulin-mediated vasodilation (Ueda et al, 1998a), the aims o f  this thesis were as 
follows:
•  to explore the mechanisms o f  local insulin/glucose-mediated vasodilation
• to examine the relationship between local insulin/glucose-mediated vasodilation 
and whole-body insulin sensitivity
• to assess the effect on whole-body insulin sensitivity o f systemic inhibition o f 
endothelial function
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• to demonstrate whether skeletal muscle fibre type and capillary density might be 
candidates for a ‘third factor’ to explain the association between insulin’s metabolic 
and vascular effects
• to extend these studies to groups of patients with either essential hypertension or 
type 2 diabetes (as well as age- and BMI-matched healthy volunteers)
• to establish a robust ‘washed platelets’ model with which to study mechanisms of 
insulin-mediated inhibition of platelet aggregation
• to initiate a pilot study using the technique of GLUT4 immunogold electron 
microscopy with the ultimate aim of demonstrating insulin-stimulated GLUT4 
translocation in intact human skeletal muscle cells
Thus, the following hypotheses were generated and subsequently tested:
Young healthy volunteers
• ‘If insulin is predominantly an endothelium-dependent vasodilator, acting via 
stimulation of nitric oxide synthase (NOS), then co-infusion of a substrate inhibitor 
of NOS will abolish insulin’s vascular effect, while vasodilation should still be 
apparent during co-infusion with low-dose angiotensin II, which causes a similar 
degree of vasoconstriction but is not endothelium-dependent.’ (chapter 3)
• ‘If insulin is predominantly an endothelium-dependent vasodilator, and 
endothelial function is positively associated with whole-body insulin sensitivity, then 
insulin-mediated vasodilation should be associated with insulin sensitivity.’ (chapter 
4)
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• ‘If endothelial dysfunction causes relative insulin resistance, then inducing an 
artificial state of endothelial dysfunction by systemically infusing a substrate inhibitor 
of NOS should result in a decrease in whole-body insulin-mediated glucose uptake.’ 
(chapter 5)
• 'Skeletal muscle fibre type should be related to whole-body insulin sensitivity 
while capillary density may be related to insulin-mediated vasodilation; since fibre 
type and capillary density are related, this may partly explain any relationship 
between insulin’s metabolic and vascular actions.’ (chapter 6)
Older subjects
• 'Endothelial function and insulin-mediated vasodilation should be blunted in 
patients with either type 2 diabetes or essential hypertension, in parallel with 
reductions in whole-body insulin sensitivity.’ (chapter 7)
• ‘Sensitivity of platelets to thrombin-induced aggregation should be increased in 
more insulin-resistant subjects’ (chapter 8)
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Chapter 2
Methods
2.0 Summary
This chapter provides a description of the general protocols for the clinical 
techniques used in the studies described in this thesis.
2.1 Healthy volunteers and patients
All the studies were performed in the Clinical Investigation and Research Unit 
(CIRU), Department of Medicine and Therapeutics, Western Infirmary.
Young male healthy volunteers and older non-diabetic normotensive control subjects 
were recruited by advertisement (medical and nursing students were excluded). 
Non-diabetic hypertensive patients were recruited from the Glasgow Blood Pressure 
Clinic at the Western Infirmary; patients with type 2 diabetes were recruited from 
the Diabetes Centre at Gartnavel General Hospital. The study protocols were 
individually approved by the Ethics Committee of the West Glasgow Hospitals 
University NHS Trust.
Young healthy volunteers (chapters 3-6) and older healthy control subjects (chapter 
7) were excluded if they were taking any form of regular medication, were smokers, 
were consuming more than 20 units of alcohol per week or had elevated fasting 
cholesterol levels (> 6mmol/l). They underwent routine medical screening at the
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Clinical Investigation and Research Unit and were deemed to be healthy on the basis 
of past medical history, physical examination, routine biochemical and 
haematological indices, hepatitis screen and electrocardiography. All subjects gave 
written informed consent for their participation.
Hypertensive subjects were often newly-diagnosed with mild-to-moderate 
hypertension. Patients already on medication were asked to discontinue their drugs 
for at least three weeks after which time sitting blood pressure was re-measured in 
triplicate. The ‘window* for recruitment was systolic 140-180mmHg and diastolic 
90-1 lOmmHg. Exclusion criteria were as follows:
• smoker
• alcohol intake > 20 units/week
• BMI > 30
• fasting hyperlipidaemia (cholesterol > 8mmol/l;triglycerides > 4mmol/l)
• co-existing peripheral vascular disease or cerebrovascular disease
• co-existing active ischaemic heart disease
• co-existing microalbuminuria
• co-existing type 2 diabetes or impaired glucose tolerance
• other conditions, for example urinary frequency and chronic low back pain,
which would complicate being able to lie still for a number of hours
Type 2 diabetes was defined according to WHO criteria (World Health 
Organisation, 1980). Newly-diagnosed patients were stabilised on diet for three
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months prior to study entry. Patients already attending the Return Clinic were 
recruited if glycaemic control was stable on either diet alone or a small dose of 
gliclazide (< 80 mg/day). Exclusion criteria were as follows:
• smoker
• alcohol intake > 20 units/week
• BMI > 30
• fasting hyperlipidaemia (cholesterol > 8mmol/l; triglycerides > 4mmol/l)
• co-existing peripheral vascular disease or cerebrovascular disease
• co-existing active ischaemic heart disease
• co-existing microalbuminuria
• co-existing hypertension
• other conditions, for example urinary frequency and chronic low back pain, 
which would complicate being able to lie still for a number of hours
2.2 General clinical protocol
Before study entry, all volunteers and patients underwent a health questionnaire and 
full clinical screening including physical examination, routine biochemistry, 
haematology, dip-stick urinalysis and an electrocardiogram as a screening test for 
significant cardiovascular disease or end-organ damage. In addition, random urine 
drug screens were carried out in a subset of volunteers to detect traces of any illicit 
drugs. Written informed consent was obtained form all subjects.
87
On each study day, subjects were transported by taxi to the CIRU at 0830hrs after 
an overnight fast from 2200hrs. All subjects were asked to avoid alcohol, caffeine 
and vigorous exercise in the 24 hours prior to an assessment. Following each study, 
a light meal was provided for subjects prior to taxi transport home.
2.3 Clinical and morphometric measurements
2.3.1 Body mass index
Body weight and height were measured with subjects in light clothes and without 
shoes to the nearest 0.5 kg of weight and to the nearest 0.5 cm of height. The same 
equipment was used throughout the studies, and the calibration of the weighing 
scales (Seca, Germany) was checked regularly. Body mass index (BMI, kg/m2) was 
calculated as:
body weight (kg)
BMI = -----------------
(height (m))2
2.3.2 Blood pressure and heart rate
During all the clinical studies the technique of blood pressure and heart rate 
measurement was uniform. Systolic and diastolic blood pressure and heart rate were 
measured, after 10 minutes supine rest, by an oscillometric technique using a 
Dinamap Critikon (Johnson and Johnson Professional Products Ltd., U.K.) semi­
automatic sphygmomanometer, maintained and calibrated at regular intervals by the
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Department o f Clinical Physics, Western Infirmary. Hypertension was defined as a 
mean supine diastolic BP o f  > 95 mmHg, or systolic > 160 mmHg, on three readings 
after 10 minutes supine rest (Sever et al, 1993).
2.4 Hyperinsulinaemic clamp technique
Insulin sensitivity was assessed using a modification o f the hyperinsulinaemic clamp 
described by DeFronzo et al (1979). Rather than the 120 minute clamps described by 
DeFronzo, a duration o f 180 minutes was chosen, except when hepatic glucose 
production was being measured concurrently, in which case the clamp was 
shortened to 150 minutes (to optimise total duration o f protocol for subjects).
2.4.1 General clinical procedure
Subjects attended the CIRU according to the usual protocol (section 2.2). Two 18- 
gauge intravenous cannulae (Venflon, Helsinborg, Sweden) were inserted: the first 
antegradely into the left antecubital fossa for administration o f infusions, and the 
second retrogradely into the right dorsal hand vein for blood sampling. Three-way 
taps enabled easy sampling and simultaneous infusion o f insulin and glucose.
The infusion o f soluble human insulin (Actrapid, NovoNordisk A/S, DK2880 
Bagsvaerd, Denmark) was prepared in 45mls saline + 5mls (10% vol/vol) o f  each 
patient’s own blood in order to  minimise adsorption o f insulin to the plastic surfaces 
o f syringes and infusion lines. It was administered using a Braun Perfiisor pump as a
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primed, constant rate infusion for 180 minutes with the aim of achieving a steady- 
state serum insulin concentration approximately 120pU/ml above the fasting level 
(high physiological range). The priming regime was as follows:
0-4 minutes 4.5 mU/kg/min
4-7 minutes 3.0 mU/kg/min
7-180 minutes 1.5 mU/kg/min
After placement of cannulae, 20 minutes* supine rest was allowed during which 
baseline blood samples were withdrawn and blood pressure and heart rate were 
measured; subsequently, insulin infusion commenced at time (t) = 0 mins. A variable 
rate infusion of 20% glucose (Baxter Healthcare, Norfolk, U.K.) was administered 
via an IMED infusion system (IMED, Abingdon, U.K.) from t = 2-180 mins. Serum 
glucose concentrations were maintained at euglycaemia (target serum glucose 5.2 
mmol/1) in subjects who did not have type 2 diabetes. In subjects with diabetes, 
serum glucose concentrations were maintained at isoglycaemia [target serum 
glucose = fasting glucose (Saad et al 1994)] in order to avoid the potentially 
confounding effect of inter-individual variations in fasting serum glucose 
concentrations. The infusion rate was adjusted for body weight for each individual 
and expressed as milligrams of glucose infused per kilogram of body weight per 
minute (mg/kg/min). For example, the infusion rate of 20% glucose equal to 
lmg/kg/min for a 70kg man would be calculated as:
60 minutes
-----------------  x 70kg = 21 ml/hour
200g glucose
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At 5 minute intervals, 1.5 ml blood samples were withdrawn from the cannulated 
dorsal hand vein. Cannula patency was maintained using a slow infusion of 0.9% 
saline; a total of approximately 100 ml was administered during each procedure. 
After centrifugation at the bedside, the serum glucose concentration was determined 
(section 2.9.2), and the glucose infusion rate was manually adjusted to maintain 
target serum glucose concentration. The dorsal hand vein was surrounded by a 
heated box (55°C) with the aim of arterialising venous blood (section 2.6). 
Additional hourly blood samples were obtained for estimation of serum insulin and 
plasma potassium levels
2.4.2 Calculation o f insulin sensitivity from the euglycaemic hyperinsulinaemic 
clamp
During hyperinsulinaemia with steady-state plasma glucose concentrations (usually 
during the last 40-60 minutes of the procedure), the rate of glucose infusion is equal 
to that of glucose removal from the glucose space (i.e. glucose metabolised, M). 
Assuming suppression of endogenous glucose production, the M-value is an 
estimate of total body glucose metabolism, and reflects the ability of insulin to 
enhance tissue glucose disposal.
In practice, the glucose infusion rate must be modified by two factors before it can 
be equated with M:
M = I - UC + SC
where: I = glucose infusion rate (mg/kg/min)
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correction for urinary glucose loss 
(usually negligible during a clamp)
SC ‘space correction’ (mg/kg/min)
(for inevitable deviations from euglycaemia)
The space correction is calculated as follows (DeFronzo et al 1979):
where: G
SC (5.2-G )x  17.86 x 0.095
ambient glucose concentration over last
40 minutes of clamp (mmol/1)
0.095
17.86 unit conversion factor (mmol/1 to mg/dl) 
glucose space constant
When the achieved ambient glucose concentration at steady-state is less than the 
desired value of 5.2 mmol/1 (too little glucose has been infused) the space correction 
will be positive: M will therefore be greater than I; the converse also applies.
In some groups of subjects, particularly in those who are obese, use of a weight- 
adjusted insulin infusion protocol may result in higher steady-state serum insulin 
concentrations, and in this situation the M-value underestimates the degree of insulin 
resistance. In this situation, the insulin sensitivity index (Sn» x 104 dl/(min.kg) per 
mU/1) is calculated from the glucose infusion rate and ambient insulin and glucose 
concentrations at steady state (Bergman et al 1987):
Sip = ARi / (Al x G)
where: ARd = increment in glucose uptake (basal to steady state)
Al increment in [insulin] (basal to steady state)
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G = steady state [glucose]
When subjects are clamped at fasting glucose levels (for example, type 2 diabetic 
patients, chapter 7), further adjustment is required to take these differences into 
consideration, since a higher proportion o f  glucose disposal will be insulin- 
independent (mass action) in those subjects with higher fasting glucose levels 
(Greenfield et al, 1981). The best index is M CR (metabolic clearance rate) o f  
glucose which equates to the M-value divided by the fasting glucose value; glucose 
levels should be converted to mg/dl from mmol/1 (multiply by 18.019) so that MCR 
can be expressed as dl/kg/min (usually, this value is multiplied by 100 and expressed 
in ml/kg/min).
The reproducibility o f M  has previously been evaluated in the CIRU: between-day 
intra-subject coefficient o f variation is 6% in healthy subjects (Morris et al 1997).
2.5 Measurement of endogenous (hepatic) glucose production using tracer 
infusates
Hepatic glucose production (both basal and during hyperinsulinaemia) was measured 
using tracer infusates (chapter 7).
2.5.1 C linical procedure
The protocol was identical to that given above (section 2.4.1) except that the 
duration o f the euglycaemic/isoglycaemic clamp was reduced to 150 minutes and
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also for the following modifications. A primed continuous infusion o f HPLC-purified 
[3-3H] glucose was given during a 2 hour equilibration period (t = -120 to 0 mins) 
and continued throughout the procedure. The dose was halved (t = 20 to 40 mins) 
and then halved again (t = 40 to  150 mins). In order to avoid the underestimation o f 
endogenous glucose production associated with inter-compartmental tracer fluxes, a 
variable rate infusion o f  exogenous 20% glucose pre-labelled with [3-JH] glucose 
aiming to match basal plasma glucose specific activity was administered (t = 2 to 
150 mins) (Finegood et al 1987, Levy et al 1989, Finegood et al 1990, Hother- 
Nielsen & Beck-Nielsen 1990, Hother-Nielsen et al 1992, Neely et al 1992).
2.5.2 Calculation o f endogenous glucose production
The specific activity o f  glucose in plasma is measured in disintegrations per minute 
(dpm) per pmol o f  plasma glucose (section 2.9.3). At steady state, the total rate o f 
glucose appearance (Tra, pmol /  min) can be calculated by dividing the rate o f tracer 
administration (dpm / min) by the glucose specific activity (SA = dpm / pmol) o f 
plasma. Endogenous (hepatic) glucose production (EGP) is determined by 
subtracting the known rate o f  exogenous glucose infusion (I) [per kg o f body 
weight] from the rate o f  glucose appearance (Ra) [per kg o f body weight],
EGP = Ra - 1
In practice, steady state assumptions may not be fully met, and the non-steady state 
equations of Steele et al (1956), as modified by DeBodo et al (1963) may be used as 
follows to determine rates o f  glucose appearance (Ra) and disappearance (Rd)
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during t = -30 to 0 mins and t = 120 to 150 mins, assuming a pool fraction of 0.65 
and an extracellular volume of 190 ml/kg.
The calculation of endogenous glucose production (EGP) can be summarised as 
follows:
i) Assuming steady state (ss):
H *-i £ II Ftoui/SA (|imol/min)
SA = glucose specific activity (dpm/min)
FtoUl ~ (Rcoort x + (Rdcx x Fto) (dpm/min)
F const specific activity of constant [3-3H] glucose infusion
Rconst rate of constant [3-3H] glucose infusion
Fdex = specific activity of variable [3-3H] glucose infusion
Rdex = rate of variable [3-3H] glucose infusion
ii) Adjusting for deviations from steady state: 
Tra{11M) = Tra<„) - error term 
where:
Error term = (p.V.G.dSA/dt.weight)/SA (pmol/min)
and: p = pool fraction (0,65)
V volume of distribution (190 ml/kg)
G plasma glucose concentration (mmol/1)
SA = glucose specific activity of plasma (dpm/min)
weight = weight (kg)
iii) Final step:
EGP = Ra<nss) - GIR (|imol/kg/min) 
where:
Ra<ms) = Tra<nS8/weight (|imol/kg/min)
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G IR  =  (Rdex x Cdex)/weight (pmol/kg/min)
Cdex = 20% glucose concentration (|Limol/ml)
2.6 Arterialisation of venous blood
In the original description o f  the euglycaemic clamp, the glucose infusion rate was 
adjusted according to glucose values in arterial blood (DeFronzo et al 1979). 
However, in order to  avoid cannulation o f systemic arteries, many investigators now 
adjust the glucose rate on the basis o f  ‘arterialised’ venous blood withdrawn from 
the retrogradely cannulated dorsal hand vein. To enable arterialisation o f  venous 
blood, the hand was placed in a cylindrical perspex heated-air box at the beginning 
o f  the period o f  supine rest prior to the start o f the procedure (Liu et al 1992). 
Under thermostatic conditions, the heated box maintains the ambient temperature 
surrounding the hand at 55°C (University o f  Nottingham, Department o f Physiology 
and Pharmacology, U.K.).
2.7 Forearm venous occlusion plethysmography
Forearm blood flow (FBF) was measured in the studies described in this thesis using 
forearm venous occlusion plethysmography (chapters 3,4,5 & 7). In this technique, 
the measurement o f flow is derived from the rate o f change in forearm volume 
during intermittent occlusion o f venous return (with continued arterial inflow). The
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original technique, dating from the late nineteenth century, required the use of 
cumbersome water jackets to measure changes in forearm volume (reviewed in 
Greenfield et al, 1963), but has been more readily applicable since the advent of 
mercury strain gauges together with a mathematical model for deriving changes in 
forearm volume (expressed in ml of blood flow / 100ml forearm / minute) from 
changes in circumference (Whitney 1953). The development of an electrical 
calibration technique for strain gauges (Hokanson et al, 1975), and the availability of 
computerised chart recorders, has led to increasing use of the technique to assess the 
effects on resistance vessel tone of agents infused directly into the brachial artery at 
subsystemic doses (Calver et al 1992; Benjamin et al 1995). An additional 
refinement is the simultaneous measurement of forearm blood flow in both arms: 
measurements in the experimental arm are adjusted for systemic changes unrelated 
to the local stimulus by expressing the two measurements as a ratio:
x 100%
F(i)a m
F(ni)d F(ni)v
m i
F(ni)v
where: F = flow
i = infused arm
ni = non-infiised arm
v = vehicle
d = drug
A validation study was carried out in our department to investigate the 
reproducibility of forearm venous occlusion plethysmography (Petrie et al 1997). It
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was demonstrated that the between-day intra-subject variation in unilateral FBF 
measurement was relatively high (coefficient of variation: 31-39%). However, the 
variability was less (coefficient of variation: 19%) when bilateral FBF measurement 
was made and responses were expressed as ratios (intervention : control arms).
2.7.1 General clinical procedure
These studies were carried out in a dedicated investigation room which was quiet 
and in which the lighting was dimmed. Room temperature was kept constant at 
around 24 - 25 °C. Subjects lay supine with arms supported on foam blocks at an 
angle of 30° to allow emptying of hand and forearm veins. Paediatric arterial 
occlusion cuffs (Hokanson SC5, PMS instruments, Maidenhead, Berkshire) were 
placed around the wrists and inflated to 200 mmHg for three minutes during each set 
of recordings. Hand circulation is occluded during the measurements of forearm 
blood flow because the physiology (especially the well-developed system of 
arteriovenous shunting) differs markedly from the forearm (mainly resistance 
arterioles in skeletal muscle vascular beds). Collecting cuffs (Hokanson SC 10) were 
placed around the upper arms, and inflated and deflated (40 mmHg) in a 12 second 
cycle. Rapid cuff inflation was achieved using a commercially available air source 
(Hokanson AG101), coupled to rapid cuff inflators (Hokanson E20). On the first 
study day, the left forearm was measured at the largest circumference (usually 
around 24 - 28 cm), and a mercury-in-silicone elastomer (Silastic) strain gauge 
(Hokanson forearm set) 2 cm shorter was selected (in other words, the aim was to 
achieve roughly 10% resting stretch on the strain gauge which allows maximum 
sensitivity to any changes in circumference). The distance from the olecranon was
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measured and recorded in order to standardise strain gauge position from day to 
day. The strain gauge was calibrated electrically on the arm to the chart recorder 
programme (MacLab, AD instruments, UK) and test readings were recorded.
In studies examining the effect of local intra-arterial infusions on forearm blood 
flow, a 27G unmounted steel needle (Cooper’s Needleworks, Birmingham, UK) was 
inserted under local anaesthesia into the brachial artery of the non-dominant arm for 
drug infusion. Infusions were administered via an epidural giving set and needle 
patency was maintained using an infusion of 0.9% saline (1-2 ml/min). All solutions 
were prepared in 0.9% saline in the Pharmacy Sterile Productions Unit, Western 
Infirmary. When preparing an intra-arterial insulin solution, 4 ml of the volunteer’s 
own blood was mixed with 45 ml of saline and 1ml of diluted soluble human insulin 
(Actrapid, Novo Nordisk, Denmark) (250 mU/ml for 5 mU/min). The insulin 
solution was prepared in the sterile unit of the hospital pharmacy using glass 
syringes and bottles and diluted in the research unit immediately before each study. 
With this method, the recovery of insulin was approximately 95% (S Ueda, 
unpublished data). When required, a venous cannula was introduced retrogradely 
into a cubital vein draining the deep venous supply of the forearm. Deep vein 
cannulation was confirmed when the tip of the catheter was not palpable, and 
oxygen saturation of samples was less than 50%.
Blood flow recordings began 45 seconds after wrist cuff inflation and continued for 
135 seconds. Following insertion of the intra-brachial needle, subjects were allowed 
to acclimatise to inflation and deflation of the wrist and upper arm cuffs for 20
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minutes before two baseline measurements 10 minutes apart: the mean o f these was 
used as the baseline forearm blood flow.
2.7.2 Calculation o f forearm blood flow
During venous occlusion, forearm circumference increases in proportion with the 
rate o f arterial in-flow. Therefore, the gradient o f the slope recorded on the 
plethysmographic traces is a surrogate measure o f forearm blood flow - a steep 
gradient represents high blood flow, while a flatter gradient represents low blood 
flow. Data were acquired via a MacLab II chart recorder (AD instruments, 
Hampstead, London). Absolute values for forearm blood flow were derived 
according to the equation o f  Whitney (1953). Each blood flow measurement was the 
mean o f five sequential recordings. Slopes were calculated from data points by 
acquiring co-ordinates using MacChart software (AD instruments), and pasting them 
into a customised spreadsheet (Microsoft Excel). Data from both infused and 
control arms were used to calculate the percentage change in forearm blood flow 
ratio, which is a more valid means o f expressing blood flow changes (Petrie et al,
1998).
2.8 Percutaneous skeletal muscle biopsy
2.8.1 General clinical procedure
This procedure was performed during a routine weekly muscle biopsy list in the 
Western Infirmary (Dr W. Behan, Senior Lecturer in Pathology). Subjects attended
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in a post-absorptive state and were positioned on a bed in order to achieve minimal 
postural contraction o f  thigh muscles. With an aseptic technique, 4ml o f 2% 
lignocaine was injected into skin and subcutaneous tissue at a point on the lateral 
aspect o f the thigh o f  the non-dominant leg, half-way between the knee and greater 
trochanter. An 8mm skin incision was then made with a disposable scalpel. A blunt- 
ended biopsy needle was then introduced through the fascial layer into vastus 
lateralis. Once in place, the central core o f  the needle was removed and a vacuum 
was applied using a 20ml syringe. Muscle tissue was sucked into the needle via a 
side-opening and removed using a side-cutting mechanism. This procedure is 
repeated twice at the same site in order to accumulate, on average, 200mg o f  tissue. 
The tissue is processed immediately by an experienced on-site technician. Firstly, the 
tissue is removed from the biopsy needle and placed onto dental wax resting on 
saline-soaked filter paper in a petri dish. Then the tissue is examined macroscopically 
to ensure that fat has not been biopsied. The tissue is then carefully organised to 
maintain the parallel nature o f  the muscle fibres; failure o f  this step results in poor- 
quality cross-sectional slides when cut for microscopy.
2.8.2 Preparation o f frozen sections
The time from biopsy to freezing should be no longer than 30 seconds. The fresh 
sample is mounted upon a cork disc. The disc and tissue are then rapidly frozen by 
placing in isopentane. Once frozen, the sample is immersed and stored in liquid 
nitrogen (-70°C). When required, the biopsy block is cut into 10 pm sections using a 
carbon dioxide freezing stage and a cryostat. These sections are picked up by APES 
slides and stored at 4 °C prior to histochemical analysis.
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2.8.3 Immunohistochemical analysis for fibre type and capillary density 
Muscle fibre types consist of discrete myosins with different characteristics and 
expressed from different genes. Antibodies which differentiate fast and slow myosins 
are commercially available. Slow myosin antibody recognises an epitope within the 
heavy meromyosin portion of adult muscle slow myosin. Indirect visualisation of 
‘slow’ type I fibres is therefore possible using the secondary antibody Rabbit anti- 
Mouse Peroxidase (RAM Po), which can subsequently be stained black using Vector 
Black. Fast myosin antibody recognises an epitope within skeletal muscle heavy 
chains. It cross-reacts with fast twitch fibres ELA and KB and direct visualisation is 
possible after conjugation with Rabbit anti-Mouse Alkaline Phosphatase (RAM AP) 
allowing direct red staining.
There are several ways of quantifying capillary density within a given microscopic 
field, including number of capillaries per field, capillary number to fibre number 
ratio, capillary area to fibre area ratio. We chose to quantify an area ratio by staining 
endothelial cells with an antibody to CD45, an antigen which is selectively expressed 
on vascular endothelium. Direct visualisation is possible using RAM AP.
Tissue samples were taken from the freezer, labelled and air-dried for 10 minutes. 
Tissue was then fixed to the slides by immersing in acetone for 10 minutes. After 
fixation, slides were air-dried, sections were encircled with a grease pen and the 
blocker 5% NGS was applied for 10 minutes. The slides were tipped to drain off the 
blocker and the primary antibodies (slow myosin antibody or CD45 antibody) were
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applied. The slides were left to incubate for 30 minutes in a humid environment 
before being washed off* with PBS for 10 minutes. Secondary antibodies were then 
applied to the sections: RAM Po (30 minutes, for type I fibres) or RAM AP (60 
minutes, for capillaries). To visualise type I fibres, the antibody is washed off and the 
commercial kit ‘Vector SG’ is applied for 5 minutes. The fibres immediately stain 
black. This reaction is stopped by applying water after which the sections are 
blocked again using 5% NGS. The process is repeated using fast myosin antibody as 
the primary antibody (incubated for 60 minutes) followed by RAM AP as the 
secondary antibody (incubated for 60 minutes). Both fast myosin and CD45 
antibodies are visualised using the commercial kit alkaline phosphatase. This is 
applied to the slides for 15-20 minutes before the slides are mounted and red 
staining occurs. In addition, the intensity of staining varies between type IIB and 
type ILA fibres, the latter staining more weakly: this difference in staining intensity 
can be picked up by the image analysis system and the proportion of type ILA to IIB 
fibres can be determined.
Quantification of data was achieved using an image analysis system. This technique 
allows quantification of captured images from a microscope using a television 
camera. Two television screens are used: one showing the microscopic field under 
analysis, and the other showing details of the MCID version 3 programme being 
used. At random, 500 fibres were counted and the area of each was calculated by 
drawing around the perimeter of the structure using ‘mouse’ control. As far as 
possible, only fibres cut in cross-section were included and only the fibres in one 
biopsy section were analysed to prevent repetition. The edges of the section were
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also avoided where fibres were often distorted. Results are expressed as percentages 
for both total number and total area of the three fibre types.
To measure vascularity, the proportion of endothelial cell area was measured. Two 
sections were analysed, large vessels were ignored and only capillaries cut in cross- 
section were evaluated. The program was set using the autoscan tool. This allows a 
chosen degree of colour to be detected within the screen and this was kept constant 
throughout. In addition, microscope illumination was also kept at a constant level. 
Results are expressed as endothelial cell area as a percentage of total area.
2.9 Laboratory methods
Venous blood samples for laboratory assay were withdrawn during clamp studies 
(chapters 4,5 & 7) from the right dorsal hand vein cannula and collected into plain 
(insulin, electolytes, lipids), lithium heparin (aldosterone) or potassium EDTA 
(renin) tubes. Samples for angiotensin II measurement were collected into tubes 
containing a mixture of enzyme inhibitors (25 mM o-phenanthroline, 125 mM 
EDTA, 2% ethanol, 0.2% neomycin sulphate, and 20 pM human renin inhibitor 
HI42). All samples were immediately placed in crushed ice prior to centrifugation 
(3000 rpm, 4°C), decanting, and storage at -20°C, except those for insulin (which 
were allowed to clot at room temperature for 20 minutes). Samples for angiotensin 
II measurement were stored at -70°C. Assays were performed in batches in the 
laboratories of the Department of Medicine and Therapeutics.
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2.9.1 Serum insulin concentrations
Serum insulin concentrations were determined at hourly intervals during clamp 
studies and at half-hourly intervals during plethysmography studies. They were 
measured by the Incstar radioimmunoassay (Stillwater, Minnesota, USA). This assay 
is non-specific for insulin with a molar cross-reactivity with intact proinsulin of 30%. 
Inter-assay coefficient of variation is 8 - 11%. Serum insulin concentrations were 
expressed in pU/ml.
2.9.2 Serum and plasma glucose concentrations
During the clamp studies, serum glucose was measured at 5 - 10 minute intervals at 
the bedside by the glucose oxidase method using a Beckman 2 glucose analyser 
(Beckman Instruments, Fullerton, CA, USA; inter-assay coefficient of variation = 
2%). Results were expressed in mmol/1. For assessment of deep venous glucose 
levels during plethysmography studies, plasma samples were collected in fluoride- 
oxalate tubes and analysed in the hospital routine biochemistry laboratory.
2.9.3 Glucose specific activity
Plasma samples were collected in fluoride-oxalate tubes (15ml) at the following time 
points in relation to the euglycaemic hyperinsulinaemic clamp procedure (see chapter
7):
-30 mins, -20 mins, -10 mins, 0 mins, 120 mins, 130 mins, 140 mins, 150 mins 
In addition, three control samples were prepared:
• ‘background’ - pre-infiisate plasma collected in 6 fluoride-oxalate tubes
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• ‘syringe spike’ -10% solution of glucose syringe infusate in pre-infusate plasma
• ‘bag spike’ - 10% solution of variable-rate glucose bag infusion in pre-infusate 
plasma
Glucose specific activity was measured in triplicate for all timed samples and four 
times for each control. Tritiated glucose was extracted according to the following 
procedure:
• To deproteinise, add 5% barium hydroxide and 5% zinc sulphate. Vortex 
thoroughly until complete precipitation has occurred.
• Spin down precipitate at 1400 rpm for 10 mins at 4°C and transfer supernatant to 
numbered 20ml plastic scintillation vials.
• Resuspend precipitates in 1ml water and spin down at 2400 rpm for 10 mins at 
4°C. Transfer second supernatants to corresponding vials.
• Freeze and dry samples.
• Reconstitute samples with 1ml water. Add scintillation fluid (8ml, Ultima Gold, 
Packard). Cap and shake vigorously.
• Count for 10 mins in scintillation counter.
Values obtained for glucose specific activity were entered into a spreadsheet 
(Microsoft Excel) and hepatic glucose production was calculated as explained above 
(section 2.5).
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2.9.4 Plasma aldosterone concentrations
Plasma aldosterone concentrations were measured in batches by a commercially 
available radioimmunoassay kit (Biodat, Milan) according to the technique described 
by MacKenzie & Clements (1974) (Chapter 3). Results were expressed in pmol/1. 
The intra- and inter-assay coefficients of variation were 5.0 and 5.4% respectively.
2.9.5 Plasma renin concentrations
Plasma renin concentrations were measured by an radioimmunoassay technique 
developed in the laboratories of the Department of Medicine and Therapeutics.
2.9.6 Plasma angiotensin II concentrations
Plasma angiotensin II was assayed after HPLC separation by direct 
radioimmunoassay according to a previously described technique (Ducsterdieck & 
McElwee, 1971). The intra- and inter-assay coefficients of variation were 6.4% and 
8.8% respectively (Morton & Webb, 1985).
2.9.7 Serum potassium concentrations
Potassium (mmol/1) was measured in the hospital routine biochemistry laboratory by 
a diluting ion-selective electrode on an Olympus AU5200 auto-analyser.
2.9.8 Serum lipid concentrations
Lipid measurements were co-ordinated by Dr Naveed Sattar, Dept of Pathological 
Biochemistry, Glasgow Royal Infirmary. The following fasting measurements were
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performed by a modification of the standard Lipid Research Clinics protocol (1975) 
on serum of patients and volunteers participating in the study described in chapter 7:
• total cholesterol
• triglycerides
• low density cholesterol (LDL)
• high density cholesterol (HDL)
• very low density cholesterol (VLDL)
2.9.9 Serum markers o f endothelial junction
Measurements of serum markers of endothelial function were organised by Dr 
Naveed Sattar, Dept of Pathological Biochemistry, Glasgow Royal Infirmary, in 
conjunction with Professor Gordon Lowe, Department of Medicine, Glasgow Royal 
Infirmary. The following fasting measurements were made on serum of patients and 
volunteers participating in the study described in chapter 7:
• Von Willebrand Factor (vWF) - ELISA; units: IU/dl
• Factor VDc - one stage clotting assay; units: % activity
• Tissue Plasminogen Activator (tPA) - ELISA; units: ng/ml
• Fibrin D-dimer antigen - ELISA
• fibrinogen - units: g/1
2.10 Platelet aggregation studies
2.10.1 Preparation o f human washed platelets
Peripheral venous blood (45ml) was obtained via a large bore cannula from subjects 
in the post-absorptive state who had not taken any aspirin-containing preparations
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for at least 10 days. Washed platelets were then prepared according to the method 
of Radomski & Moncada (1983). Briefly, blood was collected into a trisodium 
citrate / prostacyclin mixture (0.315% / 2pg/ml) and centrifuged at 222xg at room ^  
temperature for 20 minutes. The resulting supernatant (platelet rich plasma) was 
carefully removed and centrifuged at 700xg at room temperature for 10 minutes in 
the presence of prostacyclin (0.3pg/ml). The platelet pellet was resuspended in 
Tyrode’s solution including prostacyclin (0.3jig/ml), and centrifuged at 680xg at 
room temperature for 10 minutes. The pellet was washed three times with Tyrode’s 
solution alone before resuspension. The platelet density was counted and adjusted to 
2 - 2.5 x 10* cells/ml.
2.10.2 Measurement o f platelet aggregation
Platelet aggregation was measured by a turbidimetric method in a Chrono-log dual 
channel whole blood lumi-aggregometer connected to a dual pen recorder 
(previously described by Whittle et al, 1978). Aliquots (240jil) of washed platelets 
were incubated at 37°C prior to the addition of one of 10 different doses of 
thrombin. Platelet samples were stirred with teflon coated magnetic stirrers at 1000 
rev/min and the aggregation monitored for 6 minutes. Thrombin is known to induce 
a concentration-dependent aggregation of washed platelets; however, it cannot be 
used in platelet-rich plasma since it catalyses the formation of fibrin strands in the 
preparation, thus affecting turbidometric analysis. A dose-response curve of platelet 
aggregation to thrombin was constructed and the ED50 value (dose of agonist which 
causes 50% of maximum aggregation) was calculated.
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2.11 Immunogold electon micoscopy studies
The main aim o f this section was to produce a working protocol for the localisation 
o f  the glucose transporter GLUT-4 in skeletal muscle using electron microscopy 
immunohistochemistry. Since no experiments o f  this kind had been attempted in the 
EM  Unit before, a number o f  technical questions had to  be addressed:
•  how best to fix skeletal muscle tissue in preparation for EM  analysis
•  whether ultrasections were best produced from frozen sectioning or resin 
processing
•  for cryoultramicrotomy, which temperature was best for cutting sections
• which staining protocol gave the best resolution for gold-labelled GLUT-4 
antibodies
In summary, what follows is a protocol which yielded the most promising results:
1. harvest and dissect rat hind leg muscle
2. fix at room temperature for 2 hours at 4°C, in 4% paraformaldehyde & 1% 
glutaraldehyde
3. wash in Sorensen phosphate buffer (SPB) containing 10% sucrose
4. transfer to 2.3M sucrose & SPB solution for cryoprotection (16 hours)
5. attach to stubs for ultra sectioning
6. freeze in liquid nitrogen
7. set up ultramicrotome temperatures: specimen -90 °C and glass knife -100°C
8. take ultrasections (Reichter Jung Ultracut E with an FC 4D cryoattachment)
9. pick up sections with 2mm wire loop containing 2.3M  sucrose
10.place on carbon coated formvar grids
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11.place grids face down on a solution o f Tris-HCl containing 1% BSA (allows 
sucrose to diffuse away) (3 x 2mins)
12.place grids onto 2% gelatin (reduces background staining) (10 mins)
13.place grids onto 0.02M glycine (quenches free aldehyde groups) (2 mins)
14.wash in Tris-HCl + 1% BSA (6 x lmin)
15.apply affinity-purified rabbit polyclonal GLUT-4 antibody: titre 1:200 (Tris-HCl 
+ 1% BSA) (30 min at room temperature)
16.wash in Tris-HCl + 1% BSA ( 3 x 5  min)
17.apply colloidal (Protein A) gold conjugate: titre 1:10 (PBS + 1% BSA) (30 min 
at room temperature)
18.wash in Tris-HCl ( 1 5 x 2  min)
19.fix in 2% glutaradehyde (2 min)
20.wash in double distilled H 2O ( 1 0 x 1  min)
21.apply 10% uranyl acetate solution in a 9:1 solution o f 1% methyl cellulose (20 
min)
22. observation o f grids in Phillips CM 10 electron microscope (magnification approx: 
x38000)
Results, technical problems encountered, and plans for further experiments are
outlined in chapter 9.
2.12 Statistical analysis
All data were checked for normality using the Shapiro-Wilks test (Minitab statistical
package, Minitab Inc, Pennsylvania, USA). Normally-distributed data are
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summarised as mean ± standard deviation (or standard error). Skewed data were 
analysed by non-parametric methods (summaries as median ± interquartile ranges; 
Wilcoxon signed rank test for correlation analysis) or logarithmically transformed 
(logio) prior to multiple regression analysis.
Where possible, summary measures were calculated to prevent multiple 
comparisons. Details of specific statistical procedures used for each study are 
described in respective chapters.
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Chapter 3
Physiological mechanisms of insulin-mediated vasodilation in man 
3.0 Summary
In this clinical physiological study, the effects on insulin/glucose-mediated 
vasodilation o f  co-infusions o f  L-NMMA, angiotensin II, and ouabain were studied, 
in a double-blind, random-order, placebo-controlled manner using bilateral venous- 
occlusion strain-gauge plethysmography. It was concluded that insulin-mediated 
vasodilation may be dependent on endothelial nitric oxide production or stimulation 
o f  the Na+K+ATPase pump or both; however, these data cast doubt upon the widely- 
prevalent assumption that insulin-mediated vasodilation is specifically NO- 
dependent.
3.1 Introduction
There is increasing recognition that insulin, in addition to its well-known metabolic 
actions, exerts significant vascular effects. Elucidation o f mechanisms o f insulin- 
mediated vasodilation is critical in the search for pathophysiological links between 
metabolic insulin resistance and vascular endothelial dysfunction. The current 
consensus o f opinion is that insulin is an endothelium-dependent vasodilator via an 
increase in basal endothelial nitric oxide (NO) production. This conclusion is mainly 
based on two widely-cited studies which demonstrated in man that insulin-mediated 
vasodilation was blocked by co-infusion o f the substrate inhibitor o f NO synthase,
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N^monomethyl-L-arginine (L-NMMA) (Scherrer et al, 1994a; Steinberg et al, 
1994).
However, these results should be interpreted with caution since intra-arterial L- 
NMMA infusion caused vasoconstriction and insulin’s ability to cause vasodilation 
may have been blunted simply by virtue of non-specific pre-constriction. If it is to be 
demonstrated unequivocally that the mechanism of insulin-mediated vasodilation is 
specifically via stimulation of endothelial NO production, then it should be inhibited 
by L-NMMA but not to the same extent by blockers of other enzymes determining 
basal blood flow, or by matched doses of vasoconstrictor agents. In addition, the 
extent of insulin-mediated vasodilation should be greatest in those subjects whose 
basal blood flow is most dependent on endothelial NO production. It is well 
recognised that there are a number of other putative mechanisms by which insulin 
could cause vasodilation independently of endothelial NO production, the most 
obvious being direct stimulation of the Na+-K+ ATPase pump in vascular smooth 
muscle cells with subsequent membrane hyperpolarisation and vasorelaxation.
In order to address these issues, the present study was performed, using a 
previously-validated human forearm model with brachial artery infusion (Benjamin et 
al, 1995; section 2.7.1) The first hypothesis was that if insulin-mediated vasodilation 
is not specifically NO dependent, then infusion of a control vasoconstrictor agonist 
(angiotensin II) or an inhibitor of Na+-K+ ATPase (ouabain), designed to pre­
constrict the forearm vascular bed to the same extent as NO synthase inhibition, 
would also be expected to abolish insulin-mediated vasodilation. The second
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hypothesis was that if endothelial NO production was the most important 
mechanism mediating insulin’s vascular effects, then the extent of insulin-mediated 
vasodilation on one study day would be positively associated with the extent of 
vasoconstriction in response to L-NMMA infusion (which is determined by basal 
endothelial NO production) on a separate study day.
3.2 Methods
3.2.1 Subjects
Nineteen healthy, normotensive, male volunteers with normal glucose tolerance 
participated in this study with the approval of the West Ethical Committee of the 
West Glasgow Hospitals University NHS Trust (protocol 1: n=9; protocol 2: n=10). 
None of the subjects was taking medication, and all subjects abstained from alcohol, 
tobacco and heavy physical exertion for 24 hours and from food and caffeine- 
containing drinks overnight before study days. At a screening visit, physical health 
was confirmed by history and physical examination and supine blood pressure was 
measured in triplicate (Dinamap Critikon, Johnson and Johnson Professional 
Products Ltd). Characteristics (mean + SD) of the subjects were as follows: 
protocol 1: age 23+5.4 years, body mass index 22+1.8 kg/m2, and blood pressure 
125/69+13/8 mmHg; protocol 2: age 29±6.5 years, body mass index 24+2.8 kg/m2, 
and blood pressure 131/68+14/9 mmHg. Six subjects were smokers and median 
weekly alcohol consumption was 70g (range 0-200g).
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3.2.2 Clinical procedure
Forearm blood flow was measured by bilateral venous occlusion plethysmography as 
described in section 2.7.1.
3.2.3 Study Protocols
The protocols were designed in a double-blind, placebo-controlled, random order 
manner with measurements o f  forearm blood flow during infusion o f vasoactive 
substances on three occasions, at least one week apart in all subjects. On each day, 
after baseline readings had been obtained, subjects received an intra-arterial infusion 
o f low-dose D-glucose (75jimol/min) for 120 minutes in order to  maintain local 
venous euglycaemia in the forearm vascular bed, and which we have shown 
maximises insulin-mediated vasodilation (Ueda et al, 1998a). After 30 minutes, and 
for the remaining 90 minutes, soluble human insulin (Actrapid, Novo Nordisk, 
Denmark) was co-infused at a dose o f 5mU/min. This solution was prepared in the 
sterile unit o f the hospital pharmacy using glass syringes and bottles, and diluted 
(with saline and 4ml o f the subject’s blood, 8% vol/vol) at the bedside immediately 
before each study (mean recovery o f  insulin was 95% - data not shown). In addition, 
subjects received (figure 3.1) a 120 minute concominant intra-arterial infusion o f 
either N G-monomethyl-L-arginine (L-NMMA, Clinalfa AG) at a dose o f lmg/min 
(n=19), ouabain at a dose o f  3.5pg/min (protocol 1, n=9), angiotensin II (Ang II, 
CIBA Pharmaceuticals) at a dose o f  20pmol/min (protocol 2, n=10), or placebo 
(0.9% sodium chloride, Baxter Healthcare) at a rate o f  lml/min (n=19). The local 
Ethical Committee did not permit cannulation o f  the brachial artery on four
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consecutive occasions in the same subject; for this reason, while all subjects (n=19) 
received placebo and L-NMMA, nine received ouabain and ten received Ang n. A 
uniform infusion rate (2ml/min) was used throughout the study.
3.2.4 Statistical Evaluation
Percentage change from basal values in the ratio of blood flow between infused and 
non-infiised arms was calculated, using the blood flow in the non-infused arm as a 
concurrent control. In order to avoid multiple comparisons, two summary measures 
were calculated; firstly, the mean value at 20-30 minutes and, secondly, the mean 
value at 100-120 minutes. As these values were non-parametricaily distributed, they 
were expressed as median values with interquartile ranges. The Wilcoxon Signed 
Rank Test was used to assess changes in blood flow over time. In addition, the 
summary measure for insulin-mediated vasodilation (placebo-day) for each subject 
was plotted against the degree of vasoconstriction induced by L-NMMA (n=19), 
Ang II (n=10) and ouabain (n=9) and the rank correlation coefficient was calculated 
in each case. Glucose, potassium and insulin levels were normally distributed; 
summary measures were calculated as mean+S.D. of the final three deep vein 
samples (90, 120 and 150 minutes) and results were compared by analysis of 
variance.
3.3 Results
The procedures were carried out without complication and were well tolerated by all 
subjects.
3.3.1 Forearm blood flow
D-glucose infusion alone for 30 minutes (placebo-day) resulted in no change in FBF 
[ -5.0% (-16.0, 1.25)]; insulin and D-glucose infusion together caused significant 
vasodilation on the placebo day [35.9% (12.1, 76.0)] (p<0.01, n=19, figure 3.2a: 
raw data; figure 3.2b). Significant forearm vasoconstriction occurred with L-NMMA 
[-34.3% (-44.2,-19.2)], Ang U [-27.9% (-41.7,-20.8)] and ouabain [-36.3% (-46.5,- 
23.5)], [median (interquartile range)]. Co-administration of insulin had no significant 
effect on either L-NMMA-induced vasoconstriction [-33.0% (-48.7,-18.6), n=19, 
figure 3.3], Ang II-induced vasoconstriction [-26.2% (-35.2,-9.2), n=10, figure 3.4] 
or ouabain-induced vasoconstriction [-23.4% (-30.9,-9.6), n=9, figure 3.5].
3.3.2 Insulin-mediated vasodilation and responses to vasoconstrictors
There was no significant relationship seen between insulin-mediated vasodilation and 
L-NMMA (R,=-0.21, figure 3.6a) or Ang II (R«=0.37, figure 3.6b) responses. 
However, a significant positive association was demonstrated with ouabain-induced 
vasoconstriction (R,=0.69, p<0.05, figure 3.6c).
3.3.3 Glucose, potassium and insulin levels
Fasting glucose levels were not significantly different on any of the study days: 
[4.89+0.8 placebo, 4.79+0.4 L-NMMA, 4.89+0.3 Ang n, 4.83+0.3 ouabain (mmol 
f 1)]. Steady-state deep venous euglycaemia (90-150 minutes) was achieved with co­
infusion of insulin with D-glucose: [4.89+0.6 placebo, 5.01+0.6 L-NMMA, 
5.20+0.7 Ang II, 5.00+0.6 ouabain (mmol I'1)].
118
Fasting potassium levels were not significantly different on any o f the study days: 
[3.86+0.1 placebo, 3.98+0.3 L-NMMA, 3.81+0.2 Ang II, 3.90+0.1 ouabain (mmol 
I'1)]. Steady-state deep venous potassium levels (90-150 minutes) were slightly 
lower as expected on three days: [3.75+0.2 placebo, 3.70+0.3 L-NMMA, 3.73+0.2 
Ang II (mmol I'1)]; however, they were significantly higher on the ouabain day 
(4.55+0.3 mmol I'1, p<0.0001), indicating effective inhibition o f  Na+-K+ ATPase.
Fasting insulin levels were not significantly different on any o f  the study days [2.3 
(0.0,5.3) placebo, 1.3 (0.0,5.3) L-NMMA, 4.0 (2.3,8.5) Ang II, 4.5 (1.8,7.3) 
ouabain (pU  m f1) {median (interquartile range)}]. Steady-state deep venous 
hyperinsulinaemia (90-150 minutes) was achieved with no significant differences 
detectable among the study days: [106+51 placebo, 138+86 L-NMMA, 120+53 Ang 
II, 153+67 ouabain (pU ml'1)].
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Figure 3.2
(a) Time course of indivi^luabvalues for local insulin/glucose- 
mediated vasoreactivity (n=l 0^ protocol 2). (b) Time course 
of local insulin/glucose-niediated vasoreactivity (median +
IQ) (n=19).
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Figure 33
Time course of local insulin/glucose-mediated 
vasoreactivity (median + IQ) in 19 healthy male 
volunteers, with and without co-infusion of L- 
NMMA. Double-blind, random order study 
design.
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Figure 3.4
Time course of local insulin/glucose-mediated 
vasoreactivity (median + IQ) with and without co- 
infusion of angiotensin II (n= 10).
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Figure 3.5
Time course of local insulin/glucose-mediated 
vasoreactivity (median + IQ) with and without co­
infusion of ouabain (n=9).
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Figure 3.6
Local insulin/glucose-mediated vasodilation (placebo day) plotted 
against percentage forearm vasoconstriction in response to intra- 
arterial infusion o f (a) L-NMMA (n=19), (b) angiotensin EL (n=10), 
(c) ouabain (n=9).
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3.4 Discussion
In this study a validated physiological model o f  local hyperinsulinaemia with venous 
euglycaemia in the human forearm vascular bed has been used to explore 
mechanisms o f insulin-mediated vasodilation. By infusing insulin via the brachial 
artery, any confounding systemic haemodynamic effects, such as stimulation o f the 
sympathetic nervous system, have been avoided. Infusion o f  insulin and D-glucose 
caused a significant (36%) vasodilator response after 90 minutes (consistent with 
our previous data [Ueda et al, 1998a]) but did not reverse vasoconstriction (34%) 
induced by a 30-minute intra-arterial infusion o f  L-NM MA, a substrate inhibitor o f 
endothelial NO synthesis. One interpretation o f  these findings is that insulin exerts its 
vasodilator effect via stimulation o f endothelial NO production, and this conclusion 
would be consistent with previous reports (Haylor et al, 1991; Wu H-Y et al, 1994; 
Scherrer et al, 1994a; Steinberg et al, 1994;)
However, after inducing a similar degree o f vasoconstriction (28%) in the forearm 
vascular bed, using a 30-minute intra-arterial control infusion o f  Ang II, insulin’s 
vasodilator action was also abolished. These data weaken the aforementioned 
conclusion i.e. insulin may lose its vasodilator action simply as a result o f induction 
o f non-specific background vasoconstriction
Inhibition o f vascular Na+-K+ ATPase activity by co-infusion o f  ouabain achieved a 
similar degree o f vasoconstriction (36%). Again, insulin’s vasodilator action was 
abolished, a result which is consistent with previous data (Tack et al, 1996). There 
are two ways o f interpreting this result. Firstly, as outlined above, there is the
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possibility that non-specific background vasoconstriction was responsible for 
abolition of insulin-mediated vasodilation. Secondly, there is a substantial body of 
evidence to suggest that insulin directly stimulates Na+-K+ ATPase activity (Ewart & 
Klip, 1995; Gupta et al, 1996), either by up-regulating gene expression (Tirupattur 
et al. 1993) or by causing translocation of the enzyme from intracellular stores to the 
plasma membrane surface (Omatsu-Kanbe & Kitasato, 1990) or as a secondary 
consequence of activation of Na+-H+ exchange (Sowers, 1996). In vascular smooth 
muscle the consequences include hyperpolarisation of the cell membrane leading to 
closure of voltage-gated Ca** channels, consequent decrease in intracellular calcium 
concentration, and subsequent vascular relaxation. If insulin were to cause 
vasorelaxation by stimulation of Na+-K+ ATPase activity, inhibition of this pump 
would be predicted to abolish this action. r , u
C- d Y‘V>
Additionally, the possibility remains that endothelial NO production may still be the 
predominant mechanism for insulin-mediated vasodilation but that the Na+-K+ 
ATPase pump may be important either in mediating NO effects or in the production 
of NO - therefore, inhibiting Na+-K+ ATPase activity would still block insulin’s 
vascular action. There is evidence in support of an interaction between NO and 
Na+-K+ ATPase: for example, it has been reported that insulin may stimulate vascular 
smooth muscle Na+-K+ ATPase activity indirectly via its action to increase 
endothelial-derived NO synthesis/release, a mechanism which appears to be 
independent of cGMP production (Gupta et al, 1994). It has also been proposed that 
the mechanism by which insulin stimulates endothelial NO production may be via its 
action on endothelial Na+-K+ATPase (Elliott & Schilling, 1992; Meharg et al, 1993):
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since there are no voltage-gated Ca** channels in endothelial cells, hyperpolarisation 
leads to an increase in intracellular [Ca++] (Luckhoff & Busse, 1990) which may 
activate the Ca^-dependent enzyme eNOS.
Therefore, it is clear that there are major difficulties in the interpretation of forearm 
blood flow studies with respect to drawing conclusions about underlying 
mechanisms of insulin-mediated vasodilation. It cannot be concluded from the 
present data that insulin-mediated vasodilation is specifically NO dependent, given 
the complexities and numerous interactions of mechanisms. Further insight into the 
question of which of the candidate mechanisms might be most closely coupled with 
insulin action was gained by use of the considerable inter-individual variation 
observed in vascular reactivity both to the three vasoconstrictors and to insulin, even 
in this relatively homogeneous group of fit, young, healthy subjects. The hypothesis 
was that, if endothelial NO production was the most important mechanism mediating 
insulin’s vascular effects, then the extent of insulin-mediated vasodilation on one 
study day should be positively associated with the extent of vasoconstriction in 
response to L-NMMA infusion measured on a separate study day. However, 
contrary to the hypothesis, there was not a positive relationship between these 
variables - if anything there was a trend towards a negative relationship (figure 
3.6a). In addition, there was no association between the extent of control Ang II 
vasoconstriction and insulin-mediated vasodilation (figure 3.6b).
However, a significant positive correlation between insulin-mediated vasodilation 
and ouabain-induced vasoconstriction was demonstrated (figure 3.6c). Since it is
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reasonable to suggest that vasoconstriction in response to ouabain is a measure of 
basal Na+-K+ ATPase pump activity, it is proposed that insulin’s vascular action may 
be closely coupled with Na+-K+ ATPase activity. Thus, while endothelial NO 
production may still be an important mechanism for insulin-mediated vasodilation, it 
is speculated that stimulation of Na+-K+ ATPase activity may be the most important 
primary determinant. This may reflect the dual actions of insulin on this pump at 
both the endothelium and vascular smooth muscle. In this regard, the relative delay 
and glucose enhancement of insulin-mediated vasodilation are of interest (Ueda et al, 
1998a). Most endothelium-dependent vasodilators (eg acetylcholine) act acutely to 
release NO; in contrast, the maximal dilator response to insulin takes at least 50-80 
minutes to develop. Additionally, the response is maximised by co-administration of 
D-glucose (Ueda et al, 1998a). As Na+-K+ ATPase activity is ATP-dependent, and is 
maximised by aerobic glycolysis, increased intracellular availability of glucose may 
be the initial determinant of insulin-mediated vasodilation. According to this 
hypothesis, insulin-stimulated glucose uptake and metabolism generates ATP which 
activates Na+-K+ ATPase: this, either by an endothelial effect to generate NO or a 
direct action to reduce intracellular calcium concentration in vascular smooth muscle 
cells, will result in vasodilation. This provides a unifying hypothesis which may 
account for the reported linkage between reduced insulin-mediated glucose uptake 
and metabolism and attenuated insulin vasorelaxation (Laakso et al, 1992; Feldman 
et al, 1995; see chapter 4).
Of course, it must be borne in mind that the ‘control’ vasoconstrictor used in this 
study, Ang II, may not be a ‘neutral’ vasoconstrictor, in the sense that there may be
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a degree of ‘cross-talk’ between post-receptor signalling pathways of insulin and 
Ang II. There is some evidence from in vitro work to support this notion; for 
example, Ang II receptor (type 1) activation stimulates tyrosine phosphorylation of 
insulin receptor substrate-1 (IRS-1) but inhibits activation of phosphatidylinositol 3- 
kinase (PI3-kinase) (Saad et al, 1995; Du et al, 1996; Velloso et al, 1996), which 
suggests that the octapeptide may modify insulin action, although it is unclear 
whether there is any functional association between the metabolic and vascular 
effects. Additionally, recent evidence suggests that Ang II increases vascular 
superoxide production, an effect which has been shown to inhibit relaxation to 
acetylcholine (but not norepinephrine) (Rajagopatan et al, 1996); if this mechanism 
occurs in man, insulin-mediated NO-dependent vasodilation might be similarly 
inhibited by Ang n.
In summary, it has been demonstrated in this study that local infusion of 
physiological doses of insulin and glucose causes 30-40% vasodilation in the human 
forearm vascular bed. This action is abolished by co-infusion not only of a NO 
synthase inhibitor (L-NMMA), but also of angiotensin II and ouabain (at doses 
calculated to result in a similar state of prior vasoconstriction to that induced by L- 
NMMA). One conclusion from these data is that the mechanism of insulin-mediated 
vasodilation involves stimulation of endothelial NO production, but stimulation of 
the Na*K+ATPase pump, or a combination of mechanisms can also be supported. 
This study highlights the pitfalls of interpreting data of this nature, since an 
alternative conclusion is that insulin-mediated vasodilation is inhibited in a non­
specific manner simply as a result of induction of background vasoconstriction.
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Correlation analysis of our data revealed that insulin-mediated vasodilation appears 
to be most closely coupled with the activity of the Na*K+ATPase pump, possibly due 
to the dual action of insulin on this pump at both an endothelial and vascular smooth 
muscle level.
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Chapter 4
Insulin-mediated vasodilation and glucose uptake are functionally linked in 
man
4.0 Summary
This clinical physiology study was designed to test the hypothesis that insulin- 
mediated vasodilation and insulin sensitivity are functionally related. Eighteen 
healthy volunteers attended on two separate occasions for measurement of whole- 
body insulin sensitivity and forearm vasodilation in response to an intra-arterial 
infusion of insulin and glucose. In multiple regression analysis, insulin-mediated 
vasodilation was, indeed, a significant independent predictor of insulin sensitivity.
4.1 Introduction
Epidemiological studies have demonstrated a link between metabolic disorders (such 
as obesity and type 2 diabetes, and cardiovascular diseases such as essential 
hypertension, congestive cardiac failure and atherosclerosis (DeFronzo & Ferrannini, 
1991). These disorders share two important pathophysiological features, namely 
relative resistance to insulin-mediated glucose uptake (Yki-Jarvinen & Koivisto, 
1983; DeFronzo et al, 1992; Ferrannini et al, 1987; Swan et al, 1994) and vascular 
endothelial dysfunction, characterised by reduced basal and stimulated endothelial 
nitric oxide production (Williams et al, 1996; Calver et al, 1992; Panza et al, 1993; 
Drexler et al, 1993). However, the underlying mechanism(s) and significance of this 
association remain unclear.
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Our group has previously reported a significant, positive relationship, in healthy 
volunteers, between insulin sensitivity and basal endothelial nitric oxide production 
(Petrie et al, 1996a) consistent with a functional link between insulin-mediated 
glucose uptake and endothelial function. However, in addition to its metabolic 
effects, insulin is also a directly acting vasodilator, an action which has been 
demonstrated to be largely dependent on endothelial nitric oxide production 
(Scherrer et al, 1994a; Steinberg et al, 1994). The importance of this phenomenon 
in cardiovascular regulation and the nature of the relationship between insulin- 
stimulated blood flow and glucose uptake are uncertain. However, in view of the 
evidence that both insulin sensitivity and insulin-mediated vasodilation are directly 
linked to endothelial function, the hypothesis was generated that insulin-mediated 
vasodilation would be directly related to insulin sensitivity. Previous studies 
reporting such a relationship in man have been subject to potentially confounding 
factors, including sympathetic nervous system activation, as they have examined 
vasodilation during systemic insulin infusions (Baron et al, 1995; Utriainen et al, 
1997). There is, however, data to suggest a positive relationship, albeit using the 
rather unphysiological model of infusing insulin into preconstricted dorsal hand veins 
(Feldman et al, 1995). In the absence of published data adequately testing the 
hypothesis of a relationship between whole-body insulin sensitivity and vasodilation 
secondary to local intra-arterial infusion of insulin, the current study was designed to 
investigate this issue in a group of healthy male volunteers.
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4.2 Methods
4.2.1 Subjects
Eighteen healthy, normotensive male volunteers aged 18-37 years participated in this 
study which was approved by the Ethics Committee of the West Glasgow Hospitals 
University NHS Trust. No subjects were taking medication, and all abstained from 
alcohol, tobacco and strenuous physical activity for 24 hours and from food and 
caffeine-containing drinks overnight before the two study days, which were at least 
one week apart. At a screening visit, physical health was confirmed by history and 
physical examination and supine blood pressure was measured in triplicate (Dinamap 
Critikon, Johnson and Johnson Professional Products Ltd). Subject characteristics 
included age 26±5.4 years, mean arterial pressure (MAP) 89+8.8 mmHg 
(mean+SD) and body mass index (BMI) 23.2 (21.9, 26.3) kg/m2 (median, 
interquartile range); 2 subjects were smokers; median alcohol consumption was 
20g/week.
4.2.2 Clinical procedures
Subjects attended for measurement of whole-body insulin sensitivity (M) using a 
180-minute hyperinsulinaemic euglycaemic clamp as described in section 2.4.1. On a 
separate study day, subjects attended for measurement of forearm blood flow by 
bilateral venous occlusion plethysmography, as described in section 2.7.1. After 
baseline readings had been obtained, subjects received an intra-arterial infusion of 
low-dose D-glucose (75pmol/min) for 120 minutes in order to maintain local venous 
euglycaemia in the forearm vascular bed (Ueda et al, 1998a). After 30 minutes, and 
for the remaining 90 minutes, soluble human insulin (Actrapid, Novo Nordisk,
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Denmark) was co-infiised at a dose of 5mU/min. A uniform infusion rate (2ml/min) 
was used throughout the study.
4.2.3 Statistical Evaluation
For the forearm plethysmography data, percentage change from basal values in the 
ratio of blood flow between infused and non-infiised arms was calculated, using the 
blood flow in the non-infused arm as a concurrent control (Benjamin et al, 1995). In 
order to avoid multiple comparisons, a summary measure was calculated which was 
the mean value of the last three readings (100-120 minutes) (Matthews et al, 1990).
Data were initially examined using simple correlation; multiple regression analysis 
(Minitab for Windows, Minitab Inc.) was performed in order to examine potential 
confounders. Insulin sensitivity, age and MAP data were normally distributed; insulin 
vasodilation and BMI data were non-parametrically distributed and were therefore 
log-transformed before undergoing multiple regression analysis. For simple 
correlation involving data which were non-parametrically distributed, the rank 
correlation coefficient was calculated.
4.3 Results
The procedures were carried out without complication and were well tolerated by all 
subjects.
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4.3.1 Insulin levels
During the euglycaemic clamps, systemic insulin levels were raised to 86+13.9 
liUml'1 during the last hour. During the local insulin infusions, insulin levels in the 
forearm vascular bed were raised to 109+39 |iUml*1 during the last hour.
4.3.2 Whole-body insulin sensitivity
M-value (mean+S.D.) for the group was 10.0+2.2 mg kg*1 min*1 [range: 6.8 - 14.7].
4.3.3 Insulin-mediated vasodilation
Percentage change in forearm blood flow ratio (%FBFR) for the group (median, 
interquartile range) was 28.2% (13.6, 48.6).
4.3.4 Univariate analysis
Depending on the distribution of the data, simple (r) or rank correlation (r,) analysis 
was performed. M-value was significantly correlated with %FBFR (r, = 0.60, p < 
0.05, figure 4.1), but not with BMI (r, = -0.42, p < 0.1), age (r = -0.39, p < 0.2) or 
MAP (r = 0.13, p > 0.2) [figure 4.2]. %FBFR was not significantly correlated with 
BMI (r, = -0.15), age (r, = 0.16) or MAP (r, = 0.15) [p > 0.2].
4.3.5 Multiple regression analysis
Table 4.1 displays adjusted R2 and t for %FBFR as a predictor of M-value, with 
forward stepwise addition of BMI, age and MAP. %FBFR remains a significant
136
independent predictor of M-value after these potentially confounding variables are 
included in the model (R2 (adj) = 0.48, t = 3.23, p < 0.01).
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Figure 4.1
Whole-body insulin sensitivity (M) plotted against 
local insulin/glucose-mediated vasoreactivity in 18 
healthy male volunteers.
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Figure 4.2
Whole-body insulin sensitivity (M) plotted against 
(a) age (b) body mass index (c) mean arterial 
pressure, in 18 healthy male volunteers.
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Table 4.1
Multiple regression models with insulin sensitivity (M) as dependent variable.
Model insulin
vasodilation
age BMI MAP Adjusted
R2
t  for insulin 
vasodilation
P
1 V 0.20 2.28 0.04
2 V V 0.44 3.26 0.005
3 V V V 0.51 3.32 0.004
4 V V 4 V 0.48 3.23 0.007
Prediction of insulin sensitivity (M) from percentage change in forearm blood flow 
ratio in response to local insulin infusion (insulin vasodilation), age, body mass index 
(BMI) and mean arterial pressure (MAP).Changes are shown as adjusted R2 and t for 
insulin vasodilation, with addition of age, BMI and MAP into the model. Predictor 
variables, model 1, insulin vasodilation; model 2, insulin vasodilation +age; model 2, 
insulin vasodilation + age + BMI; model 4, insulin vasodilation + BMI + age + MAP.
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4.4 Discussion
This study is the first to examine the relationship between whole-body insulin 
sensitivity and insulin-mediated vasodilation using a physiological model in the 
absence of potentially confounding haemodynamic variables such as stimulation of 
the sympathetic nervous system. The results demonstrate that vasodilation induced 
by local intra-arterial infusion of insulin/glucose was independently associated with 
whole-body insulin-mediated glucose uptake in healthy male volunteers. As expected 
there was a trend for insulin sensitivity to decrease with increasing age and body 
mass index, but these relationships were not significant due to the relatively narrow 
range of values in this group of young healthy volunteers.
There is currently a great deal of interest in the vascular effects of insulin, and 
especially whether its vasodilator action is coupled in a functional manner with its 
ability to stimulate cellular glucose uptake. Given that insulin is thought to be an 
endothelium-dependent vasodilator (Scherrer et al, 1994a; Steinberg et al, 1994), the 
mechanism of any functional coupling between insulin’s vascular and metabolic 
actions may help to explain the observed association between endothelial 
dysfunction and insulin resistance in metabolic and cardiovascular disorders. Baron’s 
group has repeatedly demonstrated a significant relationship between whole-body 
insulin sensitivity and clamp-induced leg vasodilation in healthy subjects (Baron et 
al, 1995). However, Yki-Jarvinen’s group, while conceding that endothelial function 
is a significant determinant of insulin-mediated vasodilation (Utriainen et al, 1996a), 
has reported a lack of relationship between insulin sensitivity and forearm 
vasodilation in response to systemic hyperinsulinaemia (Utriainen et al, 1996a;
141
Utriainen et al, 1996b). In support of this conclusion, the same group used positron 
emission tomography (PET) and [18F]fluoro-2-deoxy-D-glucose uptake to 
demonstrate a dissociation of insulin-stimulated blood flow and glucose uptake in 
thigh skeletal muscle; however, despite this finding, they demonstrated a significant 
relationship between the insulin-induced increase in whole leg blood flow and whole- 
body insulin sensitivity (Raitakari et al, 1996). In a more recent study, in which 
higher resolution methods were used, these investigators conceded that insulin- 
stimulated muscle blood flow co-localized with regional glucose uptake, consistent 
with redirection of flow by insulin to areas where it stimulates glucose uptake 
(Utriainen et al, 1997). The current data, which demonstrate a close correlation 
between direct insulin-induced arterial vasodilation and whole-body stimulated 
glucose uptake, support this hypothesis.
There are three possible explanations for this observation: firstly, that insulin- 
mediated vasodilation is an important determinant of insulin-mediated glucose 
uptake; secondly, that glucose uptake modulates the vascular response to insulin, 
possibly at an endothelial level; thirdly, that a third factor is responsible for 
determining both the metabolic and vascular actions of insulin.
If substrate delivery is the rate-limiting step for insulin-mediated glucose uptake (in 
other words, if skeletal muscle blood flow is a determinant of glucose uptake), then 
it can be argued that endothelial dysfunction, resulting in a relative inability of 
mediators, including insulin, to stimulate muscle blood flow, may be the underlying 
mechanism accounting for the association of atherosclerosis and other
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cardiovascular disorders with insulin resistance (Baron, 1994). However, it has been 
suggested that substrate delivery is only likely to be rate-limiting for glucose disposal 
at supra-physiological insulin levels maintained for many hours and does not, 
therefore, explain the physiological association between endothelial function and 
insulin sensitivity (Yki-Jarvinen, 1995). One approach to resolve this issue is to 
manipulate limb blood flow during hyperinsulinaemia and assess whether insulin- 
mediated glucose uptake is affected. There is some evidence from this type of study 
that skeletal muscle blood flow may be a determinant of insulin-mediated glucose 
uptake; infusion of N° - monomethyl-L-arginine (L-NMMA) into the femoral artery 
during a clamp reduces insulin-mediated stimulation of blood flow (via inhibition of 
endothelial nitric oxide production) resulting in a 25% decrease in limb glucose 
uptake (despite a 50% increase in arteriovenous fractional glucose extraction) 
(Baron et al, 1995). This observation is consistent with the notion that 20-30% of 
insulin-mediated glucose uptake is blood-flow dependent. In the same study, whole- 
body insulin sensitivity correlated significantly with the decrement in limb blood flow 
as a result of L-NMMA infusion (Baron et al, 1995). However, other investigations 
have failed to support the notion that skeletal muscle blood flow and tissue glucose 
uptake are functionally related. In one study, when human volunteers were fed a 
mixed physiological meal, arteriovenous glucose extraction was found to be the 
main determinant of limb glucose uptake; this rose by a factor of five, while blood 
flow increased by only 16% (Mijares & Jensen, 1995). In another study, no 
significant increases in forearm blood flow were observed during an oral glucose 
tolerance test (Kelly et al, 1988). Furthermore, dissociation of insulin-mediated 
glucose uptake from blood flow was observed in a study in which both limb blood
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flow and muscle sympathetic nerve activity were stimulated to similar degrees at 
different systemic insulin concentrations, ranging from 100 to 400pmol/l (Anderson 
et al, 1991). Finally, again in man, forearm blood flow has been augmented by 100% 
using intra-arterial adenosine (Natali et al, 1994) and bradykinin (Nuutila et al, 1996) 
without a detectable effect on forearm glucose uptake, and it must be concluded that 
the case for skeletal muscle blood flow being a determinant of insulin sensitivity 
remains uncertain.
An alternative, and more tenable, hypothesis is that insulin-stimulated glucose 
uptake may determine muscle blood flow in response to the hormone by causing an 
increase in ATP production, as a consequence of aerobic glycolysis. This will 
provide energy for membrane ion pumps (for example Na+-K+ ATPase) resulting in 
hyperpolarisation and changes in Ca2+ fluxes in both endothelium and vascular 
smooth muscle cells (Sowers, 1996). It has been shown that insulin-mediated 
vasodilation can be inhibited by ouabain, an inhibitor of Na+-K+ ATPase (Tack et al, 
1996; see chapter 3), which would support this proposal. Furthermore, if nitric oxide 
synthase activity is enhanced by stimulation of ATP-dependent ion pumps such as 
Na+-K+ ATPase, insulin-stimulated glucose uptake may result in increased nitric 
oxide production as a consequence of endothelial cell glucose metabolism; 
conversely, reduced glucose uptake would be predicted to lead to diminished nitric 
oxide production. In support of the notion that glucose uptake is necessary for 
insulin-mediated vasodilation is the finding that clamping glucose at 20 mmol*1 
during hyperinsulinaemia causes 50% augmentation of insulin-stimulated blood flow 
in man (Baron, 1993). In addition, a number of in vitro studies provide evidence that
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glucose uptake may be important in determining vascular smooth muscle cell 
relaxation (Sobrevia et al, 1996; Graier et al, 1993; Kahn et al, 1995); of particular 
note is a recently published study demonstrating nitric oxide production secondary 
to insulin stimulation in endothelial cell culture and subsequent blocking of this in the 
presence of wortmannin, which inhibits phosphatidyl inositol 3-kinase, an essential 
enzyme involved in intracellular insulin-stimulated glucose transport and metabolism 
(Zeng & Quon, 1996). Furthermore, the delayed time course of insulin-mediated 
vasodilation would support this hypothesis, in that the vasodilator effect of the 
hormone is only evident after 30-40 minutes, consistent with primary effects to 
increase glucose uptake and metabolism. One implication of this hypothesis would 
be that a primary derangement of glucose uptake would lead to reduced insulin- 
mediated vasodilation (and, possibly, effects on other aspects of vascular endothelial 
function), so providing an explanation of the link between insulin resistance and 
vascular disease.
However, the current data, and most of the studies cited above, are based on studies 
performed in healthy subjects, and it is reasonable to examine whether similar 
relationships between insulin’s metabolic and vascular effects are observed in 
disease. Previous studies in these circumstances have produced conflicting results. 
For example, it has been demonstrated in obese subjects (Laakso et al, 1990) and in 
patients with type 2 diabetes (Laakso et al, 1992) and insulin-dependent diabetes 
mellitus (Baron et al, 1991) that there is blunting of insulin-mediated vasodilation in 
parallel with reductions in whole-body insulin sensitivity, which would be consistent 
with the current data. However, the physiological relevance of some of these studies
145
has been questioned in view of the doses of insulin administered and the clamping of 
glucose values at the relatively hypoglycaemic value of 5mmol/l in type 2 diabetic 
subjects (Laakso et al, 1992). In another study, in which glucose levels were 
clamped at fasting levels in subjects with type 2 diabetes, blunting of the blood flow 
response to insulin was observed (Dela et al, 1995). Using PET scanning to measure 
forearm blood flow, Yki-Jarvinen et al recently demonstrated no defect in insulin- 
stimulated muscle blood flow in a group of patients with type 2 diabetes despite a 
significant reduction in muscle glucose uptake compared with controls, implying that 
insulin’s metabolic function is impaired but its vascular action is preserved in type 2 
diabetes (Raitakari et al, 1996). In a group of patients with essential hypertension, 
calf blood flow measured during systemic hyperinsulinaemia was not directly related 
to insulin sensitivity and there was no difference compared with a group of healthy 
matched controls (Hunter et al, 1997). More recently it was demonstrated in 
hypertensive patients that insulin sensitivity was weakly related to insulin-stimulated 
forearm blood flow, but not to stimulated endothelial function, although the lack of a 
control group reduces the ability to interpret these results (Natali et al, 1997). It 
should be borne in mind, however, that in all of the above experiments the 
measurements of limb blood flow were made during systemic administration of 
insulin, and may not give a true reflection of the direct vascular effects of the 
hormone: there is a need for investigations in patient groups to be re-evaluated in 
this regard (see chapter 7).
Finally, the possibility remains that insulin’s metabolic and vascular actions are not 
causally related but are influenced by a third factor. The most obvious candidate is
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skeletal muscle structure, fibre type and related capillarisation, which is largely 
determined by inheritance. It has been demonstrated that the proportion of type 1 
fibres (oxidative, slow-twitch) is related to forearm and whole-body glucose uptake 
in healthy males, while the ratio of capillaries per fibre correlates with both basal and 
insulin-stimulated forearm blood flow (Utriainen et al, 1996c, but see chapter 6). 
Since type 1 fibres tend to be surrounded by a more dense capillary network, this 
raises the possibility that skeletal muscle structure is the common link between 
insulin’s metabolic and vascular effects. In this context, it is of interest to note that 
similar structural characteristics (reduced capillary density, a predominance of type 
IIB glycolytic, fast-twitch fibres and a relative lack of type I fibres) are present in 
skeletal muscle of subjects not only with metabolic disorders, such as central obesity 
(Krotkiewski & Bjomtorp, 1986) and type 2 diabetes (Lilloja et al, 1987), but also 
with cardiovascular disorders, such as essential hypertension (Juhlin-Dannfelt et al, 
1979). Therefore, underlying muscle structure could theoretically contribute to the 
observed insulin resistance and vascular dysfunction in these conditions (see chapter 
6).
Finally, another possible confounding factor is obesity, which may affect insulin- 
mediated glucose uptake and vascular endothelial function by different mechanisms. 
It has been shown that obese insulin-resistant subjects are characterised by 
endothelial dysfunction and resistance to insulin’s effect on enhancement of 
endothelium-dependent vasodilation, and that there is no difference in these variables 
in a group of patients with type 2 diabetes, matched for age and BMI (Steinberg et 
al, 1996). These results suggest that obesity may play a primary role in the link
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between insulin resistance and endothelial dysfunction, and may help to explain why 
results obtained in obese diabetic and hypertensive patient groups cannot necessarily 
be extrapolated to patients of normal BMI. However, it should be noted that BMI 
was not a confounding variable in the current study.
In summary, in the current study, evidence is presented supporting a significant 
functional link between insulin sensitivity and local insulin-mediated vasodilation 
(which avoids the confounding haemodynamic effects of systemic hyperinsulinaemia) 
in young healthy male volunteers. The potential pathophysiological relevance and 
mechanisms remain unknown, although a more detailed understanding of the 
association may shed light on the underlying pathophysiology which leads to insulin 
resistance in a variety of disease states. Further studies in groups of patients with 
metabolic and cardiovascular disease are now required (see chapter 7).
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Chapter 5
Systemic inhibition of endothelial nitric oxide synthesis does not impair insulin 
sensitivity in man.
5.0 Summary
In this clinical physiology study, an experimental state of systemic endothelial 
dysfunction was induced in healthy male volunteers and the effect on whole-body 
insulin sensitivity was assessed in a randomised double-blind, placebo-controlled 
manner. The results indicate that impairment of endothelial nitric oxide synthesis 
does not result in an impairment of whole-body insulin sensitivity, suggesting that 
substrate delivery to nutritive capillary beds is unlikely to be rate-limiting for insulin- 
mediated glucose uptake.
5.1 Introduction
Resistance to insulin-mediated glucose uptake and endothelial dysfunction have both 
been implicated in the pathogenesis of essential hypertension (Ferrannini et al, 1987; 
Lind et al, 1995; Panza et al, 1993a) and other forms of cardiovascular disease, 
including type 2 diabetes (DeFronzo et al, 1992; McVeigh et al, 1992). As stated 
previously, our group has demonstrated a relationship, in healthy subjects, between 
insulin sensitivity and basal endothelial nitric oxide production (Petrie et al, 1996a), 
and it was suggested that variations in endothelial function might account for 
variations in insulin sensitivity by decreasing skeletal muscle blood flow, which may 
be a determinant of insulin-mediated glucose uptake (Baron, 1994). However, it
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remains unclear whether insulin sensitivity and endothelial function are causally 
related or whether both phenotypes are influenced by a common antecedent. In 
order to examine this hypothesis in the current study, an experimental state of 
impaired endothelial function has been induced in healthy male volunteers by 
systemic inhibition of endothelial nitric oxide synthesis, and the effect on insulin 
sensitivity has been assessed. In addition, the effects of No-monomethyl L-arginine 
(L-NMMA) were compared with angiotensin II (Ang II), which raises blood 
pressure predominantly by an endothelium-independent effect on vascular smooth 
muscle cells; in other words, Ang II acted as a pressor control infusate. 
Furthermore, since it has been proposed that altered blood flow to skeletal muscle is 
a determinant of insulin sensitivity, the effects of systemic L-NMMA on forearm 
blood flow were also assessed using venous occlusion plethysmography.
5.2 Methods
5.2.1 Subjects
Nine healthy, normotensive male volunteers aged 23-35 years participated in these 
randomised, double-blind, placebo-controlled studies which were approved by the 
Ethics Committee of the West Glasgow Hospitals University NHS Trust. No 
subjects were taking medication, and all abstained from alcohol, tobacco and 
strenuous physical activity for 24 hours and from food and caffeine-containing 
drinks overnight before study days. At a screening visit, physical health was 
confirmed by history and physical examination and supine blood pressure was 
measured in triplicate (Dinamap Critikon, Johnson and Johnson Professional 
Products Ltd). Subject characteristics (mean+SD) included body mass index (BMI)
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25.5+2.4 kg/m2, fasting glucose level 5.1 ±0.17 mmol/1, fasting cholesterol level 
4.6+0.65 mmol/1, fasting triglyceride level 1.06+0.57 mmol/1 and blood pressure 
136+11/73+6 mmHg. Mean (±SD) age was 27.8+5 years; 2 subjects were smokers; 
median alcohol consumption was 50g/week. All subjects gave full informed consent 
prior to participation in the study.
5.2.2 Clinical procedures
Subjects attended on three study days, one week apart, for measurement of whole- 
body insulin sensitivity (M) using a 180-minute hyperinsulinaemic euglycaemic 
clamp (see section 2.4.1). At 120 minutes, a further infusion was commenced of 
either: 1) L-NMMA (Clinalfa, 0.8 pmol/kg/min for 15 minutes, followed by vehicle 
for a further 45 minutes); 2) angiotensin II (ANG H, Ciba-Geigy, 5 pmol/kg/min for 
60 minutes); or 3) vehicle (normal saline 1 ml/min for 60 minutes). These were 
administered in a randomised double-blind manner, using a double-dummy design 
because of the different infusion periods. L-NMMA was administered in this fashion 
to mimic a previous protocol in healthy volunteers in which the safety of systemic 
infusion was established (Haynes et al, 1993); its physiological effect is known to be 
long-lasting (hours) and therefore it was assumed that endothelial dysfunction would 
be induced throughout the whole of the third hour of the clamp procedure.
Blood pressure and heart rate were measured every 10 minutes throughout the 
procedure (Dinamap; Critikon Inc., Tampa, Florida, USA).
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In addition blood samples were taken at 0, 60, 120 and 180 minutes for 
measurement of insulin, potassium, cholesterol, triglycerides (serum), plasma renin 
concentration and aldosterone (plasma). Blood was taken at 0 and 180 minutes for 
measurement of plasma angiotensin II concentration. Assay methods are described in 
section 2.9.
Six subjects from the original nine attended on a fourth study day designed to assess 
the haemodynamic effects of a systemic L-NMMA infusion in the absence of 
background hyperinsulinaemia. The protocol was the same as for the previous study 
days except that a saline infusion was substituted for insulin and 20% dextrose 
(‘sham clamp’); the subjects were not aware of this difference. Heart rate and blood 
pressure were assessed at 10 minute intervals during the second hour and at 5 
minute intervals during the third hour.
In order to confirm that a systemic infusion of L-NMMA at the test dose would 
result in a change in forearm blood flow (FBF), FBF during systemic L-NMMA 
versus placebo was assessed in four volunteers of similar age and BMI to the 
original nine. Subjects attended on two occasions and, after a run-in period of 30 
minutes to establish baseline values for limb blood flow, received a systemic infusion 
of either L-NMMA (12 pmol/kg over 15 minutes) or placebo (saline for 15 minutes) 
in a random-order, double-blind manner. Forearm blood flow in the non-infiised arm 
was measured using venous occlusion plethysmography (see section 2.7.1.).
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5.2.3 Statistical analysis
All data were assessed for normality using the Shapiro-Wilks test. Mean blood 
pressure, heart rate, and insulin sensitivity (M) values in the final hour were 
calculated as summary measures (Matthews et al, 1990) and any differences were 
assessed using paired t-tests with Bonferroni correction.
Forearm blood flow and haemodynamic data as well as serum concentrations of 
insulin, potassium, cholesterol, triglycerides, and plasma concentrations of 
aldosterone, renin and angiotensin n  on the different study days were compared 
using repeated-measures three-way ANOVA The statistical significance of 
differences at individual time-points were assessed using a t-test with Bonferroni 
correction. All data are expressed as mean ± standard deviation.
5.3 Results
The euglycaemic clamps and systemic L-NMMA infusions were well tolerated in all 
subjects with no significant adverse effects.
5.3.1 Insulin sensitivity
M-value (mean±SD) was 9.9±2.52, 10.9±2.23 & 10.4±2.10 mg kg^min*1 after 
placebo, Ang II or L-NMMA respectively (figure 5.1: raw data). L-NMMA infusion 
did not cause a significant change in M when compared with either placebo (p=0.48) 
or the pressor control Ang II (p=0.17). Ang II infusion tended to increase insulin
153
sensitivity compared with placebo (p=0.04), but this was not significant (significance 
level: <0.01, when corrected for multiple comparisons).
5.3.2 BP and HR
There were small but statistically significant increases in blood pressure with both L- 
NMMA and Ang n. Diastolic BP rose by 3.2+2.2 mmHg during L-NMMA (p<0.01) 
and by 6.0±3.8 during Ang II (p<0.01). Systolic BP did not change significantly with 
L-NMMA (+0.43+4.2) but rose by 4.6+5.8 with Ang II (p<0.05). MAP rose by 
2.3+2.4 mmHg during L-NMMA (p<0.05) and by 5.6+4.2mmHg during Ang II 
(p<0.01). HR fell by 4.4+3.6 bpm during L-NMMA (p<0.01) and by 2.0+7.4 bpm 
during Ang II (p<0.05).
During the L-NMMA / ‘sham clamp’ study (n=6), MAP rose by 3.5+1.9 mmHg 
(p<0.005) which was not significantly different from the rise in MAP during the 
clamps (2.3+2.4 mmHg). HR fell by 3.7+3.6 bpm (p=0.05) during the ‘sham clamp’ 
study. The pattern and the extent of the haemodynamic changes in response to L- 
NMMA were similar when fasting euglycaemia and hyperinsulinaemic euglycaemia 
were compared (figure 5.2).
5.3.3 Forearm blood flow
Systemic L-NMMA infusion caused significant forearm vasoconstriction when 
compared with placebo at 40, 50 and 60 minutes after commencing the infusion 
(figure 5.3).
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5.3.4 Serum insulin, potassium, cholesterol and triglycerides
Values obtained on the three study days were not significantly different at any of the 
time-points (figure 5.4). Insulin results [time-points 0, 60, 120 and 180 minutes 
(liUmr1): 10.2±4.4, 116.2+22.1, 125.1±27.1, 136.3±26.2 (placebo); 13.0±13.7, 
107.8+20.8, 112.2+11.2, 127.4±21.5 (Ang II), 8.4±4.4, 119.4±23.1, 120.6±18.5, 
137.0+18.0 (L-NMMA) (figure 5.5).
5.3.5 Plasma aldosterone, angiotensin n, and renin concentrations
As expected, values at 180 minutes from the days on which subjects received Ang II 
infusions were significantly higher for Ang II concentration and aldosterone 
concentration (p<0.001); there was a decrease in plasma renin concentration after 
Ang n, which failed to reach statistical significance. L-NMMA had no significant 
effect on concentrations of these hormones (table 5.1).
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Figure 5.1
Individual values for whole-body insulin sensitivity (M) in 
nine healthy male volunteers on three separate occasions, 
who received a systemic infusion in the final hour of (a) 
placebo (b) angiotensin II (c) L-NMMA.
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Figure 5.2
Time course o f blood pressure and heart rate responses to systemic 
L-NMMA infusion (mean + S.D.) in six healthy male volunteers 
(a) during clamp (b) fasting conditions.
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Figure 53
Time course of changes in absolute forearm blood flow 
(mean ± S.D.) in response to 15 minute systemic 
infusions of either placebo or L-NMMA (3 mg/kg). * p < 
0.05; **p< 0.01
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Figure 5.5
Serum insulin levels (mean ± S.D.) during 180 minute 
euglycaemic clamps in nine healthy male volunteers. 
During the final hour systemic infusions were given of (a) 
placebo (b) angiotensin II (c) L-NMMA.
placebo 
Ang II 
L-NMMA
0 60 120 180
Time (mins)
160
Variables 0
Time (rruns) 
60 120
ooo
Angiotensin II (pmolA)
Placebo 11.8±9.6 16.8+11.5
L-NM M A 10.5+10.1 14.4+10.9
ANG II 12.5+14.4 90.4+33.9 X
Aldosterone (pmol/l)
Placebo 3 7 2 ± l18 211+61 2 33±158 216+118
L-NM M A 4 4 5 ± 179 233±92 2 2 6 ± 8 1 327+191
ANG II 4 0 5 ± 1 18 251± 167 246±86 765+178*
Renin (uU/ml)
Placebo 34.0±19.1 32.8±14.7 33.5± 15.8 29.6±10.2
L-NM M A 26.4±8.4 29.5±7.9 32.4+11.8 27.2±8.2
ANG II 2 0 .7 ± 1 1.7 23.7±10.0 26.0±5.3 13.4±5.5
Values given are M ean+S.D. ^Indicates a significant change in these variables 
following ANG II infusion (by analysis o f variance). Infusion of L-NM M A  had no 
significant effect on these variables.
Table 5.1 Plasma a ld o s te r o n e , a n g io te n s in  I I  and ren in  c o n c e n tr a t io n s  dui 
eu g lycaem ic clam ps.
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5.4 Discussion
These results demonstrate that systemic inhibition o f endothelial nitric oxide 
synthesis by acute infusion o f L-NMMA (12 umol/kg over 15 mins) in healthy 
subjects is not associated with a reduction in whole-body insulin sensitivity as 
determined by the euglycaemic clamp technique. A systemic infusion o f angiotensin 
II in a dose sufficient to  cause a similar rise in blood pressure resulted in a small but 
non-significant increase in insulin sensitivity, consistent with previous results from 
our group in healthy volunteers (Morris et al, 1993). Furthermore, when the M- 
values are compared for L-NMMA and Ang II, there is no significant difference. 
Thus, despite attempting to control for haemodynamic influences on insulin 
sensitivity, it was not possible to demonstrate that systemic inhibition o f endothelial 
nitric oxide synthesis, which is confirmed by a rise in blood pressure, impairs insulin 
sensitivity. In addition, it has been shown that systemic L-NMMA infusion causes 
similar changes in blood pressure and heart rate under hyperinsulinaemic and basal 
conditions, and that the increase in blood pressure is associated with significant 
forearm vasoconstriction. These haemodynamic changes during the infusion o f  L- 
NM M A are consistent with previously published results (Haynes et al, 1993). It was 
decided not to combine measurement o f forearm blood flow with the clamp 
procedure since previous work from our group showed that hand-warming (required 
for ‘arterialisation’ o f venous blood during the clamp) can, in itself, affect 
contralateral forearm blood flow (Petrie et al, 1996b). Furthermore, there were 
ethical constraints on using higher doses o f L-NMMA in volunteers. Although it has 
not been confirmed that this dose o f  systemic L-NMMA induces significant 
endothelial dysfunction in man (for example, by demonstrating blunting o f
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acetylcholine-induced forearm vasodilation), it was assumed that significant 
endothelial dysfunction was induced as indicated by the significant increase in 
diastolic blood pressure.
On the basis of previous results from our group demonstrating, in a group of healthy 
subjects, a positive correlation between insulin sensitivity (assessed by a euglycaemic 
hyperinsulinaemic clamp) and basal endothelial nitric oxide production (assessed by 
the local vasoconstrictor response to L-NMMA in the forearm vascular bed) (Petrie 
et al, 1996a), the suggestion has been made that there may be a causal link between 
insulin resistance and endothelial dysfunction in the pathogenesis of cardiovascular 
disease. In the current study, it was decided to test the hypothesis that acute 
disruption of endothelial function would decrease insulin sensitivity. Ang II was used 
as a control pressure infusate in a dose designed to raise blood pressure to a similar 
extent without affecting vascular endothelial function. It is acknowledged that the 
haemodynamic effects of Ang n  differed from those of L-NMMA, thus weakening 
its value as a pressor control infusate. However, our group had already 
demonstrated in a previous study that this dose of Ang II had significant 
haemodynamic effects without significantly affecting whole-body insulin sensitivity 
(Morris et al, 1993) and, therefore, this seemed a reasonable choice of agent to 
control for any direct effects of blood pressure changes per se on insulin sensitivity.
There are several areas of evidence to link insulin action with vascular endothelial 
nitric oxide production. Firstly, systemic hyperinsulinaemia causes peripheral 
vasodilation and there is evidence that this is dependent on nitric oxide production in
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both the leg and forearm vascular beds (Scherrer et al, 1994a; Steinberg et al, 1994). 
Secondly, vasodilator responses to pharmacological doses of insulin in the human 
leg vascular bed are blunted in insulin-resistant states such as obesity (Laakso et al, 
1990) and type 2 diabetes (Laakso et al, 1992); leg vasodilation secondary to 
systemic hyperinsulinaemia correlates well with whole-body insulin sensitivity 
(Baron et al, 1995; see chapter 4). Thirdly, there are data showing that insulin 
vasodilation is positively related to basal endothelial nitric oxide production 
(Utriainen et al, 1996a). These lines of evidence have led to the suggestion that 
decreased insulin sensitivity occurs as a result of decreased basal endothelial nitric 
oxide production, and hence decreased insulin-mediated vasodilation, with a 
consequent reduction in delivery of insulin and glucose to target tissues. 
Alternatively, insulin may, in some way, determine endothelial function, so that 
altered insulin sensitivity accounts for variations in endothelium-dependent 
vasodilation.
There is independent support for the hypothesis that endothelial dysfunction causes 
insulin resistance. Firstly, systemic infusion of L-NMMA induced insulin resistance 
in rats (Keech et al, 1993) although this was not confirmed by a separate study 
(Kohlman et al, 1995). Secondly, superimposing an infusion of L-NMMA into the 
femoral artery of healthy human subjects during a hyperinsulinaemic euglycaemic 
clamp resulted in reversal of insulin-mediated vasodilation and a 25% reduction in 
leg glucose uptake, despite a 50% increase in arterio-venous glucose extraction 
(Baron et al, 1995). In this latter study a significant inverse relationship was reported 
between whole-body insulin sensitivity and the decrease in leg glucose uptake during
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intra-arterial L-NMMA, suggesting that inter-individual variation in insulin 
sensitivity may be partly explained by variation in insulin’s ability to increase skeletal 
muscle blood flow (Baron et al, 1995). Thirdly, infusion of intra-arterial 
methacholine during hyperinsulinaemic euglycaemia increased limb blood flow and 
resulted in a significant increase in limb glucose uptake, leading to the conclusion 
that blood flow is a rate-limiting step for insulin-mediated glucose disposal (Baron et 
al, 1994).
However, evidence against the hypothesis that blood flow is a determinant of insulin 
sensitivity comes from studies in which limb blood flow during a clamp was 
increased by intra-arterial infusion of either adenosine (Natali et al, 1994) or 
bradykinin (Nuutila et al, 1996). In neither case did limb glucose uptake rise, despite 
a doubling of blood flow.
In the present study the hypothesis has been tested that induction of a state of 
relative endothelial dysfunction by systemic L-NMMA infusion would result in a 
decrease in insulin sensitivity. The results do not, therefore, support the notion that 
impairment of endothelial function is a direct cause of insulin resistance. Moreover, 
since it has been demonstrated that this dose of systemic L-NMMA causes 
significant limb vasoconstriction, it is concluded that skeletal muscle blood flow per 
se is unlikely to be a rate-limiting determinant of insulin-stimulated glucose uptake. 
Of course, it is conceded that using higher doses of L-NMMA for a longer period 
may have caused significant differences in insulin sensitivity, but ethical and safety 
constraints prevailed.
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The discrepancy between these findings and those cited above, in which local 
administration of L-NMMA caused a decrease in limb glucose uptake, needs to be 
considered. Firstly, it cannot be assumed that infusing a vasoactive compound 
systemically will induce the same changes in peripheral blood flow as a local intra- 
arterial infusion. This has been demonstrated with Ang II: local infusion causes 
vasoconstriction while systemic infusion is reported to cause peripheral (limb) 
vasodilation (Buchanan et al, 1993). This may be due to differential effects in 
regional vascular beds causing re-distribution of blood flow from renal and 
splanchnic beds to the periphery. In addition, there is evidence from studies in rats 
that a bolus dose of systemic L-NMMA (12 pmol/kg) causes transient limb 
vasodilation, while higher doses (40 - 120 pmol/kg) cause limb vasoconstriction 
(Gardiner et al, 1990). However, the current study confirms in man, in the fasting 
state, that systemic L-NMMA (12 pmol/kg) causes significant forearm 
vasoconstriction. Since the pattern of blood pressure and heart rate responses during 
hyperinsulinaemia was identical, it was assumed that systemic L-NMMA also caused 
peripheral vasoconstriction in the clamp study (it was decided not to combine the 
two techniques for reasons stated above (Petrie et al, 1996b)). A second potential 
confounding factor is the effect of L-NMMA on renal haemodynamics: if L-NMMA 
caused significant renal vasoconstriction, reduced insulin clearance might increase 
insulin levels and consequent glucose disposal. However, in the current study there 
were no differences in insulin levels among the three study days.
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Finally, central to the original hypothesis that systemic L-NMMA would decrease 
insulin-mediated glucose uptake was the assumption that the only effect of L- 
NMMA would be to attenuate insulin’s stimulation of skeletal muscle blood flow via 
the endothelial nitric oxide pathway. There are very few published data on the 
metabolic effects of nitric oxide and substrate inhibitors of nitric oxide synthase. 
Therefore, when interpreting the results of this study, a possible non-haemodynamic 
role for nitric oxide in modifying insulin-mediated glucose uptake needs to be taken 
into account.
In summary, this study in healthy male volunteers demonstrated that whole-body 
insulin-mediated glucose uptake is not reduced during systemic inhibition of nitric 
oxide synthesis. In addition, systemic L-NMMA infusion caused significant forearm 
vasoconstriction. These data do not support the hypothesis that impairment of 
endothelial function results in insulin resistance.
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Chapter 6
Skeletal muscle capillary density is unrelated to insulin’s vasodilator action
6.0 Summary
Skeletal muscle fibre type is known to be associated with insulin sensitivity. Since 
fibre type is also related to capillary density, this study set out to test the hypothesis 
that insulin's vasodilator action is linked with muscle capillary density, which would 
support the notion that skeletal muscle structure and function may be a significant 
"third factor’ accounting for the observed association between insulin’s metabolic 
and vascular actions. Following immunohistochemical staining of sections of muscle 
biopsy samples from 13 healthy volunteers in whom insulin sensitivity and local 
insulin/glucose-mediated vasodilation had already been measured, it was concluded 
that the quantity of capillary endothelium in muscle is unlikely to be a significant 
determinant of insulin’s vascular action.
6.1 Introduction
Associations have been noted between skeletal muscle fibre types and both 
metabolic and cardiovascular disorders. Subjects with obesity (Lilloja et al, 1987; 
Wade et al, 1990; Simoneau & Bouchard, 1993), central obesity (Lilloja et al, 1987; 
Krotkiewski et al, 1986), hypertension (Juhlin-Dannfelt et al, 1979; Frisk-Holmberg 
et al, 1983) and type 2 diabetes (Lilloja et al, 1987) have a predominance of type HB 
glycolytic, fast-twitch fibres and a relative lack of type I oxidative, slow-twitch 
fibres, which is associated with reduced capillary density. Given that there appears to
168
be increased basal blood flow in skeletal muscle comprising predominantly type I 
fibres (Frisk-Holmberg et al, 1981), it may be possible that insulin-induced changes 
in muscle blood flow are determined by capillary density and that muscle histology 
may be an underlying ‘third factor’ explaining the association between insulin’s 
metabolic and vascular actions.
Using the same subjects as in chapter 4 (n=18), in whom a significant association 
was demonstrated between whole-body insulin-mediated glucose uptake and local 
insulin/glucose-mediated vasodilation, this hypothesis was tested by obtaining 
samples of skeletal muscle for immunohistochemical processing.
6.2 Methods
6.2.1 Subjects
Eighteen healthy, normotensive male volunteers aged 18-37 years participated in this 
study which was approved by the Ethics Committee of the West Glasgow Hospitals
s
University NHS Trust. No subjects were taking medication, and all abstained from 
alcohol, tobacco and strenuous physical activity for 24 hours and from food and 
caffeine-containing drinks overnight before attending for muscle biopsy. At a 
screening visit, physical health was confirmed by history and physical examination 
and supine blood pressure was measured in triplicate (Dinamap Critikon, Johnson 
and Johnson Professional Products Ltd).
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6.2.2 Clinical procedures
Subjects had previously attended (chapter 4) for measurement of whole-body insulin 
sensitivity (M) using a 180-minute hyperinsulinaemic euglycaemic clamp (section 
2.4.1) and measurement of local insulin/glucose-mediated vasoreactivity by bilateral 
venous occlusion forearm plethysmography (section 2.7.1).
The procedure for vastus lateralis muscle biopsy is described in detail in section 
2.8.1. It has been demonstrated that the proportions of fibre types in this muscle are 
similar to those found in muscles of the forearm (Johnson et al, 1973).
6.2.3 Measurement of fibre type and capillary density
Once obtained, muscle biopsy specimens were immediately frozen in liquid nitrogen 
to allow the process of frozen sectioning (section 2.8.2). Muscle fibre type was 
established by use of immunohistochemical techniques, utilising commercially- 
available antibodies to fast and slow myosin (section 2.8.3). Capillary density was 
quantified in terms of an area ratio by immunostaining for CD45, an antigen which is 
selectively expressed on vascular endothelium. Direct visualisation was possible 
using rabbit anti-mouse alkaline phosphatase (RAM AP) allowing direct red staining. 
Area ratio was calculated in two good-quality cross-sections by an image analysis 
camera as described in section 2.8.3.
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6.3 Results
The procedure of muscle biopsy was tolerated well with no serious adverse events. 
Quantification of both fibre type and capillary density was only possible in 13 
subjects for technical reasons (mainly inadequate quality of sample obtained by 
biopsy). Subject characteristics were as follows: age 26.5+5.6 yrs, BMI 24.0+2.8 
kg/m2.
6.3.1 Muscle fibre type
Type I fibres made up 45.8+9.2% (mean±SD) [range 29-63%] of the cross-sectional 
area, which is consistent with previous studies (Lilloja et al, 1987; Utriainen et al, 
1996) where different techniques were used.
Type Ub fibres accounted for 46.1+5.7% (range 37-56%), and type Ha for 
8.1+5.6% (range 0-17%) of the cross-sectional area. These proportions differ from 
previous studies (Ob 27%, Ha 27% [Lilloja et al, 1987]; nb 16%, Ha 32% 
[Utriainen et al, 1996c]). Whether the current results reflect differences in technique 
for fibre staining or differences in subject population is unclear. Type I fibre area, 
which appears to be the most robust muscle fibre parameter, was used in subsequent 
correlation analyses.
6.3.2 Capillary density
Percent cross-sectional area comprising vascular endothelial cells was 5.1+1.8% 
(range 3.0-9.6%).
171
6.3.3 Insulin sensitivity (M)
M-value (n=13) was 9.87+2.4 mg/kg/min.
6.3.4 Local insulin/glucose-mediated vasodilation (IGMV)
Percent change in forearm blood flow ratio (n=13) was 33.7% (13.4, 42.9) [median 
(IQ range)].
6.3.5 Univariate analysis
There was a trend for % type I area to be positively related to capillary density (r =  
0.52, p < 0.1), and for an inverse relationship between % type nb area and capillaiy 
density (r = -0.49, p < 0.1) which would be expected in light of previous results 
(figure 6.1).
Contrary to the primary hypothesis that IGMV would be positively related with 
capillary density, there was no association (r = -0.04, p = 0.9, figure 6.2).
Likewise, there were no significant associations between M and either % type I area 
(r = -0.002) or capillary density (r = -0.01) or between IGMV and % type I area (r = 
-0 .02).
172
Figure 6.1
(a) Percentage area of type I fibres and (b) percentage area 
of type nb fibres, plotted against capillary density 
(percentage area of endothelial cells), in skeletal muscle 
biopsy cross-sections from 13 healthy male volunteers.
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Figure 6.2
Local (forearm) insulin/glucose-mediated 
vasoreactivity plotted against capillary density 
(percentage area of endothelial cells) in skeletal 
muscle biopsy cross-sections from 13 healthy 
male volunteers.
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6.4 Discussion
Insulin is, in large part, an endothelium-dependent vasodilator in skeletal muscle 
vascular beds (Steinberg et al, 1994; Scherrer et al, 1994) and has been shown to 
stimulate endothelial nitric oxide production in number of experimental studies (Wu 
H-Y et al, 1994; Chen & Messina, 1996; Zeng & Quon, 1996). However, even in 
healthy individuals there is a fivefold variation in insulin-mediated vasodilation 
(Utriainen et al, 1995; chapter 4) which is much greater than the expected variation 
in studies measuring either basal or stimulated endothelial function. This finding has 
led to interest in factors which might contribute to this variation and has generated 
the current study hypothesis - that quantitative differences in vascular endothelium in 
skeletal muscle might contribute to insulin’s vasoactive effectiveness.
One previous study has addressed the issue of insulin’s vascular action with 
reference to skeletal muscle histology (Utriainen et al, 1996c). The investigators 
studied sixteen healthy male volunteers and found that forearm fractional extraction 
of glucose in response to systemic hyperinsulinaemia was related directly to % type I 
fibres and inversely to % type nb fibres. They also demonstrated that muscle 
capillary density was strongly related to forearm vasodilation induced by systemic 
hyperinsulinaemia. Taken together, these results imply that inherent properties of 
skeletal muscle may partly explain the observed association between insulin’s 
metabolic and vascular actions (Feldman et al, 1995; Baron et al, 1995; Chapter 4 & 
7). The results of the current study do not support these findings, although there are 
technical differences both in the method of insulin/glucose administration and of 
determining capillary density which may partly explain the different conclusions.
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It has been established in a number of previous studies that conditions associated 
with insulin resistance (obesity, type 2 diabetes and hypertension) tend also to be 
associated with a certain muscle phenotype comprising predominance of type Eb 
glycolytic fibres and reduction in capillary density (Lilloja et al, 1987; Wade et al, 
1990; Juhlin-Dannfelt et al, 1979; Frisk-Holmberg et al, 1983). The reasons for this 
are not clear. It has been suggested that a common factor might be lack of physical 
fitness since chronic aerobic exercise training has been shown to result in a shift 
from type ECB to type DA (oxidative) fibres and also an increase in muscle capillary 
density (Anderson et al, 1977a; Anderson et al, 1977b; Krotkiewski et al, 1983), as 
well as improvements in insulin sensitivity (Erikkson et al, 1997) and blood pressure 
(Halbert et al, 1997). Alternatively, differences in muscle corticosteroid metabolism 
may be of relevance since excess of corticosteroids, both endogenous (Rebuffe- 
Scrive et al, 1988) and exogenous (Danneskjold-Samsoe & Grimby, 1986), has been 
shown to produce a similar histological picture in muscle, as well as being associated 
with components of the metabolic syndrome (Walker et al, 1996). Results from 
studies in rats have suggested that insulin itself may play a role in determining fibre 
type and capillary density (Holmang et al, 1993) - it is possible, therefore, that the 
muscle phenotype is a consequence of metabolic abnormalities.
In conclusion, the notion that quantitative differences in skeletal muscle vascular 
endothelium are important in determining vascular reactivity to insulin is not 
supported by the data in the current study. Thus, while differences in fibre type may, 
in part, determine insulin-mediated glucose uptake in muscle, it is more likely that
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qualitative, not quantitative, differences in vascular endothelial function contribute to 
the large biological variability inherent in insulin’s vasodilator action.
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Chapter 7
Insulin action and endothelial function in type 2 diabetes and essential 
hypertension
7.0 Summary
Twenty seven men participated in this clinical physiology study (9 controls, 9 
hypertensives and 9 type 2 diabetics) which was designed to characterise insulin 
action and basal endothelial function. There was a trend for reduced insulin- 
mediated vasodilation in type 2 diabetic patients although statistical significance was 
not achieved due to high biological variability. Pooled analysis revealed a significant 
association between (1) insulin's metabolic and vascular actions, (2) insulin 
sensitivity and basal endothelial NO production, and (3) insulin-mediated 
vasodilation and basal endothelial NO production. Multiple regression analysis with 
basal endothelial NO production as the dependent variable revealed that a model 
including insulin-mediated vasodilation and age accounted for over 40% of the 
variance. The fact that insulin sensitivity did not persist as an independent predictor 
is supportive of the hypothesis that insulin-stimulated endothelial NO production is a / 
key intermediate mechanism linking insulin-mediated glucose uptake with basal i
endothelial function. f
r -  f  ' I
178
7.1 Introduction
Reduced insulin-mediated glucose uptake and endothelial dysfunction are shared 
features of both metabolic (type 2 diabetes and obesity) and cardiovascular (essential 
hypertension and heart failure) disorders (see introduction to chapter 4). As 
previously discussed, insulin’s predominant vascular action is considered to be 
dependent on an increase in endothelial NO production (chapter 2) and it is possible 
that this, in turn, is dependent on insulin-mediated cellular glucose uptake (see 
section 1.4.1) which may account for the observed physiological association 
between insulin’s metabolic and vascular actions (chapter 4).
Based on this evidence, one would expect patients with disorders characterised by 
insulin resistance (such as type 2 diabetes or essential hypertension) to exhibit 
blunting of vascular responsiveness to insulin with associated reductions in basal 
endothelial NO production. Therefore, the primary objective of this study was to 
characterise insulin action and endothelial function in three groups of subjects - 
essential hypertensives, type 2 diabetics and healthy controls - carefully matched for 
obvious confounding factors such as age and body mass index.
The secondary objective of this study was to search for possible ‘third factors’ which 
might be contributing to defects in both insulin action and endothelial function. The 
most obvious candidates (as discussed in section 1.6.2) are lipid components and 
these were characterised in detail in the following study.
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7.2 Methods
7.2.1 Subjects
Twenty seven male volunteers participated in this study which was approved by the 
Ethics Committee of the West Glasgow Hospitals University NHS Trust. No 
subjects were taking medication during the study, and all abstained from alcohol, 
tobacco and strenuous physical activity for 24 hours and from food and caffeine- 
containing drinks overnight before the three study days, which were at least one 
week apart.
Nine healthy control volunteers, recruited by advertisement, attended a screening 
visit at which physical health was confirmed by history, physical examination, 
routine biochemical and haematological blood tests and ECG. Nine patients with 
uncomplicated diet-controlled type 2 diabetes were recruited via the Diabetes 
Centre, Gartnavel General Hospital. Nine patients with essential hypertension were 
recruited from the Glasgow Blood Pressure Clinic, Western Infirmary. Patients were 
included according to the recruitment criteria detailed in section 2.1. All subjects 
gave informed consent. Six subjects were smokers (3 diabetics, 2 hypertensives, 1 
control). None of the subjects consumed more than the recommended weekly 
alcohol intake (280g). Details of age, BMI, BP and fasting glucose are displayed in 
figure 1.
7.2.2 Clinical procedures
Subjects attended for measurement of whole-body insulin sensitivity using a 180- 
minute hyperinsulinaemic isoglycaemic clamp as described in section 2.4.1. with
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concurrent measurement o f hepatic glucose output using the isotope tracer 
technique (section 2.5.1). To adjust for differences in fasting glucose concentrations, 
insulin sensitivity is expressed as the metabolic clearance ratio o f  glucose (MCR; 
ml/kg/min).
On two further study days, subjects attended for measurement o f forearm blood 
flow by bilateral venous occlusion plethysmography, as described in section 2.7.1, 
On one day, they received an intra-arterial infusion o f insulin (5mU/min) and D- 
glucose (75pmol/min) for 96 mins, with concurrent infusion o f L-NMMA (lmg/min) 
for the final 24 mins. Forearm blood flow was measured every 8 mins throughout; 
the mean o f three readings (56-72 mins) was used as a summary measure for insulin 
vasodilation. On a separate day, they received an intra-arterial infusion o f 
noradrenaline (50ng/min) for 24 mins followed by a 16 minute washout period and 
then L-NMMA (lm g/min) for a further 24 mins. Again, forearm blood flow was 
measured every 8 mins throughout, and the final measurement for each infusate was 
used in subsequent analysis.
In addition, fasting blood samples were processed for measurement o f lipid profile 
and markers o f endothelial activation, as described in section 2.9.8 and 2.9.9.
7.2.3 Statistical E valuation
To compare results among the three groups, summary measures were calculated 
where appropriate, and unpaired t-tests were used. Data from all three groups were 
pooled for correlation and multiple regression analyses, after ensuring that the
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associations under examination were not influenced by either blood pressure or 
glucose levels which could result in clustering o f  patient groups and misleading 
results.
7.3 Results
The procedures were carried out without complication and were well tolerated by all 
subjects. All results are summarised as mean + standard error unless otherwise 
stated.
7.3.1 Insulin sensitivity
MCR (ml/kg/min) was 7.22+0.99 (controls), 6.32+0.78 (hypertensives) and 
5.06+0.53 (diabetics). This trend is as expected although there were no significant 
differences between either patient group and the control group due to the high inter­
individual variability and relatively small numbers. Raw data are displayed in figure 
7.2. Insulin levels achieved during the clamp studies were not different among 
groups, reflecting tight BMI matching (figure 7.3).
7.3.2 Hepatic glucose output during systemic hyperinsulinaemia
Data are available on 25 subjects (data not obtained on two for technical reasons). 
In general, results obtained are physiologically plausible, since estimates o f  basal 
hepatic glucose production are markedly suppressed during hyperinsulinaemia in the 
majority o f cases (raw data displayed in figure 7.4). However, one would predict 
that insulin-mediated suppression o f hepatic glucose output would be associated 
with whole-body insulin sensitivity, but this is not the case (r = 0.12, figure 7.5a). In
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addition, one might expect estimates o f  basal hepatic glucose output to be related to 
fasting variables such as glucose, triglycerides and VLDL-cholesterol, but there are 
no associations, although clamp hepatic glucose output does correlate with fasting 
glucose in the diabetic sub-group (r = 0.83, p = 0.01, figure 7.5b). Originally, the 
intention was simply to add estimates o f  hepatic glucose production (during clamp) 
to whole-body insulin sensitivity to obtain estimates o f peripheral insulin sensitivity, 
thought to be a more relevant parameter for comparison with insulin’s vascular 
effects in skeletal muscle. However, in view o f the uncertainty about the 
physiological meaning o f  the data, it was decided to use the metabolic clearance rate 
o f glucose (section 2.4.2) as the measurement o f  ‘insulin sensitivity’ for use in 
further analyses.
7.3.3 Local insulin/glucose-mediated vasodilation
Percentage change in forearm blood flow ratio was 17.1+5.6% (controls), 
17.2+5.5% (hypertensives) and 12.3+6.4% (diabetics). Raw data for summary 
measures are displayed in figure 7.6. Again, due to high variability within each group 
and relatively small numbers, there were no significant differences between either 
patient group and the control group. The time-course o f vasodilation is plotted in 
figure 7.7. Even if the area under the curve is calculated for controls and diabetics, 
there is no significant difference between groups (p = 0.34).
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7.3.4 Insulin sensitivity v insulin vasodilation
When data from the three groups are pooled and plotted (figure 7.8a) there is no 
clustering of patient groups. This allows justification of pooled correlation analysis 
(figure 7.8b) which demonstrates a significant positive association (r = 0.46, p < 
0.05) between insulin's metabolic and vascular effects which persists independently 
of either hyperglycaemia or high blood pressure. This relationship is in keeping with 
the results obtained in chapter 4 in younger, leaner healthy volunteers.
7.3.5 Vasoreactivity to LrNMMA and noradrenaline
Percent vasoconstriction to L-NMMA was 37.9±5.1% (controls), 37.5+2.3% 
(hypertensives) and 33.6±2.8% (diabetics). Raw data are displayed in figure 7.9, 
demonstrating the large biological variability, especially in the control group. There 
were no significant differences among groups for L-NMMA vasoconstriction.
Percent vasoconstriction to noradrenaline was 20.9±6.2% (controls), 21.9+5.6% 
(hypertensives) and 29.4+5.6% (diabetics). Again, there were no significant 
differences among groups.
7.3.6 L-NMMA vasoconstriction - fasting v hyperinsulinaemia
On a background of hyperinsulinaemia, percentage changes in FBF ratio in response 
to L-NMMA can be expressed in two ways: firstly, with reference to baseline (prior 
to insulin/glucose infusion): 25.3+6.0% (controls), 20.8+5.5% (hypertensives) and 
26.6+8.4% (diabetics); secondly, with reference to achieved vasoreactivity to
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insulin/glucose: 35.6+4.5% (controls), 30.1+3.1% (hypertensives) and 35.0+6.5% 
(diabetics). In neither case are there any significant differences among groups.
Taking the latter values and pooling data to look at the time-course of 
vasoconstriction, it is clear that the vascular response to L-NMMA is delayed and 
steady-state has still not been achieved at 24 mins, while it appears that L-NMMA 
infused in fasting conditions achieves near-steady-state vasoconstriction within the 
first 10 mins (figure 7.10).
7.3.7 Insulin sensitivity v L-NMMA vasoconstriction
Pooled correlation analysis (n=27) reveals that insulin sensitivity (MCR) is 
significantly positively related to % L-NMMA vasoconstriction (surrogate for basal 
endothelial NO production) (r = 0.44, p < 0.05) but not to % noradrenaline 
vasoconstriction (r = -0.35) (figure 7.11).
7.3.8 Insulin vasodilation v L-NMMA vasoconstriction
Pooled correlation analysis (n=27) reveals that insulin/glucose-mediated vasodilation 
is significantly positively related to % L-NMMA vasoconstriction (surrogate for 
basal endothelial NO production) (r = 0.52, p < 0.01) but not to % noradrenaline 
vasoconstriction (r = -0.15) (figure 7.12).
7.3.9 Fasting lipids
Figure 7.13 displays data for total cholesterol, triglycerides, LDL-cholesterol and 
HDL-cholesterol for all three groups. There were no significant differences among
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groups for any of the measured lipid parameters. In addition, VLDL-cholesterol 
levels (mmol/1) were 0.73+0.15 (controls), 0.53+0.11 (hypertensives) and 0.85+0.18 
(diabetics).
Of all the lipid parameters, HDL-cholesterol level was most closely related to both 
BMI (r = -0.48, p < 0.05) and insulin sensitivity (r = 0.44, p < 0.05) (figure 7.14).
7.3.10 Markers of endothelial activation
Pooled data: TPA 11.2+2.9 ng/ml; FVIIc 132.9+26.8 % activity; fibrinogen 
3.16+0.8 gfl; vWF 121.7±44.5 IU/dl (mean±SD); D-dimers 41 [23, 68] (median & 
IQ range). There were no differences among the three groups for these variables 
(one-way ANOVA). Table 7.1 displays simple correlation co-efficient values for 
each marker against (1) L-NMMA vasoconstriction (2) MCR (3) insulin/glucose- 
mediated vasodilation. None of the correlations reached statistical significance.
7.3.11 Multiple regression analysis
Three dependent variables were studied separately: insulin sensitivity, insulin 
vasodilation and L-NMMA vasoconstriction. The following additional factors were 
entered into the initial models: age, BMI, diastolic BP, fasting glucose, triglycerides 
and vWF. Minitab’s ‘Best Subsets’ analysis was used to identify the best model to 
predict each dependent variable.
With insulin sensitivity as dependent variable, a model including BMI, insulin 
vasodilation, triglycerides and age explained 59% (adj R2) of the variance.
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With insulin vasodilation as dependent variable, a model including L-NMMA 
vasoconstriction, insulin sensitivity and age explained 42% (adj R2) of the variation.
With L-NMMA vasoconstriction as dependent variable, a model including insulin 
vasodilation and age explained 41% (adj R2) of the variance.
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Figure 7.2
Individual values for whole-body insulin sensitivity (mean 
clearance rate of glucose: MCR) in healthy controls (n=9), 
and patients with essential hypertension (n=9) or type 2 
diabetes (n=9). Group means also displayed.
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Figure 7.3
Serum insulin levels (mean + S.E., mU/1) during 150-minute 
isoglycaemic clamp.
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Figure 7.5
Endogenous (hepatic) glucose production (mg/kg/min) during 
hyperinsulinaemia plotted against (a) whole-body insulin 
sensitivity (M-value) in 25 subjects (b) fasting plasma [glucose] in 
eight patients with type 2 diabetes.
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Figure 7.6
Individual values for percentage change in forearm blood flow 
ratio in response to intra-arterial infusion of insulin and D- 
glucose in healthy controls (n=9), and patients with essential 
hypertension (n=9) or type 2 diabetes (n=9). Group means also 
displayed.
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Figure 7.7
Time course for percentage change in forearm blood flow ratio in 
response to intra-arterial infusion of insulin and D-glucose (mean 
+ S.E.) in healthy controls (n=9), and patients with essential 
hypertension (n=9) or type 2 diabetes (n=9).
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Figure 7.8
Insulin sensitivity (MCR) v insulin vasodilation (percentage change in 
FBF ratio): (a) data displayed for each sub-group (b) pooled correlation 
analysis (n=27).
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Figure 7.9
Individual values for percentage forearm vasoconstriction in 
response to intra-arterial infusion of L-NMMA (surrogate 
measurement of basal endothelial NO production) in healthy controls 
(n=9), and patients with essential hypertension (n=9) or type 2 
diabetes (n=9). Group means also displayed.
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Figure 7.10
Comparison of the time course of percentage change in FBF ratio in 
response to intra-arterial L-NMMA (mean + S.E.) between (a) basal 
conditions and (b) superimposed on a background of local 
hyperinsulinaemia. Pooled data (n=27)
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Figure 7.11
Percentage change in forearm blood flow ratio in response 
to intra-arterial infusions of L-NMMA and noradrenaline 
plotted against insulin sensitivity (MCR). Pooled 
correlation analysis (n=27).
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Figure 7.12
Percentage change in forearm blood flow ratio in response 
to intra-arterial infusions of L-NMMA and noradrenaline 
plotted against local insulin/glucose-mediated vasodilation 
(percentage change in FBF ratio). Pooled correlation 
analysis (n=27).
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Figure 7.14
Pooled correlation analysis (n=27): HDL-cholesterol plotted against 
(a) body mass index and (b) insulin sensitivity (MCR glucose).
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Table 7.1
Simple correlation co-efficients ( r ) for markers of endothelial activation plotted 
against (1) L-NMMA vasoconstriction (% change blood flow ratio) (2) Insulin 
sensitivity (MCR) (3) insulin/glucose-mediated vasodilation (% change blood flow 
ratio (n=27). ‘TPA’: tissue plasminogen activator (ng/ml); ‘FVIIc’: % activity of 
factor VHc; ‘fibrinogen’ (g/1); ‘vWF’ von Willebrand factor (IU/dl); ‘D-Dimers’ D- 
Dimer antigen.
L-NMMA
VASOCONSTRICTION
INSULIN
SENSITIVITY
INSULIN
VASODILATION
TPA -0.14 -0.30 -0.10
FVIIc -0.06 0.09 0.10
Fibrinogen -0.33 -0.34 0.13
vWF -0.26 -0.20 0.05
D-Dimers 0.00 -0.03 -0.07
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7.4 Discussion
The main purpose of this study was to characterise insulin action and endothelial 
function in a group of older subjects sub-grouped into healthy controls, essential 
hypertensives and type 2 diabetics. The primary hypothesis was that the more 
insulin-resistant groups (ie the patients) would exhibit blunting of vasoreactivity to 
insulin with associated reduction in basal endothelial function.
To ensure as ‘clean* a study as possible, recruitment criteria were extremely tight 
and patients were free of other cardiovascular and metabolic complications as well 
as being of similar age and level of obesity. By definition, therefore, patients had 
very mild disease and this is reflected in the obvious overlap in measurement of 
insulin action and endothelial function in apparently ‘healthy* volunteers. While the 
large range of biological variability in these parameters means that inter-group 
comparisons are unlikely to show differences without very large numbers of 
subjects, there is greater potential for interesting correlation analyses and multiple 
regression. It has been necessary to pool data from all three sub-groups to facilitate 
these analyses - this is valid on the premise that there is no clustering of the sub­
groups which might produce misleading results. The presence of sub-group 
clustering has been carefully excluded in any correlation analysis presented in this 
study.
As in younger, leaner healthy volunteers, local insulin/glucose-mediated vasodilation 
was a feature in older healthy subjects, although the mean value (17%) is 
approximately half of that seen in the younger subjects (see chapter 4). The time-
course of insulin vasodilation is similar with a slow onset over the initial 40-50 mins 
with near-steady-state thereafter. This tends to imply that insulin is unlikely to be a 
physiologically-relevant vasodilator in the traditional sense, since insulin levels are 
only elevated temporarily to this extent in the post-prandial period. Rather, the 
implication is that insulin may play a role in modulating basal activity of eNOS, 
possibly by up-regulation of gene expression. Taken together with our previous 
results demonstrating the importance of cellular glucose uptake in determining 
insulin’s vasoactive effect (Ueda et al, 1998a), this has led to the generation of a 
working hypothesis, presented in figure 7.15. The hypothesis states that the post­
receptor pathway for insulin-stimulated endothelial nitric oxide production is 
common to the pathway involved in glucose uptake (via IRS-1, PI3-K etc) and, 
therefore, any reason for a reduction in efficacy of the metabolic pathway (ie cellular 
insulin resistance) will also result in blunted NO production and reduced 
vasodilation. If insulin does, indeed, exert a promoting influence on eNOS activity, 
this may account for observed associations between measurements of insulin- 
mediated glucose uptake and basal endothelial NO production in both experimental 
and clinical studies. Taking this hypothesis one step further, it may be that insulin 
plays a crucial role in the post-prandial period, especially after a high-fat meal. 
Recent studies have demonstrated that endothelial function is temporarily blunted 
post-prandially, probably due to increased oxidant stress caused by oxidised lipid 
particles (Vogel et al, 1997; Plotnick et al, 1997). Insulin may help to buffer this 
oxidant stress by stimulating endothelial NO production. This hypothesis, displayed 
in figure 7.16, is open for testing in future studies.
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Figure 7.15
Hypothetical mechanism for insulin resistance to cause endothelial 
dysfunction via a reduction in endothelial nitric oxide production.
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Figure 7.16
Hypothetical mechanism for an adverse lipid profile in the post-prandial 
period to cause endothelial dysfunction both directly via quenching of nitric 
oxide and indirectly via a reduction in insulin-mediated glucose uptake.
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Do the results presented in the current study support the tenets of the above 
hypothesis? Firstly, one would predict that the metabolic and vascular actions of 
insulin are significantly associated, which appears to be the case in pooled 
correlation analysis (figure 7.8b). This relationship persists despite differences in BP 
and glycaemic level.
Secondly, one would predict a positive association between insulin’s vascular action 
and basal endothelial NO production (assessed by degree of vasoconstriction in 
response to inhibition of eNOS). This proved to be a convincing relationship, 
contrary to the result obtained in younger volunteers (chapter 3) where, if anything, 
there was a trend for the opposite association. How can these two results be 
reconciled? It is possible that other mechanisms of insulin-mediated vasodilation are 
more important in younger (or leaner) men (eg stimulation of Na^-A TPase on 
vascular smooth muscle cells) and, with ageing, the predominant mechanism 
becomes stimulation of endothelial NO production.
Thirdly, one would expect similar results in the current study to those forming the 
platform for this thesis, demonstrating that insulin sensitivity correlates with L- 
NMMA vasoconstriction in young healthy men (Petrie et al, 1996a). This is indeed 
the case (figure 7.11) although it is interesting that this relationship does not persist 
in multiple regression analysis, with the best model to predict L-NMMA
i l!vasoconstriction including insulin vasodilation and age (adj R = 41%). Although | 
one must be cautious when proposing cause / effect mechanisms with this type of 
analysis, the data are consistent with the notion that insulin-stimulation of
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endothelial NO production is a key intermediate mechanism accounting for the 
observed association between insulin-mediated glucose uptake and basal endothelial 
function (figure 7.15).
Further evidence to support the proposal that insulin stimulates endothelial NO 
production comes from the comparison of vascular response to L-NMMA in fasting 
or hyperinsulinaemic conditions (figure 7.10). The delayed time-course of effect on a 
background of hyperinsulinaemia implies that eNOS is more active. However, the 
extent of L-NMMA vasoconstriction after 24 mins is similar under both conditions, 
which is contrary to the findings of Steinberg et al (1994) and Scherrer et al (1994). 
The main difference in the current study is that vasoreactivity to insulih/jglucose is 
relatively small due to differences in technique and study demographics.
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Chapter 8
Sensitivity of washed platelets to thrombin-induced aggregation is not 
associated with whole-body insulin sensitivity
8.0 Summary
Previous studies have demonstrated that platelet aggregation is increased in 
association with insulin resistance. However, it remains unclear whether this feature 
is intrinsic to platelet function or secondary to influencing factors in plasma. In the 
present study, a washed platelet preparation was used to determine sensitivity of 
platelets to thrombin-induced aggregation in the absence of plasma. There was no 
association between platelet aggregation and either insulin sensitivity or insulin- 
mediated vasodilation. This negative result might be due to differences in technique 
from previous studies and supports the notion that plasma factors associated with 
insulin resistance exert influences on platelet function rather than there being 
intrinsic platelet defects secondary to insulin resistance.
8.1 Introduction
Platelet aggregability has been shown to be increased in conditions of insulin 
resistance and this may be a key factor in terms of predisposition to thrombotic 
vascular disease. However, there are a number of experimental methods in use for 
measurement of platelet aggregation and results may vary depending on the method
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used. Previous published studies on insulin and platelet aggregation have tended to 
use either whole blood (eg Mandal et al, 1993) or platelet-rich plasma (eg Trovati et 
al, 1995). Conclusions reached from these studies are limited since it remains unclear 
whether increased sensitivity of platelets to agonist-induced aggregation in insulin 
resistance represents a defect in platelet function per se or an influencing factors) 
present in plasma. Use of the washed platelet model may help to differentiate these 
effects since experiments are conducted in a plasma-free environment.
Data are presented on 11 subjects (2 from study described in chapter 4, and 9 from 
study described in chapter 7) who exhibit a wide range of metabolic and vascular 
sensitivity to insulin in vivo.
8.2 Methods
8.2.1 Subjects
Eleven male subjects participated in this study. All subjects had been well 
characterised in terms of in vivo insulin action and basal endothelial function 
(chapters 4 and 7). Subject characteristics (mean + S.D.) were as follows: age 
53+18 years, BMI 24.7+3.2 kg/m2, MAP 105+14 mmHg, fasting glucose (FG) 
6.3+1.5 mmol/1, insulin sensitivity (MCR) 7.1+3.0 ml/kg/min, % change FBF to 
local insulin/glucose (IGMV) 13+20 %.
2 1 0
8.2.2 Preparation of washed platelets
Peripheral venous blood (45ml) was obtained via a large bore cannula from subjects 
in the post-absorptive state (prior to the clamp studies) who had not taken any 
aspirin-containing preparations for at least 10 days. Washed platelets were then 
prepared according to the method o f  Radomski and M oncada (1983) (section 
2 . 10 . 1).
8.2.3 Measurement of platelet aggregation
Platelet aggregation was measured by a turbidimetric method in a Chrono-log dual 
channel whole blood lumi-aggregometer as described in section 2.10.2. A dose- 
response curve (‘Hill plot’: figure 8.1) o f platelet aggregation to  thrombin was 
constructed and the ED 50 value (dose o f agonist which causes 50% o f maximum 
aggregation) was calculated.
8.3 Results
E D 5o (log thrombin) was unrelated in univariate analysis to age, BMI, MAP or 
fasting glucose. In addition, there was no association between ED50 and MCR (r = - 
0.06, p = 0.85, figure 8.2) or IGMV (r = 0.07, p = 0.82, figure 8.3).
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Figure 8.1
Example of Hill Plot: percentage platelet aggregation 
is measured in response to ten doses of thrombin. 
ED50 = estimated dose of thrombin required which 
causes 50% of maximal platelet aggregation 
(measurement of sensitivity of washed platelets to 
thrombin-induced aggregation).
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Figure 8.2
Insulin sensitivity (MCR glucose) in 11 subjects 
plotted against ED50 (measurement of sensitivity of 
washed platelets to thrombin-induced aggregation).
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Figure 8.3
Forearm insulin/glucose-mediated vasoreactivity in 
11 subjects plotted against ED50 (measurement of 
sensitivity of washed platelets to thrombin-induced 
aggregation).
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8.4 Discussion
In newly-diagnosed NIDDM there appears to be significant platelet 
hyperaggregation in whole blood (Mandal et al, 1993; Menys et al, 1995). After 
metabohc control of blood glucose there is significant reduction in platelet 
aggregability, suggesting that both hyperinsulinaemia and hyperglycaemia may be 
influencing aggregation mechanisms (Mandal et al, 1993). In another study, platelet 
aggregation was measured in healthy volunteers before and after intravenous insulin: 
aggregation was significantly reduced after insulin suggesting that insulin may have 
important anti-aggregatory properties (Kahn et al, 1993).
One group has used platelet-rich plasma (PRP) to study the relationship between 
insulin and platelet aggregability: firstly, they demonstrated an anti-aggregatory 
effect of insulin to platelet stimulation by collagen or ADP in PRP form healthy 
volunteers (Trovati et al, 1994). They also measured cGMP production and 
concluded that insulin’s anti-aggregatory effect was via a cGMP-dependent 
mechanism. They went on to show that this effect was significantly impaired in the 
insulin resistant states of obesity and type 2 diabetes (Trovati et al, 1995) and, 
recently, they demonstrated that lean patients with type 2 diabetes exhibited normal 
insulin anti-aggregation (Anfossi et al, 1998), suggesting that insulin resistance is the 
most important underlying mechanism for this effect rather than hyperglycaemia.
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However, it remains unclear whether platelet function per se is defective in insulin 
resistance or whether platelets are influenced by as-yet-unknown plasma factors 
since the studies cited above are conducted in the presence of the subject’s plasma. 
Using a washed platelet technique, it can be concluded that any association between 
platelet aggregation and insulin action is due to an intrinsic defect in platelet function 
rather than an adverse environmental effect. The lack of any relationship in the 
current study would tend to suggest that plasma factors play a key role in mediating 
increased platelet aggregation in insulin-resistant conditions. The negative result may 
also be a reflection of the agonist used. In studies cited above, collagen or ADP 
tends to be used rather than thrombin - it is possible that increased sensitivity to 
platelet aggregation in insulin resistance is agonist-specific. Clearly, there are a 
number of further studies required to clarify these issues, including a study 
comparing different platelet preparations and different agonists of aggregation in the 
same group of subjects.
The L-arginine/nitric oxide pathway has been known for some time to be an 
important mechanism regulating aggregation in platelets (Radomski et al, 1990), and 
it appears likely that insulin’s anti-aggregatory effect is mediated via production of 
nitric oxide and consequent elevated levels of cGMP (Trovati et al, 1996; Trovati et 
al, 1997). Plans for further studies using the washed platelet technique include in 
vitro incubation with varying doses of insulin and concomitant manipulation of 
platelet NO synthase.
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Finally, the role of insulin-mediated platelet glucose uptake in determining sensitivity 
to aggregation can be investigated using in vitro incubation with insulin and either 
D- or L-glucose in a similar way to limb infusion studies investigating mechanisms of 
insulin-mediated vasodilation (Ueda et al, 1998a). The presence of GLUT3, an 
insulin-regulatable glucose transporter, has been confirmed in platelets in our 
Department using immunoblotting and autoradiographic techniques (C. Clark, 
unpublished observations). It is not known whether platelet glucose uptake is 
reduced in insulin-resistant conditions, but if platelet metabolic function depends on 
adequate glucose uptake, this is a potential mechanism for platelet dysfunction 
secondary to insulin resistance.
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Chapter 9
Direct visualisation of glucose transporter protein GLUT4 in skeletal muscle 
using immunogold electron microscopy
9.0 Summary
In this pilot study, a collaboration was initiated with experts in membrane 
biochemistry and cell ultrastructure with a view to developing the technique of 
immunogold electron microscopy for use in direct visualisation of key cellular 
proteins involved in the insulin signalling pathway. The primary aim of this ongoing 
work is to demonstrate and quantify GLUT4 translocation to myocyte t-tubules in 
response to insulin stimulation. Once this technique is established, it is planned to 
explore mechanisms of GLUT4 translocation to provide chxes for possible defects 
which may underlie cellular insulin resistance.
9.1 Introduction
Insulin stimulates glucose uptake into adipocytes and muscle by virtue of the specific 
expression of an insulin-regulatable glucose transporter, GLUT4. The translocation 
of this transporter from an intracellular site to the plasma membrane in insulin- 
exposed cells is responsible for the large increase in glucose transport observed. 
Under basal conditions in both fat and muscle, >90% of GLUT4 is sequestered 
intracellularly (Slot et aL, 1991; Slot et al, 1997). It has been suggested that the 
majority of the intracellular GLUT4 is housed in vesicular structures similar to small
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synaptic vesicles observed in neuroendocrine cells (Slot et al, 1991; Slot et al, 1997; 
Martin et al, 1998).
Recent studies have established that GLUT4 translocation in muscle is sufficient to 
account for the effects of insulin on glucose transport (Lund et al, 1995; Zorzano et 
al, 1996; Lund et al, 1997). Skeletal muscle t-tubules possess insulin receptors, and 
thus may be a potential site for translocation of glucose transporters in response to 
msnlm in addition to the sarcolemma (Zorzano et al, 1996). There is some debate 
regarding the relative contributions of translocation of GLUT4 to the sarcolemma 
and t-tubular regions. Biochemical and immuno-EM evidence has clearly 
demonstrated insulin-stimulated translocation of GLUT4 to both these sites in rat 
skeletal muscle (reviewed in Zorzano et al, 1996). The present consensus suggests 
that t-tubules contain more GLUT4 per unit membrane than the sarcolemma after 
insulin treatment, suggesting some heterogeneity in the translocation process to 
these different plasma membrane domains (reviewed in Zorzano et al, 1996).
Reductions in cellular glucose uptake in response to insulin may be secondary to 
defects in GLUT4 translocation. The technique of immunogold-EM allows direct 
vision of GLUT4 and its relationship with membrane structures such as sarcolemma, 
t-tubules and sarcoplasmic reticulum. This chapter describes the process of setting 
up this technique and the methodological problems encountered. Thus far, rat 
muscle has been studied in the basal state with the result that GLUT4 can be 
consistently demonstrated in relation to intracellular membrane structures. The next 
step in this ongoing work is to study the response of GLUT4 to insulin stimulation
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and to attempt quantification of GLUT4 translocation. The eventual aim is to use 
this technique as a model to characterise the biochemical steps involved in GLUT4 
translocation and possible defects in this process which may account for cellular 
insulin resistance.
9.2 Methods
A detailed description of methods is contained in section 2.11. Briefly, rat skeletal 
muscle was harvested, fixed and cryoprotected. After freezing the sample in liquid 
nitrogen, ultrasections were obtained and placed on grids. Polyclonal GLUT4 
antisera was applied followed by colloidal (Protein A) gold conjugate (lOnm). The 
sections were embedded with methyl cellulose and uranyl acetate was applied to 
optimise contrast. Grids were observed using a Phillips CM10 electron microscope 
(magnification approx: x38000).
9.3 Results
9.3.1 Modifications to technique
Embedding and Contrast
Cryo-ultrathin sections need support to withstand the surface tension produced by 
air-drying and the effects of the electron beam. Methyl cellulose acts as this support 
but a balance needs to be achieved to obtain the optimal protection and allow the 
beam to penetrate. Too thick a support layer and the electron beam has difficulty 
penetrating, resulting in reduced contrast; too thin a layer and the sections rupture. 
Methyl cellulose concentrations of 1 %, 2 %, and 3% were used to determine the 
optimal support film. Sections with 2 % and 3 % methyl cellulose, although stable
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under the electron beam, had diminished contrast resulting in poor membrane 
visualisation. The best result was achieved using 1 % methyl cellulose as the support 
film. This resulted in good visualisation o f membrane structures, while allowing for 
sufficient support.
Using high density colloidal gold allows for negative “staining” and the heavy metal 
solution helps to support the cell structures. With higher concentrations o f  uranyl 
acetate, increased negative staining is seen. Different concentrations o f  uranyl 
acetate (3, 6 and 10 %  as a 1:1 and 1:9 solution with methyl cellulose) were used to  
establish optimal contrast o f  membrane structures within the muscle tissue sections. 
Superior contrast and support was achieved with the 9:1 methyl cellulose /  10 % 
uranyl acetate solution. Using methyl cellulose as a 1:1 solution with uranyl acetate 
did not provide enough support for the sections.
Background staining
The reduction in incubation times to 30 minutes (originally 1 hour) and increased 
washing decreased background staining. The introduction o f Tris-HCL buffer at pH
8.2 assisted the removal o f  non-specific background staining. The original 
immunogold technique employed gelatine to block non-specific background. 
However, by a process o f  trial and error, it was found that gelatine actually 
introduced non-specific staining with the Protein A colloidal gold solution and 
consequently the GLUT4 antiserum staining appeared heavier than expected. After 
removal o f gelatine from the protocol, the non-specific background staining 
diminished considerably (Figure 9.1). This reduction in background staining
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permitted the increase in concentration o f GLUT4 antiserum from 1:800 (with the 
use o f gelatine) to  1:200 without gelatine (Figure 9.2).
9.3.2 Cryo-ultrastructural Immunocytochemistry
The GLUT4 antiserum showed positive localisation with the immunogold technique. 
Labelling o f  the GLUT4 antigenic sites in rat muscle tissue in fasting conditions was 
observed in the I band, near the A -  I band junction o f  the myofibrils and close to 
the triad junctions, and also associated with the sarcoplasmic reticulum (SR) (Figure 
9.3). Immunolabelling is also observed in close proximity to t-tubules and at the 
sarcolemma (Figure 9.4).
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9.4 Discussion
In collaboration with colleagues in membrane biochemistry and electron microscopy, 
the technique of immunogold-EM has been successfully established with a view to 
characterising the response of GLUT4 to insulin stimulation in skeletal muscle cells. 
The technique has been refined so that GLUT4 protein can be consistently and 
clearly demonstrated in relation to intracellular membrane structures. Background 
staining has been minimised and contrast has been optimised resulting in high quality 
images on a par with previously published work from other groups.
The next stage of this ongoing work is to visualise GLUT4 in myocytes following 
insulin stimulation. Translocation of GLUT4 to t-tubules and sarcolemma is 
predicted and, hopefully, it will be possible to quantify the degree of translocation to 
these sites compared with basal conditions. Once this has been established, a number 
of potential studies can be initiated. Using biochemical techniques it may be possible 
to characterise the key steps of the insulin signalling pathway which stimulate 
GLUT4 translocation. Studies in muscle from insulin resistant animals may reveal 
differences in GLUT4 translocation in response to insulin. Finally, it is hoped to 
extend these studies to human muscle, with the ultimate aim of studying muscle from 
subjects in whom detailed characterisation of in vivo insulin action has been 
obtained.
Chapter 10
General discussion
In recent years there has been intense interest in physiological mechanisms linking 
aspects of metabolism with vascular control. This has been fuelled by observations 
that insulin resistance and vascular endothelial dysfunction are common features in 
both metabolic disorders, such as obesity and type 2 diabetes, and cardiovascular 
disorders, such as essential hypertension and heart failure. The demonstration of 
insulin as a vascular hormone, causing vasodilation by endothelium-dependent 
mechanisms, has led to speculation that a generalised defect in insulin action might 
be important as a determinant of both metabolic and vascular dysfunction.
Prior to this thesis commencing, the predominant hypothesis concerning insulin 
action and blood flow (Baron’s group, USA) was that primary endothelial 
dysfunction results in blunting of insulin-mediated vasodilation with subsequent 
reduction of nutrient blood flow to skeletal muscle vascular beds; this, in turn, 
causes reduced insulin-mediated glucose uptake in muscle cells. This hypothesis 
depended on muscle blood flow and substrate delivery being rate-limiting to the 
process of limb glucose uptake. Baron’s results from the early 1990s (discussed in 
detail in section 7.5.3) appeared to support this hypothesis
A number of European investigators (most influential being Yki-Jarvinen, Finland) 
went on to refute Baron’s conclusions, criticising the unphysiological nature of his
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studies and questioning the interpretation of his results. A number of studies 
involving manipulation of limb blood flow showed no effect on limb glucose uptake 
suggesting that substrate delivery was unlikely to be rate-limiting for glucose uptake. 
The current feeling is that Baron’s hypothesis is no longer tenable, although recent 
work by Clark in Australia has introduced the concept of ‘nutritive’ and ‘non­
nutritive’ vascular beds within skeletal muscle which might be differentially 
stimulated by insulin, and the notion that insulin redirects blood flow in order to 
optimise nutrient uptake remains teleologically attractive.
In addition to providing evidence against Baron’s hypothesis, Yki-Jarvinen (1998) 
and others proceeded to argue that there was unlikely to be any functional coupling 
between insulin’s vascular and metabolic actions, although these same investigators 
are tending to concede in recently published studies that their results are, indeed, 
compatible with a common physiological mechanism linking glucose uptake and 
vasodilation.
The alternative hypothesis that reduced insulin-mediated glucose uptake is the 
primary event leading to blunting of insulin’s vascular action (and associated 
vascular endothelial dysfunction) has been previously discounted, mainly on the basis 
of one published study by Vollenweider et al (1993) which showed that a fructose- 
mediated increase in intracellular metabolism did not cause vasodilation. However, 
this result is still compatible with the notion extended in this thesis that insulin’s 
vascular action and promotion of glucose uptake may have a common intracellular 
signalling pathway.
Indeed, there is increasing evidence from ex vivo studies (section 1.4.1) that cellular 
glucose uptake plays a key role in insulin’s vascular effect, both directly in VSMCs 
and indirectly, via endothelial mechanisms. In addition, we demonstrated in the 
human forearm that co-infusion o f  glucose with insulin caused significant 
augmentation o f  vasodilation compared with co-infusion with an isomeric control 
(Ueda et al, 1998). Taking account o f previous results demonstrating a positive 
association between insulin sensitivity and basal endothelial NO production (Petrie 
et al, 1996), a working hypothesis has been generated (figure 7.15). The studies 
described in this thesis relate to this hypothesis and a general discussion o f the major 
findings follows.
(i) Physiological mechanisms of insulin-mediated vasodilation in man
Having developed experience with the forearm model, the first studies o f  this thesis 
were designed to examine potential mechanisms for insulin-mediated vasodilation. 
These studies were complicated by the long time-course o f insulin’s vascular effects 
necessitating restrictions in study design and also the somewhat unexpected results. 
The hypothesis was that local inhibition o f NO synthase would abolish insulin- 
mediated vasodilation in the forearm. To control for the fact that basal NO 
production contributes to vascular relaxation and therefore inhibition by L-NMMA 
would cause vasoconstriction, a ‘control’ endothelium-independent vasoconstrictor 
(angiotensin II) was used. Co-infusion with L-NMMA abolished vasodilation to 
insulin/glucose but a similar pattern emerged with angiotensin II as well as in a sub­
group who had local inhibition o f Na+K+-ATPase by ouabain infusion. These results
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can be interpreted in a number o f ways, as discussed in chapter 3. Unfortunately, it is 
difficult to draw any definite conclusions concerning mechanisms o f insulin’s 
vascular action from this study. However, it allows some insight into the pitfalls o f 
interpreting results from similarly-designed studies, many o f  which have been widely 
cited as providing evidence for insulin as an endothelium-dependent vasodilator. The 
correlation analyses in chapter 3 involve small numbers o f  subjects but are o f  some 
interest, especially with regard to  results obtained by similar methods from older 
subjects, described in chapter 7.
In order to examine insulin’s vasoactive mechanisms in more detail it is proposed to 
study small arteries obtained by gluteal biopsy using myographic techniques; this 
work is in the preliminary phase and will not be discussed in detail as part o f  this 
thesis.
(ii) Insulin-mediated vasodilation and glucose uptake are functionally linked in 
man
According to the working hypothesis (figure 7.15) insulin resistance should be 
associated with blunting o f insulin-mediated vasodilation. By virtue o f  the three- to 
five-fold variation in these parameters in health, it was possible to  study the 
relationship between insulin’s metabolic and vascular actions in young healthy male 
volunteers. The conclusion o f this study, described in chapter 4, is that an 
association does indeed exist between insulin-mediated glucose uptake and insulin 
vasodilation, which is independent o f potential confounding factors such as age, 
BMI and blood pressure.
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While this supports the notion of functional coupling of insulin effects, there is no 
evidence of causality, although in the context of the ‘D and L-ghicose infusion’ 
study it seems plausible that insulin-mediated glucose uptake is a primary 
determinant of insulin vasodilation.
(iii) Systemic inhibition of endothelial nitric oxide synthesis does not impair 
insulin sensitivity in man.
If Baron’s hypothesis is valid, then inducing a temporary and artificial state of 
relative endothelial dysfunction should result in reduced insulin-mediated glucose 
uptake secondary to reduced glucose delivery to skeletal muscle vascular beds. This 
was tested in the study described in chapter 5, with the conclusion that systemic 
inhibition of NO synthase had no effect on whole-body insulin sensitivity. This 
supports the notion that substrate delivery is not rate-limiting for glucose uptake and 
that primary endothelial dysfunction is not the main factor leading to relative insulin 
resistance.
However, this study is also open to criticism. Ideally, a local infusion of L-NMMA 
should have been given on a background of systemic hyperinsulinaemia and any 
changes in forearm glucose uptake. Unfortunately, due to restrictions imposed by 
the Ethics Committee concerning the lumen size of brachial artery needles, it was 
impossible to obtain the arterial samples necessary for measurement of forearm 
glucose uptake. Delivering L-NMMA systemically may not have the same effect as 
local infusion due to differential sensitivity to this substance in renal and splanchnic
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vascular beds. Thus, it cannot necessarily be assumed that limb vasoconstriction 
occurs in response to systemic L-NMMA during clamp studies. In a sub-study, 
forearm vasoconstriction was achieved in fasting conditions, but this could not be 
assessed in the context of systemic hyperinsulinaemia, since previous studies in the 
department have indicated that the procedure of hand-warming can affect blood flow 
measurements. Furthermore, while this dose of systemic L-NMMA is sufficient to 
exert haemodynamic effects, it is unclear to what degree endothelial function is 
blunted. To test this further, local endothelium-dependent vasodilators could be 
infused on a background of L-NMMA to give an indication of the degree of induced 
endothelial dysfunction.
However, despite retrospective criticism of study design, the result supports the 
working hypothesis which emphasises that metabolic derangement is the primary 
abnormality resulting in vascular dysfunction. For further study, it would be of 
interest to administer an agent which is known to induce temporary insulin resistance 
(for example, corticosteroid) and examine whether endothelial function deteriorated 
as a consequence. Of course, it could be argued that any such agent might be 
exerting direct effects on the endothelium as well as influencing insulin action.
(iv) Insulin action and endothelial function in type 2 diabetes and essential 
hypertension
Having studied aspects of insulin action and endothelial function in young healthy 
volunteers, the next step was to Study similar variables in older subjects and, 
specifically, in patients with essential hypertension and type 2 diabetes, conditions
characterised by resistance to insulin-mediated glucose uptake. The results are 
presented in chapter 7 and, in general terms, similar conclusions apply. The numbers 
in each sub-group are small (n=9) due partly to the time-consuming nature of the 
study days and difficulties in recruiting subjects according to strict inclusion and 
exclusion criteria. To facilitate a ‘clean’ study, participating patients tended to have 
very mild disease, certainly not typical of the average clinic patient with multiple 
problems and on multiple drugs. While this ensured that sub-groups were well- 
matched for possible confounders such as lipids, renal impairment and co-existing 
macrovascular disease, it led to significant overlap with ‘healthy controls’ in the 
major variables studied, rendering most inter-group comparisons meaningless.
Nevertheless, a number of conclusions can be made from the data:
• Insulin’s vascular action persists in older men although vasodilation is not as 
marked as in younger leaner subjects.
• The time-course of insulin vasodilation is similar in young and old, but the 
predominant mechanisms may be different. Comparing data from chapters 3 and 
7, there is a good correlation between insulin-mediated vasodilation and basal 
endothelial NO production in the older subjects but not in the younger group, 
where basal Na*K+ATPase activity appeared to be most closely associated with 
insulin vasodilation.
• The delayed vasoconstrictor action of L-NMMA on a background of systemic 
hyperinsulinaemia supports the notion that insulin stimulates endothelial NO 
production
• In support of previous data in young volunteers, insulin sensitivity and basal 
endothelial function are significantly related in older subjects. However, in 
multiple regression analysis, insulin sensitivity does not persist as an independent 
predictor of NO production when insulin vasodilation is included in the model 
Although not direct evidence of causality, this supports the concept of insulin’s 
stimulation of endothelial NO as a key intermediate mechanism linking insulin- 
mediated glucose uptake and basal endothelial function. It must be emphasised 
that insulin-mediated glucose uptake is predominantly into skeletal muscle cells 
rather than endothelial cells, and there is no evidence to date for the existence of 
GLUT4 transporters in vascular endothelial cells. However, this does not rule out 
a functional link since either the post-receptor insulin-signalling pathway for 
glucose metabolism may be preserved in endothelial cells or a product of 
intracellular glucose metabolism in skeletal muscle cells may diffuse back to 
stimulate endothelial NO production.
(v) Ex vivo studies on insulin action in skeletal muscle and platelets
To complement the clinical physiology studies, a number of small ex vivo studies 
were undertaken, the results of which are presented in chapters 6, 8 and 9.
There is published evidence to suggest that insulin inhibits platelet aggregation and 
that this function is defective in insulin-resistant subjects. Using a washed platelet 
technique it was possible to quantify aggregation to thrombin (section 2.10) in a 
number of subjects who were attending for clinical studies. The main conclusion 
from this preliminary study was that neither whole-body insulin sensitivity or local
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insulin/glucose-mediated vasodilation was associated with platelet sensitivity to 
thrombin-induced aggregation (chapter 8). Based on the experience gained in this 
study, further studies are planned involving in vitro exposure of platelets to varying 
doses of insulin and glucose. It is also intended to explore possible mechanisms of 
aggregation inhibition which may be related to platelet NO production.
It has been suggested that inherent structure/function characteristics of skeletal 
muscle may partly explain the observed association between insulin action and 
vascular endothelial function since predominance of fibre type, which has been 
linked with insulin sensitivity, tends to differ in parallel with capillary density, which 
may contribute to measurements of endothelial function. In chapter 6 the hypothesis 
was tested that variations in local insuhn/ghicose-mediated vasodilation were related 
to capillary density, measured by immunohistochemical techniques on samples of 
skeletal muscle biopsied from vastus lateralis. This was essentially a negative study, 
suggesting that denser capillary beds do not appear to influence the vasodilator 
response to insulin.
Finally, a collaboration was initiated with experts in membrane biochemistry and 
electron microscopy with a view to explore cellular mechanisms of insulin resistance 
(section 1.10) using immunogold electron microscopy techniques to directly 
visualise GLUT4 in skeletal muscle cells (section 2.11). This difficult technique has 
been developed to a stage where a number of interesting studies can be proposed. 
The primary aim of this work is to characterise possible defects in GLUT4
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translocation which may be responsible for cellular insulin resistance. The progress 
of this project is discussed in detail in chapter 9.
As a side-arm to the EM project the intention was to measure key steps of the 
insulin signalling pathway (1.10.4) such as IRS-1, IRS-2, PI3-K, PKB and GLUT4 
in skeletal muscle tissue obtained by percutaneous biopsy. Unfortunately, while 
histochemical analysis and EM processing only requires a small amount of tissue, 
significantly more is required for biochemical assays which limited the feasibility. In 
view of this problem, the technique of myoblast cell culture has been learned and this 
is currently being developed with a view to studying the insulin signalling pathways 
in myoblasts cultured from subjects who have been well characterised for insulin 
action in vivo.
Conclusions
• Insulin is a vasoactive hormone.
• Mechanisms of insulin-mediated vasodilation include stimulation of endothelial 
NO production and membrane hyperpolarisation via stimulation of 
Na*K+ATPase.
• Insulin-mediated vasodilation occurs gradually over 40-50 minutes suggesting 
involvement of intermediate mechanisms.
• Cellular glucose uptake augments insulin-mediated vasodilation.
• Whole-body insulin-stimulated glucose uptake and local insulin/glucose 
vasodilation are functionally linked.
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• Systemic inhibition of NO production does not impair whole-body insulin- 
mediated glucose uptake.
• Skeletal muscle capillary density is not associated with insulin's vascular action.
• Insulin resistance is not associated with increased sensitivity of washed platelets 
to thrombin-induced aggregation.
• Insulin-mediated vasodilation is preserved in older men but is blunted in parallel 
with reductions in insulin sensitivity.
• Vasoconstriction in response to local inhibition of NO synthase is delayed during 
hyperinsulinaemia compared with fasting conditions suggesting that insulin 
stimulates eNOS activity.
• Insulin sensitivity correlates with basal endothelial NO production in both young 
and older men.
• Insulin-mediated vasodilation correlates with basal endothelial NO production in 
older, but not in young men.
• Insulin’s stimulation of endothelial NO production may be a key intermediate 
mechanism linking insulin sensitivity with basal endothelial function.
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AGEs advanced glycosylation end-products
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ATP adenosine triphosphate
BMI body mass index
BP blood pressure
BSA bovine serum albumin
cAMP cyclic adenosine monophosphate
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CIRU Clinical Investigation & Research Unit
ED50 estimated dose required for 50% maximal effect
EGP endogenous glucose production
ELISA enzyme-linked immunosorbent assay
EM electron microscopy
eNOS endothelial nitric oxide synthase
FBF forearm blood flow
FBFR forearm blood flow ratio
FFA free fatty acid
FVnc factor VHc
GLUT glucose transporter
GSA glucose specific activity
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HDL high density lipoprotein
HOT Hypertension Optimal Treatment
IDDM insulin-dependent diabetes mellitus
IGF-1 insulin-related growth factor type 1
IGT impaired glucose tolerance
IQ interquartile
IRS insulin receptor substrate
LDL low density lipoprotein
L-NM M A NG-monomethyl-L-arginine
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M metabolised glucose (insulin sensitivity)
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NOS nitric oxide synthase
PAI-1 plasminogen activator inhibitor type 1
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